9TH EUROPEAN AIDS CONFERENCE (EACS) 1st EACS RESISTANCE & PHARMACOLOGY WORKSHOP October 25 - 29, 2003 Warsaw, Poland

1	F1/1 - THE QUAD STUDY: A PILOT-STUDY TO ASSESS THE EFFICACY AND SAFETY OF TRIZIVIR + RTV-BOOSTED SAQUINAVIR (TZV+SQVR) COMPARED TO COMBIVIR + RTV-BOOSTED SAQUINAVIR (CBV+SQVR) IN ART-NAÏVE PATIENTS WITH HIGH VIRAL LOAD (VL) AND LOW CD4 COUNT. 24 WEEK INTERIM ANALYSIS European AIDS Conf 2003 Oct 25-29;9:F1/1 (abstract no. 1) Staszewski S.1, Stark T.2, Knecht G.1,3, Mösch M.1, Schlitt C.1, Dauer B.1, Warncke W.4, Walli R.5 In this pilot study in a very advanced patient population, over 24 weeks, substantial antiviral activity was observed with the quadruple and triple combination therapy. Boths regimens were generally well tolerated.
2	F1/2 - TRIZIVIR IN ARV NAÏVE HIV (+) PATIENTS: CAN IT STILL BE CONSIDERED AS A FIRST LINE TREATMENT OPTION? European AIDS Conf 2003 Oct 25-29;9:F1/2 (abstract no. 2) Astriti M.1, Bugnon F.3, Bouberazi I.1, Agher R.1, Marcelin A.G.2, Calvez V.2, Bricaire F.1, Raffi F.3, Katlama C.1 Trizivir had a low rate of virological failure (15 %) in ARV naïve patients. Failures are mostly due to intolerance or non-compliance. However, after 2 years of follow-up, more than 50 % of patients are still on their initial TRZ regimen.
3	F1/3 - EFFICACY AND SAFETY OF ONCE-DAILY LOPINAVIR/RITONAVIR VS. TWICE-DAILY LOPINAVIR/RITONAVIR IN ANTIRETROVIRAL-naïve PATIENTS: 24-WEEK RESULTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 3) Podzamczer D.1, Gathe J.2, Johnson M.3, Schwartz R.4, Villacian J.5, Marsh T.6, Naylor C.6, King M.6, Tressler R.6, Brun S.6 Through 24 weeks, a QD regimen of TDF+FTC+LPV/r resulted in similar virologic responses in antiretroviral-naïve patients compared to the same regimen with LPV/r dosed BID. Both regimens were well tolerated, and diarrhea was the only AE reported more frequently in QD- vs. BID-treated patients.
4	F1/4 - INDUCTION THERAPY WITH TRIZIVIR (ZIDOVUDINE/LAMIVUDINE/ABACAVIR) [TZV] PLUS EFAVIRENZ [EFV]: TIME STUDY (AZL30004) RESULTS AT 24 WEEKS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 4) Johnson M.1, De Wit S.2, Gazzard B.3, Bergmann J.F.4, Reynes J.5, Estrada V.6, Castagna A.7, Rockstroh J.8 TZV+EFV is a compact and potent QUAD regimen but this particular regimen was associated with a high incidence of adverse events leading to drug discontinuations. Patients remaining in the study benefited from an effective reduction in vRNA (including those with very high viral load at baseline), and an improvement in CD4 cell counts.
5	F1/5 - LOPINAVIR/R AS SOLE THERAPY FOR HIV-INFECTION European AIDS Conf 2003 Oct 25-29;9:(abstract no. 5) Pierone G.1, Mieras J.2, Kantor C.2, Bulgin-Coleman D.1, Shearer J.1, McCabe J.2 Follow up observations in this small cohort of patients suggest that L/r alone has potent and durable antiviral activity. No evidence of viral resistance has been observed. Prospective trials of L/r alone are warranted.
6	F2/1 - IMPACT OF NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS) PLASMA CONCENTRATIONS ON VIROLOGICAL RESPONSE TO ANTIRETROVIRAL THERAPY IN HIV-1 INFECTED NNRTIS NAÏVE-PATIENTS (PTS) ENROLLED IN ANRS 088 TRIAL European AIDS Conf 2003 Oct 25-29;9:(abstract no. 6) Peytavin G.1, Meynard J.L.2, Lamotte C.1, Vray M.3, Matheron S.1, Morand-Joubert L.2, Girard P.M.2, Brun-Vézinet F.1, Costagliola D.3, for the Narval Trial Group In heavily pretreated but NNRTI-naïve Pts treated with NNRTI containing regimen, adequate EFV Cpl were predictive of VS. Surprisingly, NVP Cpl were subtherapeutic in half of Pts, suggesting the usefulness of TDM.
7	F2/2 - THE RELATIONSHIP BETWEEN INTRACELLULAR AND PLASMA PHARMACOKINETICS OF NELFINAVIR AND M8 IN HIV INFECTED PATIENTS WITH P-GLYCOPROTEIN EXPRESSION European AIDS Conf 2003 Oct 25-29;9:(abstract no. 7) Ford J.1, Hoggard P.G.1, Meaden E.R.1, Newton P.2, Cuthbertson Z.3, Williams I.2, Johnson M.3, Daniels E.4, Hsyu P.4, Khoo S.H.1, Back D.J.1 IC concentrations were higher than plasma concentrations for NFV and M8, suggesting lymphocyte accumulation. The mechanism of differential IC accumulation of NFV and M8 is unclear but may reflect affinities for influx transporters or inherent drug characteristics.
8	F2/3 - PHARMACOKINETICS (PK) OF SAQUINAVIR/RITONAVIR (SQV/R) ONCE DAILY (OD) IN HIV+ SUBJECTS: COMPARISON WITH STANDARD BD REGIMENS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 8) Boffito M.1, Dickinson L.2, Hill A.3, Nelson M.1, Moyle G.1, Higgs C.1, Fletcher C.1, Mandalia S.1, Back D.2, Gazzard B.1, Pozniak A.1 On SQV/r 2000/100mg OD mean AUC was 36% higher, Cmax 130% higher, but Ctrough 52% lower than the standard 1000/100 mg BD dosage. There was no increased toxicity and 13/15 pts had Ctrough>MEC of 50ng/mL. The 2000/100 OD dosage is a candidate for new clinical trials of OD SQV.
9	F2/4 - INDINAVIR PLASMA EXPOSURE IS NOT AFFECTED BY RITONAVIR/LOPINAVIR CO-ADMINISTRATION IN A BOOSTED DOUBLE PI-ONLY THERPAY REGIMEN European AIDS Conf 2003 Oct 25-29;9:(abstract no. 9) Von Hentig N.1, Dauer B.2, Moesch M.2, Carlebach A.2, Lutz T.3, Kurowski M.4, Harder S.1, Staszewski S.2 The comparison of the RTV plasma exposure in all groups is indicating, that even low RTV plasma levels sufficiently booster IDV or LPV. A dose adjustment of IDV, co-administrated with LPV/r in a double-PI regimen is not necessary.
10	F2/5 - PHARMACOKINETICS FROM A 48-WEEK RANDOMISED TRIAL TO EVALUATE SAFETY AND EFFICACY OF INDINAVIR/RITONAVIR 800/100 MG VERSUS SAQUINAVIR/RITONAVIR 1000/100 MG: THE MAXCMIN1 TRIAL European AIDS Conf 2003 Oct 25-29;9:(abstract no. 10) Justesen U., Fox Z., Pedersen C., Cahn P., Gerstoft J., Clumeck N., Duran A., Peters B., Obel N., Castagna A., Dragsted U., Lundgren J.. on behalf of the MaxCmin1 trial group Rtv-boosting of IDV and SAQ results in high concentrations with no tendency towards levering off over 48 weeks. IDV affects the rtv Cmin level differently than SAQ resulting in higher rtv Cmin levels in the IDV/rtv arm. Efficacy and safety outcomes were not dependent on IDV and SAQ Cmin levels at week 4. Gender may influence drug concentrations.
11	F2/6 - EVALUATION OF THE MULTIPLE-DOSE PHARMACOKINETICS OF LOPINAVIR/RITONAVIR (LPV/R) IN HIV AND HCV CO-INFECTED SUBJECTS WITH MILD OR MODERATE HEPATIC INSUFFICIENCY European AIDS Conf 2003 Oct 25-29;9:(abstract no. 11) Arribas J.1, Pulido F.2, Peng J.Z.3, Kemmis S.3, Li J.-L.3, Lorenzo A.1, Cepeda C.2, Reisch T.3, Moseley J.3, Grebner K.3, Cabanillas J.A.4, Da Silva B.3, Bernstein B.3, Chiu Y.-L.3, Bertz R.3 Both mild and moderate HI result in similar effects on LPV concentrations. Total and free LPV AUC12 were approximately 32% and 71% higher, respectively, in HI subjects vs. control.
12	F3/1 - SIGNIFICANCE OF DNA CMV DETECTION IN BLOOD, URINE AND SALIVA OF HIV-INFECTED PREGNANT WOMEN FOR RISK APPRAISAL OF CONGENITAL CYTOMEGALOVIRUS INFECTION European AIDS Conf 2003 Oct 25-29;9:(abstract no.12) Shakhgildian V.1, Silz V.3, Shamshurina M.2, Kalinina N.2 High frequency of active CMVI is characteristic of pregnant HIV-infected women (CMV DNA was detected in blood leukocytes of 9,2% of examined patients). Intrauterine infection of foetus by CMV happens more often (8,5 % of cases) if a pregnant woman is HIV-infected. CMV DNA detected in blood of pregnant women is the most sensitive and specific marker of a high risk of congenital CMV-infection.
13	F3/2 - DRAMATIC REDUCTION, BUT NO ELIMINATION, OF PERINATAL HIV TRANSMISSION European AIDS Conf 2003 Oct 25-29;9:(abstract no. 13) Sánchez E.1, Fortuny C.2, Loncà M.3, Coll O.3, Bogunyà J.M.2, Muñoz M.C.2, Jiménez R.2 Early identification of HIV infection in pregnant women must be emphasized: prophylactic measures lower the risk of transmission to almost-zero rate, and infants who become infected present with mild clinical conditions and good short to moderate term prognosis.
14	F3/3 - MULTIDISCIPLINARY MANAGEMENT OF HIV AND/OR HCV INFECTED COUPLES WISHING TO HAVE CHILDREN WITH LESSER RISK OF VIRAL TRANSMISSION : ASSISTED MEDICAL PROCREATION (AMP) FOR HIV -1 OR HCV SERODIFFERENT COUPLES European AIDS Conf 2003 Oct 25-29;9:(abstract no. 14) Tubiana R.1, Lefebvre G.2, Marcellin A.G.3, Rozemblum O.4, Simon A.5, Thabut D.6, Ghosn J.1, Mbida L.7, Vauthier D.2, Thibault V.3, Dominguez S.1, Bonmarchand M.6, Pauchard M.1, Katlama C.1, De Montgolfier I.8, Poirot C.7 Women median age was 36 years ( range: 26-45). 70 samples from 38 patients, 21/38 HIV, 13/38 HIV+HCV and 4 HCV infected were analyzed. The ff was positive for HIV-RNA and DNA in 5 and 5 patients respectively. All but one patients had undetectable blood HIV- RNA. HCV- RNA was positive in 6/17 patients in seminal plasma but in only one for the ff. 18 couples started Intrauterine insemination with 9 pregnancies for 44 cycles and 8 performed in vitro fertilisation or Intracytoplasmic Sperm Injection (ICSI) with 2 pregnancies. The first baby is expected in August 2003.
15	F3/4 - MATERNAL TOLERABILITY OF ANTIRETROVIRAL THERAPY (ART) IN PREVENTING VERTICAL TRANSMISSION (VT) OF HIV-1 European AIDS Conf 2003 Oct 25-29;9:(abstract no. 15) Lyons F., Hopkins S., Bergin C., Mulcahy F. ART is generally well tolerated in pregnancy and does not significantly increase anaemia. Liver abnormalities are more common with nevirapine exposure and CD4 count <300 x 106/L. Serious liver toxicity occurred with a higher median baseline CD4.
16	F3/5 - OUTCOMES IN HIV INFECTED PREGNANT WOMEN IN WARSAW COHORT IN 1994-2003 European AIDS Conf 2003 Oct 25-29;9:(abstract no. 16) Firlag-Burkacka E.1, Niemiec T.2, Kalinowska M.1, El Midaoui A.2, Kowalska A.2, Pulik P.1, Bakowska E.1, Swiecki P.1, Horban A.1 HAART and cesarean section is effective in prevention of perinatal transmission of HIV . The preterm delivery rate in HIV+ women is the same as in general pregnant women population in Poland.
17	F3/6 - A LONGITUDINAL STUDY ON HIV-RESISTANCE TESTING DURING PREGNANCY European AIDS Conf 2003 Oct 25-29;9:(abstract no. 17) Liuzzi G.1, Di Giambenedetto S.2, Forbici F.1, Bagarelli A.2, Sette P.1, Visconti E.2, Zaccarelli M.1, Pastore Celentano L.2, Tozzi V.1, Zinzi D.1, Anzidei G.1, De Luca A.2, Antinori A.1, Tamburrini E.2, Perno C.F.1, Cingolani A.2, per il Gruppo Laziale Donne Gravidanza e HIV (G.La.Do.G.HIV) The interruption of treatment at the beginning of pregnancy is related to a low level of resistance with low rate of primary mutations and better response to GRT-guded therapy. However, the importance of viral replication during interruption over HIV vertical transmission should be matter of debate in the next future.
18	F4/1 - PREDICTING THE LONG TERM SLOPE OF CD4+T-CELL COUNTS FOR DIFFERENT HIGHLY ACTIVE ANTIRETROVIRAL THERAPIES (HAART) IN THERAPY NAÏVE PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 18) Gras L.1, van de Wiel M.A.1, van Valkengoed I.1, van Sighem A.1, Ghani A.C.2, de Wolf F.1,2 for the ATHENA observational cohort Our results suggest that few clinically important differences exist in long term CD4+T-cell count between common regimens. Other factors e.g. toxicity, resistance, short term therapy effect should have priority when deciding which antiretroviral therapy to start. However, these findings require verification in larger cohorts.
19	F4/2 - KINETICS OF CYTOKINES/CHEMOKINES IN HIV INFECTED PATIENTS AFTER CESSATION OF ANTIRETROVIRAL THERAPY European AIDS Conf 2003 Oct 25-29;9:(abstract no. 19) Barqasho B.1, Birk M.1,2, Nowak P.1, Andersson J.2, Sönnerborg A.1,2 The HIV RNA levels increased rapidly in all patients after cessation of therapy. Except in IL-6 and IFN-α all other studied cytokines/chemokines seemed to display a positive or negative correlation to the HIV RNA levels. However, we could not identify a clear pattern between the HIV inductive cytokines IL-1β, IL-6, TNF-α and the HIV suppressive ß-chemokines and cytokines IFN-α and IFN-γ. However, this study included only a limited number of individuals and the inter-individual differences were considerable.
20	F4/3 - SPECIFIC T-CELL PROLIFERATIVE AND IFN-γ RESPONSES IN HIV-1-INFECTED PATIENTS UNDER HAART European AIDS Conf 2003 Oct 25-29;9:(abstract no. 20) Markova R.1, Terzieva V.1, Todorova Y.1, Drenska R.1, Elenkov I.2, Yankova M.2, Kostov K.2 A recovery of T-cell responses during HAART was registered only in patients with preserved Th function before therapy. The discordance between HIV-1-specific IFN-γ-producing T cells and HIV-1 specific lymphoproliferation could be due to active HIV-1 replication in vivo causing proliferative defects in these cells. The fact that in the course of HAART strong HIV-1-specific T-cell responses were found in some of the patients indicated that HIV-1-induced proliferative defects could be reversible.
21	F4/4 - EPIDEMIOLOGY OF IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (IRIS) IN AN ETHNICALLY DIVERSE HIV INFECTED COHORT European AIDS Conf 2003 Oct 25-29;9:(abstract no. 21) Thevarajan I., Chiu C., Murad S., Easterbrook P. Approximately one third of patients experience IRIS events within 16 weeks of initiating HAART, and this most commonly manifests as more severe or recurrent genital herpes or other dermatological infections. There are no well defined predisposing factors for the development of IRIS.
22	F5/1 - ACCESS TO LIFE SAVING HIV/AIDS TREATMENTS IN DEVELOPING COUNTRIES: MSF SCALING UP European AIDS Conf 2003 Oct 25-29;9:(abstract no. 22) Klement E. Consolidated data from seven MSF projects in South Africa, Malawi, Kenya, Cameroon, Cambodia, Thailand and Guatemala presented in Barcelona conference showed that at six months survival was 93%, with an mean weight gain of 3kg and 104 CD4cells/mm3 increase, adherence to treatment was good and where viral load was tested virus was undetectable for 82% patients (<100 copies/ml). We now propose to give a two years follow up of this cohort.
23	F5/2 - DELAYED PRESENTATION AND LATE TESTING FOR HIV: DEMOGRAPHIC AND BEHAVIOURAL RISK FACTORS IN A MULTICENTER STUDY IN ITALY European AIDS Conf 2003 Oct 25-29;9:(abstract no. 23) Girardi E., Aloisi M.S., Arici A., Pezzotti P., Serraino D., Balzano R., Vigevani G., Alberici F., Ursitti M., D'Alessandro M., d'Arminio Monforte A., Ippolito G. Interventions aimed at promoting timely access to care of persons with HIV infection should include differentiated programs that specifically address the problem of delay to presentation to medical care after testing HIV and the problem of testing late in the course of HIV infection.
24	F5/3 - PRODUCTIVITY COSTS RELATED TO PAID WORK IN HIV-INFECTED PATIENTS IN SWITZERLAND European AIDS Conf 2003 Oct 25-29;9:(abstract no. 24) Sendi P.1,2, Schellenberg F.1, Ungsedhapand C.1, Kaufmann G.1, Bucher H.2, Weber R.3, Battegay M.1 Productivity losses to society due to HIV infection are substantial. Given a patient's clinical health status, a higher education and a stable partnership is associated with a higher ability to work. Social characteristics may influence the cost-effectiveness of health care interventions in HIV-infected patients.
25	F5/4 - STUDY OF DETERMINANTS OF NON-ADHERENCE TO ANTIRETROVIRAL DRUG THERAPY IN A RESOURCE-LIMITED SETTING European AIDS Conf 2003 Oct 25-29;9:(abstract no. 25) Ekong E.1, Akinlade O.2, Uwah A.3, Grant-Isibor I.4 Non-adherence varied with sex, socioeconomic status and others. There is need for regular counseling and monitoring of patients.
26	F6/1 - FACTORS ASSOCIATED WITH HIV-1 SHEDDING IN THE GENITAL TRACT OF WOMEN WITH UNDETECTABLE PLASMA HIV-1 VIRAL LOAD. POTENTIAL SOURCES OF CELL-FREE HIV-1 IN VAGINAL SECRETIONS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 26) Gimeno A.1, Portilla J.2, Boix V.2, Plazas J.1, Sánchez-Payá J.3, Ochando M.1, Llopis C.1, Merino E.2, Arroyo E.1, Pardo M.A.1, Reus S.2, Sánchez R.2 VPMNs is associated with HIV genital shedding in aviremic women. Although plasma HCV viral load was equal to or greater than HIV, vaginal HCV is rarely detected. This difference suggests that transudation is not a major source of HIV in vaginal secretions.
27	F6/3 - INFLUENCE OF VIRAL LOAD ON THE TRANSMISSION OF DRUG-RESISTANT (DR) AND WILD TYPE (WT) HIV VARIANTS: COMPARISON OF RESISTANCE BETWEEN CHRONICALLY-INFECTED (CI) AND RECENTLY-INFECTED (RI) PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 27) Routy J.P.1, Machouf N.1,4, Brenner B.2, Thomas R.1,3,4, Trottier B.4, Rouleau D.3, Côté P.4, Baril J.G.4, Tremblay C.3, LeBlanc R.1,4, Edwardes M.1, Turner D.2, Sekaly R.P.5, Wainberg M.2 The decrease in VL observed in CI patients corroborates the decrease in DR transmission despite an augmentation of DR prevalence in the population of potential transmitters. Presence of mutations conferring lower VL looks to be less transmissible. Transmission of WT or DR variants seems to occur only with individuals having high viral load (4 log).
28	F6/4 - DIFFERENCES IN CD4 DECLINE FOLLOWING SEROCONVERSION FOR PERSONS WITH AND WITHOUT TRANSMITTED DRUG-RESISTANT HIV European AIDS Conf 2003 Oct 25-29;9:(abstract no. 28) Bhaskaran K., on behalf of the UK Register of HIV Seroconverters We found no evidence of a difference in the rate of CD4 decline between those with and without TDR after the first year following seroconversion. Longer follow-up is required and the possible differences in the first year after seroconversion should be investigated further.
29	F6/5 - VIROLOGIC OUTCOME OF PATIENTS WITH VIROLOGIC FAILURE WHO START A REGIMEN CONTAINING ABACAVIR: EUROSIDA STUDY European AIDS Conf 2003 Oct 25-29;9:(abstract no. 29) Cabrera C.1, Cozzi-Lepri A.2, Phillips A.N.2, Loveday C.3, Puig T.1, Kirk O.4, Ait-Khaled M.5, Ledergerber B.6, Lundgren J.4, Clotet B.1, Ruiz L.1 The ABC measures were not clearly associated with response, suggesting that these algorithms may need further improvements. The predictive value of other ABC resistance measures will be presented.
30	F6/6 - CLINICAL PROGRESSION AND LONG TERM VIRO-IMMUNOLOGICAL OUTCOMES DURING THE EXTENDED OBSERVATION OF ARGENTA, A RANDOMIZED TRIAL ON THE USEFULNESS OF HIV-1 DRUG RESISTANCE GENOTYPING European AIDS Conf 2003 Oct 25-29;9:(abstract no. 30) Di Giambenedetto S., Cingolani A., Bacarelli A., Murri R., Ammassari A., Cauda R., De Luca A. GRT conferred a sustained virologic and immunological benefit independently from the number of failed regimens and immediate or deferred use. Initial VL response predicted long term clinical outcomes.
31	F6/7 - THE PROGNOSTIC VALUE TO PREDICT VIROLOGICAL OUTCOMES OF 14 DISTINCT SYSTEMS USED TO INTERPRET THE RESULTS OF GENOTYPIC HIV-1 DRUG RESISTANCE TESTING IN UNTREATED PATIENTS STARTING THEIR FIRST HAART European AIDS Conf 2003 Oct 25-29;9:(abstract no. 31) De Luca A.1, Cozzi-Lepri A.2, Perno C.F.3, Balotta C.4, Di Giambenedetto S.1, Orani A.5, Mussini C.6, Toti M.7, d'Arminio-Monforte A.4, and the ICoNA study group Genotyping coupled with adequate interpretation in chronic naïve patients can usefully predict virologic outcomes of the initial HAART regimens.
32	F6/8 - THE Q151M MUTATION IN THE HAART ERA: ANALYSIS OF DETERMINANTS, DYNAMICS AND RESPONSE TO TREATMENTS, USING A LARGE DATA-BASE OF PATIENTS UNDERGOING GENOTYPE RESISTANCE TEST (GRT) AFTER FAILURE European AIDS Conf 2003 Oct 25-29;9:(abstract no. 32) Zaccarelli M., Perno C.F., Forbici F., Soldani F., Bonfigli S., Gori C., Trotta M.P., Bellocci M.C., Liuzzi G., D'Arrigo R., Boumis E., De Longis P., Bellagamba R., Narciso P., Antinori A. Our data indicate that many different demographic, clinical and laboratory factors can support the appearance of Q151M mutation. Salvage regimens can be effective even in presence of Q151M and limited drug options.
33	F6/9 - CLINICALLY RELEVANT INTERPRETATION OF GENOTYPE FOR RESISTANCE TO DIDANOSINE (VIDEX EC(R)) IN TREATMENT EXPERIENCED HIV INFECTED PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 33) Marcelin A.G.1, Molina J.M.2, Gaudichet A.3, Dujardin I.3, Leleu G.3, Calvez V.1 Genotype is strongly linked to viral response in NRTI-experienced patients receiving ddI. This study will help to develop a clinically relevant interpretation of genotype for ddI.
34	F7/1 - BIOLOGICAL RESPONSES AND CLINICAL PROGRESSION AND IN PATIENTS WITH VIROLOGIC FAILURE TO MULTIPLE CLASSES OF ANTIRETROVIRALS (ARV) European AIDS Conf 2003 Oct 25-29;9:(abstract no. 34) Potard V.1, Duval X.2, Dupont C.3, Pradier C.4, Duvivier C.5, Salmon D.6, Costagliola D.1 Prognosis of patients highly pre-exposed to ARV with virologic failure has improved between 1998 and 2001, mainly because of availability of new drugs with a more favourable resistance.
35	F7/2 - VIROLOGIC DETERMINANTS OF 24-WEEK EFFICACY OF ATAZANAVIR WITH OR WITHOUT RITONAVIR IN PATIENTS WITH PRIOR FAILURE ON A PROTEASE INHIBITOR European AIDS Conf 2003 Oct 25-29;9:(abstract no. 35) Zala C. (1), Lazzarin A.2, Casiro A.3, Grinsztejn B.4, Nieto L.5, Salazar R.6, Ledesma E.7, Kelleher T.8, McGovern R.8, Rightmire A.8, McLaren C.8 In extensively pretreated patients, response to atazanavir correlated positively with baseline atazanavir sensitivity and was inversely related to the number of baseline NRTI and PI viral mutations. Small subgroup numbers and differences between study populations limited these analyses.
36	F7/3 - ARE THOSE FAILING FIRST-LINE HAART THERAPY CONTAINING NELFINAVIR LESS LIKELY TO FAIL SECOND-LINE PI-CONTAINING HAART? European AIDS Conf 2003 Oct 25-29;9:(abstract no. 36) Ghani A.G.1, Kwong G.1, Le Fevre A.M.1, Gras L.2, van Sighem A.2, de Wolf F.2, Anderson R.M.1 Results suggest that the unique genotypic resistance of nelfinavir may be of little benefit to subsequent PI-containing regimens. Further analyses are required to confirm these findings.
37	F7/4 - DIDANOSINE (DDI) IN TREATMENT-EXPERIENCED HIV-INFECTED PATIENTS:RESULTS FROM A RANDOMIZED DOUBLE-BLIND STUDY (AI454-176 JAGUAR) European AIDS Conf 2003 Oct 25-29;9:(abstract no. 37) Molina J.M.1, Marcelin A.G.2, Pavie J.1, Heripret L.3, Merle de Boever C.4, David-Ouaknine F.5, Kirstetter M.2, Katlama C.2, Lucht F.6, Troccaz M.7, Dujardin I.7, Leleu G.7, Calvez V.2 In treatment-experienced pts, ddI retains significant antiviral activity, even in pts with previous exposure to ddI.
38	F7/5 - TREATMENT INTERRUPTION (TI) IN PATIENTS WITH MULTIPLE FAILURES TO ARV THERAPY: CAN THE CONTROVERSY BE SOLVED? European AIDS Conf 2003 Oct 25-29;9:(abstract no. 38) Costagliola D.1, Duvivier C.1,2, Delaugerre C.3, Dominguez S.1,2, Wirden M.3, Ghosn J.2, Calvez V.3, Peytavin G.4, Katlama C.1,2 This suggests that the key issue in the efficacy of a salvage therapy depends highly on the number of drugs remaining potentially active before any intervention.
39	F8/1 - ONE YEAR METABOLIC AND MORPHOLOGIC FOLLOW-UP OF HIV NAÏVE PATIENTS WITH OR WITHOUT TREATMENT European AIDS Conf 2003 Oct 25-29;9:(abstract no. 39) Bentata M.1, Taverna M.2, Mansouri R.1, Rouges F.1, Honore P.1, Vol S.3, Reach G.1 The decrease in HDLc in patients untreated during one year, as well as lower HDLc and higher insulin resistance in HIV patients compared to healthy subjects suggest a specific role of HIV. After a treatment of one year, we could not demonstrate a change in insulin secretion or sensitivity.
40	F8/2 - PREVALENCE OF LIPODYSTROPHY AND RETINOID SYNDROME IN A 48-WEEK RANDOMISED TRIAL TO EVALUATE SAFETY AND EFFICACY OF INDINAVIR/RITONAVIR 800/100 MG VERSUS SAQUINAVIR/RITONAVIR 1000/100 MG: THE MAXCMIN1 TRIAL European AIDS Conf 2003 Oct 25-29;9:(abstract no. 40) De Wit S.1, Wand H.3, Law M.3, Castagna A.4, Bruun J.N.5, Youle M.6, Vernazza P.7, Cassetti I.8, Benetucci J.9, Dragsted U.2, Lundgren J.D.2, on behalf of the MaxCmin1 trial group The prevalence of lipodystrophy at week 48 was similar in the IDV/r and SAQ/r arms, and was higher in females and patients with longer duration of HIV infection. Retinoid syndrome events were significantly more frequent in the IDV/r arm compared to the
41	F8/3 - FAVOURABLE INCREASES IN HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) CONCENTRATIONS IN CHRONIC HIV-INFECTED THERAPY NAÏVE SUBJECTS RECEIVING 908/R QD IN THE SOLO STUDY European AIDS Conf 2003 Oct 25-29;9:(abstract no. 41) Horban A.1, Staszewski S.2, Walmsley S.3, Pierone G.4, Sexton A.5, Stark T.6 In this chronically HIV infected ART-naïve population with low BL HDL-C, substantial increases in HDL-C combined with minimal changes in the TC/HDL-C ratio were observed following treatment with 908/r QD and NFV for 48-weeks. Similar observations were previously reported with NNRTIs.
42	F8/4 - EARLY IMPROVE OF LIPID DISTURBANCES IN HIV INFECTED PATIENTS WITH SUPPRESSED VIRAL LOAD WHO SIMPLIFIED THEIR FIRST PI-CONTAINING TREATMENT TO 3 NRTIS OR 2 NRTIS PLUS NEVIRAPINE European AIDS Conf 2003 Oct 25-29;9:(abstract no. 42) Bonjoch A.1, Gel S.1, Galvez J.2, Miralles C.3, de la Torre J.4, Prieto A.5, Viladés C.6, Márquez M.7, Mariño A.8, Miranda J.1, Peña D.9, Masabeu A.10, Pasquau J.11, Rubio M.12, Terron J.A.13, Lopez M.J.14, Knobel H.15, Clotet B.1 Both simplified therapies improved lipid abnormalities specially in TC and LDL-C in patients from their first HAART PI containing.
43	F8/5 - DYSLIPIDAEMIA IMPROVEMENT IN PATIENTS SWITCHING FROM D4T TO TENOFOVIR (RECOVER STUDY) European AIDS Conf 2003 Oct 25-29;9:(abstract no. 43) Domingo P.1, Labarga P.2, Llibre J.M.3, Guerrero M.F.4, Terrón J.A.5, Pérez Elías M.J.6, Ruíz Camps M.I.7, Moreno S.6, Sánchez de la Rosa R.8, and the RECOVER study group These data suggest that the use of tenofovir should improve the dyslipidaemia associated with D4T based regimens, while maintaining viral suppression. RECOVER study in currently ongoing in 120 Spanish centers, we schedule the follow up to 48 weeks for all patients.
44	F9/1 - RITUXIMAB AND INFUSIONAL CYCLOPHOSPHAMIDE, DOXORUBICIN, AND ETOPOSIDE (CDE) IN COMBINATION WITH HAART: A SAFE AND HIGHLY ACTIVE REGIMEN IN HIV-RELATED NON-HODGKIN'S LYMPHOMAS (NHL) European AIDS Conf 2003 Oct 25-29;9:(abstract no. 44) Spina M.1, Simonelli C.1, Vaccher E.1, Jaeger U.2, Sparano J.A.3, Tirelli U.1 The combination of Rituximab and CDE in HIV-NHL treated concomitantly with HAART is safe, feasible and active. CR rate (71%) and TTF at 2 years (63%) are comparable to those observed in high grade NHL of the general population. Supported by ISS and AIRC grants.
45	F9/2 - FACTORS CONTRIBUTING TO TUBERCULOSIS TREATMENT DEFAULTING AMONG HIV INFECTED PATIENTS IN NIGERIA European AIDS Conf 2003 Oct 25-29;9:(abstract no. 45) Uwah A.1, Oyenuga O.1, Ekong E.2, Joshua B.3 Risk factors associated with cause of TB defaulting in poor resource limited setting is multi-factorial, including societal stigma discrimination and denial, poor access of health facilities, poor counseling as well as poor service by health care providers attitudes. These factors need be addressed in order to succeed in TB and HIV/AIDS programmes.
46	F9/3 - HEPATITIS B (HBV) IN THE EUROSIDA COHORT: PREVALENCE AND IMPACT ON MORTALITY, AIDS PROGRESSION AND RESPONSE TO HAART European AIDS Conf 2003 Oct 25-29;9:(abstract no. 46) Konopnicki D.1, De Wit S.1, Antunes F., Ledergerber B., Katlama C., Zilmer K., Kirk O.2, Vella S., Mocroft A.2, Lundgren J.D.2, for the EuroSIDA Group The prevalence of HBV-HIV co-infection is 9% in the EuroSIDA cohort. HBV status does not influence virological and immunological responses to HAART but significantly increases overall and liver-related mortality.
47	F9/4 - STDS AND ONCOGENIC HUMAN PAPILLOMA VIRUS IN WARSAW HIV/PWA COHORT European AIDS Conf 2003 Oct 25-29;9:(abstract no. 47) Firlag-Burkacka E.1, Niemiec T.2, Kalinowska M.1, El Midaoui A.2, Kowalska A.2, Horban A.1, Swiecki P.1 STDs are significantly more frequent in HIV+ than in general population. HIV+ women are at high risk for cervical cancer and should be screened regardless of immune status.
48	F9/6 - CHANGING INCIDENCE OF CENTRAL NERVOUS SYSTEM (CNS) AIDS-RELATED DISEASES IN THE EUROSIDA COHORT European AIDS Conf 2003 Oct 25-29;9:(abstract no. 48) d'Arminio Monforte A.1, Cinque P.2, Mocroft A.3, Goebel F.-D.4, Antunes F.5, Katlama C.6, Justesen U.S.7, Vella S.8, Kirk O.9, Lundgren J.D.9, for the EuroSida Study Group The incidence of CNS-D across Europe decreased following the introduction of HAART, immune reconstitution being the main responsible. A direct effect of antiretroviral therapy on virus replication in CNS might have also accounted for the incidence decline in ADC.
49	F9/7 - CHANGES IN HOSPITAL ADMISSIONS ACROSS EUROPE IN 1995-2002 European AIDS Conf 2003 Oct 25-29;9:(abstract no. 49) d'Arminio Monforte A.1, Mocroft A.2, Kirk O.3, Johnson M.A., Friis-Moller N.3, Banhegyi D., Blaxhult A., Mulcahy F., Gatell J.M., Lundgren J.D.3, for the EuroSIDA study group There has been a considerable decline in both the proportion of patients admitted to hospital and the median duration of the stay.
50	F9/8 - STABLE PARTNERSHIP AND PROGRESSION TO AIDS OR DEATH IN HIV-INFECTED INDIVIDUALS RECEIVING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY: THE SWISS HIV COHORT STUDY European AIDS Conf 2003 Oct 25-29;9:(abstract no. 50) Bucher H.C. (1,10), Young J.1, DeGeest S.2, Spirig R.2, Flepp M.3, Rickenbach M.4, Furrer H.J.5, Bernasconi E.6, Hirschel B.7, Telenti A.8, Vernazza P.9, Battegay M.10 A stable partnership is associated with a slower rate of progression to AIDS or death in HIV-infected individuals receiving HAART.
51	F10/1 - HIGHER INCIDENCE OF PREMATURE CRANIOSYNOSTOSIS IN HIV-1 EXPOSED CHILDREN European AIDS Conf 2003 Oct 25-29;9:(abstract no. 51) Dunsch D.1, Königs C.1, Linde R.1, Elanjikal Z.1, Scheuplein M.1, Vlaho S.2, Faul-Burbes C.3, Haberl A.4, Kieslich M.2, Klingebiel T.1, Kreuz W.1 Our results show, that in all cases of premature craniosynostosis COV during pregnancy was given and thereafter new-borns were treated with AZT according to ACTG076. We speculate that the incidence of premature craniosynostosis in HIV-exposed children is higher than in normal population. In order to prove this hypothesis and evaluate the mechanisms further investigations on premature craniosynostosis, HIV-exposition and antiretroviral prophylaxis are necessary.
52	F10/2 - EXPERIENCE WITH EFAVIRENZ IN HIV-INFECTED CHILDREN IN SPAIN European AIDS Conf 2003 Oct 25-29;9:(abstract no. 52) Fortuny C.1, Parada E.1, De José M.I.2, Muñoz R.2, Bertran J.M.3, Ramos J.T.4, Gurbindo M.D.5, Navarro M.L.5, Mellado M.J.6, and The Pediatric Efavirenz Team Efavirenz was well tolerated among our patients and the reported results are equivalent to those obtained in other observational studies in HIV-infected children receiving protease inhibitors.
53	F10/3 - METABOLIC DISORDERS AND LIPODYSTROPHY IN A COHORT OF HIV-INFECTED CHILDREN European AIDS Conf 2003 Oct 25-29;9:(abstract no. 53) De José M.I.1, Mellado M.J.2, Bellón J.M.3, Sánchez-Torres A.M.1, Gurbindo M.D.3, Ramos J.T.4, Martín-Fontelos P.2, Muñoz M.A.3 One third of the children on HAART developed LD, directly associated with an advanced Tanner stage, high levels of LDL-cholesterol and triglycerides and antiretroviral therapy over 60 months. In our series, the association observed between LD in children and in their mothers is also noteworthy.
54	F10/4 - CONTROLLED INTERRUPTION OF HAART IN HIV-INFECTED CHILDREN European AIDS Conf 2003 Oct 25-29;9:(abstract no. 54) Fortuny C.1, Noguera A.1, Muñoz-Almagro M.C.1, Ruiz L.2, Tuset E.1, Pou J.1, Jiménez R.1 CIH in selected cases may represent a useful therapeutic strategy for HIV infection to prevent drug toxicity and should be also considered in the pediatric age.
55	F10/5 - HYPERLACTATEMIA IN HIV-UNINFECTED INFANTS PERINATALLY EXPOSED TO ANTIRETROVIRALS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 55) Noguera A.1, Fortuny C.1, Vilaseca M.A.2, Muñoz-Almagro M.C.2, Pou J.1, Jiménez R.1 In our series, 50% of the children exposed in utero or in the neonatal period to NRTIs developed hyperlactatemia, normally benign and self-limited. When symptomatic, NRTI-induced mitochondrial toxicity affected neurologic development.
56	F11/1 - CD4-GUIDED TREATMENT INTERRUPTIONS: A NEW POSSIBLE THERAPEUTIC STRATEGY European AIDS Conf 2003 Oct 25-29;9:(abstract no. 56) Mussini C.1, Cozzi-Lepri A.2, Borghi V.1, d'Arminio Monforte A.3, De Luca A.4, Sighinolfi L.5, Ortolani P.6, Barchi E.7, Guaraldi G.1, Bedini A.1, Bratt G.8, Eriksson L.8, Antinori A.9, Cossarizza A.1, Esposito R.1 Patients on HAART can safely discontinue treatment for a long period of time in presence of: a CD4 nadir > 350 cells/mL, an undetectable VL on treatment for more than 12 months, a pre-treatment tendency to a slow CD4 decline and a low VL rebound after discontinuation.
57	F11/2 - PHYSICIAN SUPERVISED THERAPY INTERRUPTIONS IN DAILY PRACTICE European AIDS Conf 2003 Oct 25-29;9:(abstract no. 57) Klausen G.1, Dupke S.2, Schlote F.3, Mayr C.4 During PSTI in our group no opportunistic infections occurred. The decrease of CD4-Cells and the increase of viral load were the highest in the patients who had started ART with few CD4 cells and/or with a high viral load. The results for absolute and relative CD4 cells only partially correlate. After restart of therapy in the group of patients with formerly effective HAART, viral load decrease and CD4 cell increase are slow.
58	F11/3 - THE FINAL WEEK 48 ANALYSIS OF A PHASE IV, RANDOMISED, OPEN-LABEL, MULTI-CENTRE TRIAL TO EVALUATE SAFETY AND EFFICACY OF LOPINAVIR/RITONAVIR (400/100 MG BID) VERSUS SAQUINAVIR/RITONAVIR (1000/100 MG BID): THE MAXCMIN2 TRIAL European AIDS Conf 2003 Oct 25-29;9:(abstract no. 58) Youle M., Gerstoft J., Fox Z., Losso M., Jayaweera D.T., Rieger A., Bruun J.N., Castagna A., Walmsley S., Hill A., Dragsted U.B., Lundgren J.D., for the MaxCmin2 trial group More patients in the SAQ/r arm experienced virological failure (ITT/e) as compared to the LPV/r arm. The clinical toxicity profile was comparable between the two arms, but more patients discontinued SAQ/r due to patients' choice.
59	F11/4 - SLOPE OF VIRAL LOAD DECLINE AND STEADY STATE PHARMACOKINETICS OF SPD754 MONOTHERAPY ADMINISTERED ONCE OR TWICE DAILY IN TREATMENT-NAÏVE HIV+ INDIVIDUALS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 59) Cassetti I.1, Cahn P.2, Adams J.3, Phanuphak P.4, Sawyer J.5, Anderson C.6, Shiveley L.6 SPD754 has predictable pharmacokinetics, is well tolerated and highly effective against HIV-1.
60	F11/7 - RESPONSE TO POTENT ANTIRETROVIRAL TREATMENT AND PROGNOSIS OF HIV-1 INFECTION: HOW SHOULD RESPONSE BE DEFINED? European AIDS Conf 2003 Oct 25-29;9:(abstract no. 60) Grabar S.1,2, Le Moing V.3, Egger M.4, Goujard C.5, Leport C.6, Kazatchkine M.D.7, Weiss L.7, Costagliola D.1 Both HIV-1 RNA and CD4 cell count should be taken into account independently when evaluating early treatment response. The persistent impact of early response on clinical progression at 5 years emphasizes the major importance of success of first-line HAART.
61	F12/1 - MULTIDRUG-RESISTANT TUBERCULOSIS AND HIV INFECTION.A REVIEW CONCERNING 152 PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 61) Maltez F.1, Peres H.2, Machado J.1, Pina T.2, Cardoso O.1, Rodrigues P.1, Martins T.1, Correia F.1, Serrano A.1, Rodrigues A.1, Gonçalves P.1, Silvestre M.2 In our cohort MDR TB was prevalent mainly in injecting drug users due to poor social assistance and adherence and occurred in advanced immunodeficiency with unfavorable outcome. The more rapid case suspicion and identification, improved isolation practices and use of DOTS strategy have contributed to a reduced incidence in recent years.
62	F12/2 - PROFOUND REDUCTION OF THE DIAGNOSTIC SENSITIVITY OF JCV DNA IN CSF FOR AIDS-ASSOCIATED PROGRESSIVE MULTIFOCAL LEUOKOENCEPHALOPATHY (PML) IN THE HAART ERA European AIDS Conf 2003 Oct 25-29;9:(abstract no. 62) Di Giambenedetto S., Cingolani A., Marzocchetti A., Larussa D., Ammassari A., Cauda R., De Luca A. HAART decreased yield of JCV in PML ; nPCR and repeated LP has become an insufficiently sensitive approach for the diagnosis of PML. Brain biopsy may newly be considered an option in case of PML suspect and repeatedly negative CSF assays.
63	F12/3 - INCREASING INCIDENCE OF ACUTE HEPATITIS C IN HIV POSITIVE MEN SECONDARY TO SEXUAL TRANSMISSION, EPIDEMIOLOGY AND TREATMENT European AIDS Conf 2003 Oct 25-29;9:(abstract no. 63) Nelson M., Browne R., Asboe D., Gilleece Y., Atkins M., Gazzard B. In recent months we have seen an epidemic of acute hepatitis C, probably sexually transmitted with individuals reporting unsafe sex and higher rate of recent syphilis infection. High percentage of individuals seroconvert spontaneously. Treatment response to interferon is lower than in HIV negative population.
64	F12/4 - INFLUENCE OF HEPATITIS C COINFECTION ON HIV DISEASE PROGRESSION WITHIN THE EUROSIDA COHORT European AIDS Conf 2003 Oct 25-29;9:(abstract no. 64) Rockstroh J.1, Mocroft A.2, Soriano V.3, Tural C.4, Losso M.5, Reiss P.6, Machala L.7, Kirk O.8, Ledergerber B.9, Lundgren J.D.8, for the EuroSIDA study group 1/3 of HIV-infected patients in the EuroSIDA Cohort are coinfected with HCV. HCV-coinfection doesn't influence virological and immunologic response to HAART. HCV-positive patients however, experience a higher mortality rate due to liver disease related causes.
65	F12/5 - SURVIVAL IN HIV-INFECTED INDIVIDUALS FOLLOWING LIVER TRANSPLANTATION IS INFLUENCED BY VIRAL CO-INFECTION: THE NEGATIVE IMPACT OF HCV INFECTION European AIDS Conf 2003 Oct 25-29;9:(abstract no. 65) Norris S.2, Taylor C.1,Mc Donald C.1, O'Grady J.2, Portmann B.C.2, Knisely A.S.2., Bowles M.2, Muiesan P.2, Rela M.2, Heaton N.2 Long-term outcome of LT in HIV-infected patients with HBV or other causes of chronic liver disease indicates that this is an acceptable therapeutic option for these patients. However, the long-term prognosis of HCV-HIV co-infected patients must remain guarded.
66	F14/1 - PROTECTION OF MACAQUES FROM SHIV BY DNA AND RECOMBINANT FOWLPOXVIRUS VACCINES: PHENOTYPE AND DYNAMICS OF THE T-CELL IMMUNE RESPONSE European AIDS Conf 2003 Oct 25-29;9:(abstract no. 66) Stratov I.1, Dale C.J.1, De Rose R.1, Chea S.1, Purcell D.F.J.1, Ramshaw I.A.2, Thomson S.2, Boyle D.B.3, Coupar B.3, Ramsay A.J.4, French R.5, Law M.5, Emery S.5, Cooper D.A.5, Kent S.J.1, for the Australia Thai HIV Vaccine Conso Our 2xDNA+1xrFPV prime/boost vaccine regimen elicits strong, early CD4+ followed by CD8+ responses, facilitating control of pathogenic SHIV challenge in macaques. These characteristics are potentially advantageous for a candidate vaccine against HIV.
67	F14/2 - THERAPEUTIC VACCINATION WITH MVA-HIV-1 NEF ELICITS NEF SPECIFIC T-HELPER CELL RESPONSES IN CHRONICALLY HIV-1 INFECTED INDIVIDUALS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 67) Cosma A.1, Nagaraj R.1, Bühler S.2, Hinkula J.3, Busch D.H.4, Sutter G.1,2, Goebel F.D.5, Erfle V.1,2 The strong Nef specific CD4 T-cell response elicited by MVA-nef vaccination provides a rationale for immunotherapeutic interventions in HIV infected individuals with suppressed CD4 T-cell responses. Moreover, the CD4 T-cell response elicited was comparable with that usually detected in long-term non-progressor (LTNP) suggesting an improvement in the immunological status of the vaccinated subjects. Furthermore, the new putative CD4 epitopes described here hold promise as important tools for epitope-based vaccination.
68	F14/3 - CD4 COUNT INCREASES IN PATIENTS WITH CD4 COUNTS OF 50-300 TREATED WITH INTERMITTENT IL-2: IMMUNOLOGIC RESULTS FROM THE STUDY OF IL-2 IN COMBINATION WITH ACTIVE ANTIRETROVIRAL THERAPY (SILCAAT) TRIAL European AIDS Conf 2003 Oct 25-29;9:(abstract no. 68) Levy Y., Mitsuyasu R., Tambusi G., Clotet B., Cahn P., Routy J.P., Cooper D., Hengge U., Levi G., Lange J., Emery S., Darbyshire J., Lundgren J., Lane C., Neaton J., for the SILCAAT scientific committee In the setting of a large trial, patients with low CD4 counts (50-299) receiving IL-2 showed a substantial (60%) increase in CD4 counts after 1 year. Whether or not these increases translate to clinical benefit will be determined through the long-term follow-up of this cohort.
69	F16/1 - ARE THE EARLY MANIFESTATIONS OF LIPODYSTROPHY PREDICTED BY SERUM TRIGLYCERIDE LEVEL IN PATIENTS RECEIVING ANTIRETROVIRAL THERAPY? European AIDS Conf 2003 Oct 25-29;9:(abstract no. 69) Galli M., Cozzi-Lepri A., Ridolfo A.L., Cappelletti A., Morelli P., Gianelli E., Piazza M., Mazzotta F., Montoni M., Tirelli U., Cargnel A., d'Arminio Monforte A., Gervasoni C., Moroni M., for the LipoICoNa Study Group, Italy Triglyceride levels seem to predict early LA manifestations in first-line treated patients while specific antivirals appear to play a minor role. Factors associated with LH are confirmed to be different from factors predicting LA.
70	F16/2 - GYNECOMASTIA IN HIV-INFECTED MEN UNDERGOING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY: ASSOCIATION WITH EFAVIRENZ AND DIDANOSINE TREATMENT European AIDS Conf 2003 Oct 25-29;9:(abstract no. 70) Mira J.A.1, Lozano F.2, Santos J.3, Ramayo E.4, Terrón A.5, León E.2, Palacios R.3, Macías J.1,2, García-García J.A.1, Pineda J.A.1,2 The frequency of gynecomastia in HIV-infected men undergoing HAART is considerable. Our findings show that the gynecomastia has a relationship with efavirenz and didanosine treatment. There is no association with hormone abnormalities.
71	F16/3 - LIVER MITOCHONDRIAL ABNORMALITIES ASSOCIATED WITH HCV-MONOINFECTION, HIV-HCV-COINFECTION, AND ANTIRETROVIRAL THERAPY IN A COHORT OF 68 ADULT PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 71) Calza L., Verucchi G., Biagetti C., Attard L., Costigliola P., Manfredi R., Chiodo F. In our study, mitochondrial alterations were more common in HIV-HCV-coinfected subjects, and HCV genotype 1b was more frequently associated with inclusions or crystals.
72	F16/4 - INCREASE IN MITOCHONDRIAL DNA IN PBMCS AND IMPROVEMENT OF LIPIDIC PROFILE AND LACTATE LEVELS IN PATIENTS WITH LIPOATROPHY WHEN STAVUDINE IS SWITCHED TO TENOFOVIR European AIDS Conf 2003 Oct 25-29;9:(abstract no. 72) Ribera E.1, Sauleda S.2, Paradiñeiro J.C.1, Tejeda M.2, Andreu A.L.3, Marti R.3, Garcia-Arumi E.3, Crespo M.1, Falcó V.1, Ocaña I.1, Pahissa A.1 Switching from stavudine to tenofovir was well-tolerated and virological and immunological success was maintained. Patients showed improvement of the lipidic profile, decrease in lactate levels and amelioration of mtDNA depletion in PBMCs.
73	F16/5 - SAFETY AND TOLERABILITY OF DIDANOSINE COMBINED WITH TENOFOVIR DF IN AMBULATORY HIV-1 INFECTED ADULT INDIVIDUALS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 73) Young B.1, Baker R.2, Wood K.2, and the HIV Outpatient Study (HOPS) Investigators HD ddI/TDF is associated with more frequent drug-related toxicity and frequent treatment discontinuation. By contrast, LD ddI/TDF appears generally well tolerated in this cohort of HIV infected persons.
74	1.1/1 - HIGH LEVELS OF PRIMARY ANTIRETROVIRAL GENOTIPIC RESISTANCE AND B/F RECOMBINANTS IN SANTOS SP, BRAZIL European AIDS Conf 2003 Oct 25-29;9:(abstract no. 74) Sucupira M.C.1,2, Tescarollo G.1, Janini M.1, Caseiro M.M.1, Alves K.3, Sabino E.C.4, Castelo-Filho A.1, Page-Shafer K.3, Diaz R.S.1 Primary resistance was extremely high in this population, including the presence of MDR strains, probably due to the long term use of antiretrovirals in this area of Brazil. A high prevalence of HIV-1 B/F recombinant strains was detected.
75	1.1/2 - THE IDU-A GENETIC VARIANT PREDOMINATES AMONG NEWLY DIAGNOSED HIV-1 CASES TRANSMITTED HETEROSEXUALLY IN RUSSIA European AIDS Conf 2003 Oct 25-29;9:(abstract no. 75) Sukhanova A.L.1, Kazennova E.V.2, Bobkova M.R.1, Selimova L.M.2, Pokrovsky V.V.1, Bobkov A.F.2 The IDU-A predominates among newly diagnosed cases of HIV-1 infections transmitted heterosexually in Russia demonstrating expansion of IDU-A into other risk groups. In contrast, HIV-1 epidemic among MHSM is spreading separately from that among IDUs and heterosexual infections.
76	1.1/3 - INCREASING PREVALENCE OF HIV-1 NON-B SUBTYPES IN GREECE European AIDS Conf 2003 Oct 25-29;9:(abstract no. 76) Paraskevis D.1, Magiorkinis E.1, Katsoulidou A.1, Smpiliris M.1, Ntziora F.1, Magiorkinis G.1, Gargalianos P.2, Lazanas M.3, Paparizos V.4, Panos G.5, Antoniadou A.6, Karafoulidou A.7, Hatzakis A.1, for the Hellenic Multicenter Study on HIV-1 Heterogeneity The prevalence of non-B subtypes in Greece is higher than other Southern European countries, and it has significantly increased the recent years.
77	1.1/4 - HIV-1 B/F RECOMBINANT FORMS IN SOUTHERN PORTUGAL: IDENTIFICATION OF A CLUSTER OF HIV-1 TRANSMISSION European AIDS Conf 2003 Oct 25-29;9:(abstract no. 77) Abecasis A.1, Carvalho A.P.1, Vera J.2, Cabanas J.1, Diogo I.1, Gonçalves M.F.1, Lobo M.C.1, Gomes P.1, Camacho R.1 In spite of having sequenced only part of the pol gene, data analysis suggests that several unique B/F recombinant forms are circulating in Southern Portugal and a cluster of transmission with a common recombinant form was identified. Further studies are required to evaluate the possibility of a new CRF_BF.
78	1.1/5 - MOLECULAR EPIDEMIOLOGY OF HIV-1 INFECTION IN SOUTHERN PORTUGAL: RESULTS OF A 92 WEEKS SURVEY European AIDS Conf 2003 Oct 25-29;9:(abstract no. 78) Carvalho A.P., Gomes P., Diogo I., Gonçalves M.F., Cabanas J., Abecasis A., Lobo M.C., Camacho R. A predominance of subtype G infections in patients diagnosed more recently or vertically infected was observed. The higher rate of women infected with subtype G can eventually be linked to an increased heterosexual transmission of this HIV-1 variant in Portugal. Due to it's implications on epidemiology, laboratory tests accuracy, natural history, or treatment response, this situation must be monitored by Portuguese Health Authorities.
79	1.2/1 - CC-CHEMOKINE RECEPTOR 5 (CCR5) GENOTYPING WITHOUT DNA EXTRACTION BY LIGHTCYCLER REAL-TIME PCR European AIDS Conf 2003 Oct 25-29;9:(abstract no. 79) Nischalke H.D., Nattermann J., Lichterfeld M., Woitas R., Rockstroh J., Sauerbruch T., Spengler U. We have established a new real-time PCR protocol, which enables fast, cost-saving, and reliable CCR5 genotyping.
80	1.2/2 - THE SCORPION VENOM MODEL OF AIDS : DEFENSIN ALPHA IS HOMOLOGUS TO HIV 1 NEF IN THREE DIMENSIONS (3D). TACRINE WITH SYLIMARIN AS A RESCUE FOR FAILURE AND HIV 1 CHEMORESISTANCE European AIDS Conf 2003 Oct 25-29;9:(abstract no. 80) Tran M.K.G.1, Caprani A. (2 ), Kirkiacharian S.3, Nguyen D.X.3, Maurisson G.4 In conclusion, Nef and alpha defensin superimposed on each other in 3D, suggesting that the alpha defensin protection is a competitive inhibition with Nef. Thus the scorpion venom model of AIDS (Tran M.K.G., 1989) is confirmed and this strongly boosts the clinical use of tacrine. A case of multitherapy arrest with cytomegalovirus was switched to tacrine associated with silymarin with T4 increase in one month from 80 to 120 and a fall of viral load from 150.000 to 40.000; the hepatoprotection conferred by sylimarin permits the avoidance of any severe liver damage & the tacrine efficiency permitted at least a therapeutic window with possible resensibilisation.
81	1.2/3 - THE EFFECT OF PHENOTYPIC HIV PROPERTIES UPON NON-SPECIFIC SYSTEM OF INFLAMMATORY REACTIONS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 81) Papuashvili M. The combined definition of ITI and UTI lets to estimate the prognosis of disease. The slump decreasing of ITI level in serum at the terminal stages (C1-C3) of HIV-infection may indicate to exhaustion of organism protecting resources and leads to catastrophic reduction of system efficiency with inflammatory reactions. Recently we have shown that a low production of another serine protease inhibitor (alpha1-antitrypsin) was connected with the progression of HIV-infection.
82	1.2/4 - DEVELOPMENT OF A RETROVIRAL VECTOR FOR PROTECTION OF T CELLS FROM HIV INFECTION European AIDS Conf 2003 Oct 25-29;9:(abstract no. 82) Martinius H.1, Egelhofer M.1, Brandenburg G.1, Schult-Dietrich P.1, Baum C.2, Alexandrov A.3, von Laer D.1 In conclusion, the antiviral potency of M87 was increased and the potential immunogenicity decreased to a level that warrants introduction of the optimized vector M87o into the clinic.
83	1.4/1 - REPLICATIVE FITNESS OF HIV-1 VARIANTS AFTER SERIAL PASSAGES IN THE PRESENCE OF ANTIRETROVIRAL DRUGS IN MT-4 CELLS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 83) Selimova L., Khanina T., Galegov G. If extrapolated to the clinical practice, these results indicate that all drug cocktails were effective inhibitors of HIV-1 replication because virus variants with high replicative activity were not emerged.
84	2.1/1 - THE HIV T CELL EPITOPE P24 AA14-21 STABILIZES HLA-E EXPRESSION RESULTING IN IMPAIRED CYTOTOXIC FUNCTION OF NATURAL KILLER CELLS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 84) Nattermann J.1, Nischalke H.D.1, Feldmann G.1, Hofmeister V.2, Rockstroh J.1, Weiß E.2, Sauerbruch T.1, Spengler U.1 Our data suggest that the T cell epitope HIV p24 aa14-21 can alternatively bind to HLA-E, thus strengthening interactions of HLA-E with inhibitory CD94/NKG2A receptors. This dual recognition of a major T cell epitope may contribute to reduced NK cell activity in HIV infection.
85	2.1/2 - EFFECTS ON HIV-1 REPLICATION IN MONOCYTIC CELLS BY HMGB-1 European AIDS Conf 2003 Oct 25-29;9:(abstract no. 85) Nowak P., Abdurahman S., Treuitiger C.-J., Andersson J., Sonnerborg A. HMGB-1 plays a complex role in HIV-1 infection and our data suggest that release of HMGB-1 interferes with viral replication in monocytes but not in lymphocytes.
86	2.1/3 - CELL SURFACE EXPRESSION OF CD81 IS DOWNREGULATED AT THE TRANSCRIPTIONAL/TRANSLATIONAL LEVEL ON CD4+ LYMPHOCYTES IN HIV-1 INFECTED PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 86) Meroni L., Milazzo L., Ammannato S., Mazzucchelli R., Manganaro D., Galli M., Riva A. CD81 downregulation on CD4+ T lymphocytes in HIV-1 positive patients might determine a disregulation of the immune system and favour acceleration of HCV disease because of a reduction of γIFN production and weakness of CTL specific response. Upregulation of CD81 mRNA indicates that downregulation of CD81 protein occurs at the post transcriptional/translational level.
87	2.3/1 - HIGHLY PURIFIED N-ACETYL C14-MANNOSE-AMINE [14C-NACMAN] HIV-1 - A TOOL FOR STUDY OF SOME ASPECTS OF NEUTRALIZATION PROCESS IN HIV-INFECTION European AIDS Conf 2003 Oct 25-29;9:(abstract no. 87) Gavazova R.1, Ivanov S.1., Ivanov D.1, Antonova M.1, Argirova R.2 We created a tool - 14C-NacMan-HIV-1 to study a number of aspects of neutralization process in HIV-1 infection under experimental conditions.
88	2.7/1 - IMMUNE RECONSTITUTION ON TREATMENT OF HIV-INFECTED PATIENTS WITH PHOSPHAZID, DIDANOSINE AND SAQUINAVIR/RITONAVIR ONCE DAILY IN RUSSIA European AIDS Conf 2003 Oct 25-29;9:(abstract no. 88) Sitdykova Y.R., Serebrovskaya L.V., Kravchenko A.V. After 24 weeks of therapy viral load significantly decreased, CD4+ T-cell count and CD4\CD8 ratio increased. We also observed a decline in CD3+HLA-DR+ cells (activated) and a rise in CD19 cells. CD16(56) level didn't change.
89	2.7/2 - GENITAL HERPES SIMPLEX AS AN IMMUNE RECONSTITUTION SYNDROME FOLLOWING INITIATION OF HAART European AIDS Conf 2003 Oct 25-29;9:(abstract no. 89) Thevarajan I., Chiu C., O'Donahue N., Fuller C., Easterbrook P. Immune reconstitution with HAART result in worsening of HSV particularly in Black Africans.
90	3.1/1 - GENOTYPIC ANTIRETROVIRAL RESISTANCE AFTER FIRST PI FAILURE: PRELIMINARY DATA OF THE BRAZILIAN NETWORK FOR GENOTYPIC RESISTANCE European AIDS Conf 2003 Oct 25-29;9:(abstract no. 90) Diaz R.S.1, Souza I.E.L.1, Fusuma E.1, Arakaki D.2, Dantas M.C.2, Tanuri A.3, Lima J.N.2 TAM leaded to a high prevalence of cross resistance to NRTI, and to Tenofovir. Resistance to DDI was rare. We found higher prevalence of efavirenz sensitivity compared to nevirapine. Half o patients failing to nelfinavir with limited chances of salvage by other PI, and relative high prevalence of cross resistance to lopinavir was found. The Brazilian Genotyping Network, together with free universal access of ARV and viral load/CD4 networks, may constitute an advance for AIDS patients management in Brazil.
91	3.1/2 - CHARACTERIZING EVOLUTION OF PROTEASE INHIBITOR (PI) RESISTANCE DURING LOPINAVIR/RITONAVIR (LPV/R) TREATMENT AND STUDY OF THE SALVAGE OF LOPINAVIR RESISTANCE (SOKRATES TRIALS) European AIDS Conf 2003 Oct 25-29;9:(abstract no. 91) Cernohous P., King M., Kempf D., Travers N., Moseley J., da Silva B., Brun S. Development of PI resistance when LPV/r is used as initial PI therapy has not been observed to date in clinical trials and is likely a rare event based on the sample size evaluated. Results from the surveillance program support these observations.
92	3.1/3 - TRANSMITTED RESISTANT MUTATIONS IN A COHORT OF RECENT SEROCONVERTERS IN ITALY: TEMPORAL PATTERN AND PREVALENCE ACCORDING TO HIV-1 SUBTYPE European AIDS Conf 2003 Oct 25-29;9:(abstract no. 92) Riva C.1, Violin M.1, Cozzi-Lepri A.2, Velleca R.1, Forbici F.3, Novati R.4, Castelli F.5, Bonasso M.6, Colangeli V.7, Rezza G.8, Ippolito G.3, Perno C.F. (3,9), d'Arminio Monforte A.1, Moroni M.1, Balotta C.1, for the I.Co.N.A. Study Group These data show no evidence for an increase of resistant mutations over the period 1996-2001 in seroconverters in Italy. A tendency for an increase of patients infected with non-B clades were observed in heterosexuals and women. Minor PR mutations at position 10 and 36, that may influence the virological outcome during HAART, are significantly more represented in non-B compared to B subtypes.
93	3.1/4 - TEMPORAL PATTERNS IN THE RATE OF TRANSMITTED RESISTANCE European AIDS Conf 2003 Oct 25-29;9:(abstract no. 93) Green H.1, Pozniak A.2, Porter K.1, on behalf of the UK Collaborative Group on HIV Drug Resistance and the UK Register of HIV Seroconverters The prevalence of resistance in untreated patients appears to be stabilising. Little difference is observed in prevalence of resistance when comparing drug naïve individuals with a smaller group of seroconverters. This suggests that surveillance of chronically infected drug naïve patients may be useful for monitoring transmitted drug resistance.
94	3.1/5 - TREND IN GENOTYPIC RESISTANCE AMONG PATIENTS FOLLOWED IN A LARGE COMMUNITY CLINIC: CONSEQUENCES ON DRUG RESISTANCE (DR) TRANSMISSION European AIDS Conf 2003 Oct 25-29;9:(abstract no. 94) Thomas R.1, Machouf N.1,2, Routy J.P.2, Trottier B.1, Wainberg M.3 Despite an increase in the prevalence of resistance, the overall level of viremia has decease. The decrease fitness of drug resistant mutations and the lower level of viremia may explain the decrease of drug resistance transmission observed in Montreal since 2001.
95	3.1/6 - THE RISING PREVALENCE OF ART RESISTANCE MUTATIONS IN NAÏVE PATIENTS WITH HIV/AIDS IN A UK COHORT European AIDS Conf 2003 Oct 25-29;9:(abstract no. 95) MacRae E.1, Loveday C.1, Johnson M.2, and on behalf of the ICVC Collaborative Research Group Mutations involving all 3 drug classes prior to ART are evident here. Surveillance is continuing.
96	3.1/7 - HORIZONTAL TRANSMISSION OF NNRTI RESISTANCE BETWEEN TWO PATIENTS WITH RECENT HIV INFECTION European AIDS Conf 2003 Oct 25-29;9:(abstract no. 96) Kinloch S.1, MacRae E.2, Johnson M.A.1, Loveday C.2 Horizontal transmission of K103N occurred in these patients naïve to HAART. Incidence of NNRTI resistance should continue to be routinely monitored in recently-infected patients as it has major implications in the choice of first-line therapy.
97	3.2/1 - NNRTI RESISTANCE MUTATION PATTERN OF NON-B HIV-1 STRAINS AMONG PATIENTS WHO HAVE FAILED ANTIRETROVIRAL THERAPY European AIDS Conf 2003 Oct 25-29;9:(abstract no. 97) Lehtola-Vanhanen L.1, Zetterberg V.2, Sutinen J.1, Liitsola K.2, Suni J.3, Salminen M.O.2, Ristola M.1 Statistically significant differences were found in the frequency of mutations K103N and Y190A/S between subtypes for patients known to have received nevirapine (NVP) as their NNRTI treatment. K103N in subtype B and Y190A/S in non-B subtypes were the mutations most frequently found. It seems that NVP exposure selects for different resistance mutation patterns in patients infected with either B or non-B HIV-1 strains.
98	3.2/2 - IN SILICO APPROACH TO SUPPORT PREDICTION OF HIV-1 PROTEASE DRUG RESISTANCE POSITIONS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 98) Zimmer J.-M.1,2, Boutonnet N.3, Lasters I.3, De Maeyer M.4, Vandamme A.-M.2, Schmit J.-C.1 The identified amino acid positions being more prevalent in treated patients were exclusively located in proximity of the HIV-1 PR active site. Therefore, these positions are most likely involved in resistance through alterations in ligand-protein interactions.
99	3.2/3 - MUTATIONAL PATTERNS AND QUANTITATIVE PHENOTYPIC RESISTANCE PROFILE ASSOCIATED WITH ALLELES Q/E, N AND R AT POSITION 219 IN REVERSE TRANSCRIPTASE IN A LARGE DATASET OF RECENT HIV-1 CLINICAL ISOLATES European AIDS Conf 2003 Oct 25-29;9:(abstract no. 99) Van Houtte M.1, McKenna P.1, Lecocq P.1, Bacheler L.2 K219N and K219R are more prevalent in certain NAM combinations and are associated with the highest levels of NRTI-resistance. These variants should be considered when evaluating drug resistance.
100	3.3/1 - UNUSUAL MUTATIONS AT HIV-1 RT CODON 103 CAUSE NNRTI RESISTANCE European AIDS Conf 2003 Oct 25-29;9:(abstract no. 100) Harrigan P.R.1,2, Wynhoven B.1, Montaner J.1,2, Pattery T.3, McKenna P.3, Vingeroets J.4, Bacheler L.5 Variants at position 103 other than K103N are relatively rare in clinical isolates. Some (including K103S, H, and T) confer decreased susceptibility to NNRTIs. K103S has increased > 4 fold since 1998.
101	3.3/2 - COST/LABOR STUDY OF LINE PROBE ASSAY AND DNA SEQUENCING FOR DETECTION OF HIV-1 DRUG RESISTANCE MUTATIONS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 101) Goubau P.1, Kabamba Mukadi B.1, Decruyenaere F.1, Buyens C.1, Bodéus M.1, Laurent C.2, Dewaele K.3 Direct sequencing homebrew method and Versant HIV Resistance Assay System give concordant results for most clinical isolates. Versant HIV Resistance Assay System is rapid, more sensitive for the detection of mixed virus populations but detects a limited number of mutations while sequencing has a low reagent cost but much hands-on time.
102	3.3/3 - EXAMINATION OF THE APPLICABILITY OF THE ABBOTT M 1000&trade' AUTOMATED EXTRACTION SYSTEM FOR PREPARATION OF RNA FOR THE CELERA DIAGNOSTICS VIROSEQ(TM) HIV-1 GENOTYPING SYSTEM European AIDS Conf 2003 Oct 25-29;9:(abstract no. 102) Hackett J.Jr.1, Swanson P.1, Kowal R.1, Holzmayer V.1, Devare S.G.1, Marlowe N.2, Gundling G.J.1 These data demonstrate the feasibility of using m 1000-extracted RNA for both viral load analysis and HIV genotyping. Use of the fully automated m 1000 System has the potential to significantly enhance throughput while reducing labor costs.
103	3.4/1 - PRIMARY RESISTANCE IN HIV CHILEAN PATIENTS: GENOTYPIC ASSAY European AIDS Conf 2003 Oct 25-29;9:(abstract no. 103) Afani A.1, Meyer A.1, Ayala M.1, Acevedo W.1, Cabrera R.2 This is the first study of primary resistance in HIV Chileans patients. Primary mutations associated with NRTI, NNRTI, or PI resistance were not found in antiretroviral-naïve adults. Secondary mutations were identify in this group, which could contribute to the resistance in the future.
104	3.4/2 - EXTENSIVE ANALYSIS OF SUBSTITUTIONS IN THE HIV-1 REVERSE TRANSCRIPTASE GENE FROM A COHORT OF HEAVILY PRE-TREATED PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 104) Torti C.1, Tirelli V.1, Quiros-Roldan E.1, Scudeller L.2, Lo Caputo S.3, Moretti F.1, Mazzotta F.3, Carosi G.1 High prevalence of newly recognised and non canonical substitutions at resistance positions in the RT have been found, implying that resistance may have been missed by current genotypic rules. Further studies are urgently needed to investigate the possible clinical impact of these genotype variations as this may change current interpretation algorithms.
105	3.4/3 - COMPARISON OF QUANTITATIVE PLASMA HIV-1 RNA ASSAYS IN PATIENTS WITH CLADE B AND NON-CLADE B SUBTYPES European AIDS Conf 2003 Oct 25-29;9:(abstract no. 105) Vardinon N., Yust I., Sela Y., Werner B., Zeldis I., Zackut V., Burke M. In regions where non-clade B subtypes are prevalent, it is essential to employ a method of viral load assessment detects all clades.
106	3.4/4 - PREVALENCE, PATTERN, CONCORDANCE AND IMPACT OF HIV-1 GENOTYPIC (GR) AND PHENOTYPIC RESISTANCE (PR) TESTING IN ROUTINE CLINICAL CARE European AIDS Conf 2003 Oct 25-29;9:(abstract no. 106) Hirsch H.H.1, Hamy F.2, Sendi P.1, Kaufmann G.1, Klimkait T.2, Battegay M.1 In clinical routine care for HIV-patients failing ART, GR and PR provide largely concordant results. However, active combinations according to phenotypic testing may be associated with a better outcome, particularly in heavily pretreated patients. This data requires validation in cohort studies.
107	3.4/5 - NUCLEOSIDE ANALOGUE MUTATIONS (NAMS) COMPROMISE RESCUE/SALVAGE OF DUAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NRTI) TREATMENT FAILURES WITH DUAL CLASS REGIMENS CONTAINING NEW NRTIS AND A PROTEASE INHIBITOR European AIDS Conf 2003 Oct 25-29;9:(abstract no. 107) Shivaprakash M.1, Santos B.2, Rosenthal C.3, Szumiloski J.1, Condra J.1, for BASIC study team The presence of NAMs at the institution of rescue/salvage with a regimen consisting of indinavir + nucleoside analogues compromised treatment efficacy. This was especially evident in the presence of T215, M41, and D67 substitutions when the nucleoside switches retained a thymidine analogue, i.e. ZDV to d4T or d4T to ZDV. In these situations, the protease inhibitor component of the rescue regimen appeared to primarily account for treatment effect.
108	3.4/6 - CONCORDANCE OF RESISTANCE ALGORITHM INTERPRETATIONS IMPROVED OVER THE LAST TWO YEARS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 108) Schmit J.C.1, Gonzalez D.2, Boulmé R.2 Algorithms largely agreed on tenofovir interpretations (0.81 resp. 0.77) in 2003. Adding the Rega algorithm to the analysis in 2003 did not change significantly Ks, except for tenofovir (from 0.81 to 0.48, I=S). Concordance between interpretations has improved, mainly due to a better interpretation of TAMs and of the never PI lopinavir. However, didanosine and stavudine resistance remains problematic, and agreement for abacavir is still moderate.
109	3.4/7 - ONE YEAR FOLLOW UP OF AN ACUTE HIV-INFECTION CAUSED BY A MULTI DRUG RESISTANT HIV-1 SUBTYPE B STRAIN: ANALYSIS OF THE COURSE OF VIRAL LOAD, RESISTANCE PATTERN, AND CD4-CELL COUNT European AIDS Conf 2003 Oct 25-29;9:(abstract no. 109) Berg T.1, Schlote F.2, Neifer S.1 The level of resistance to the different drugs varied between high and low. The course of viral load and CD4+-cell count differed slightly: to 16 copies/µl with 421 CD4+-cells and t13month 36 copies/µl with 493 DD4+-cells. We could show the transmission of a replication competent MDR virus via sexual transmission. The spread of MDR viruses could undermine the success of HAART and is a real threat for the future of HIV-positive patients.
110	3.4/8 - GENOTYPIC RESISTANCE PROFILES AT INITIAL REBOUND DURING THERAPY WITH ZIDOVUDINE + LAMIVUDINE + ABACAVIR IN ANTIRETROVIRAL TREATMENT naïve HIV-1 INFECTED PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 110) Marcelin A.G.1, Bugnon F.2, Astriti M.1, Ferré V.2, Boubezari I.1, Agher R.1, Katlama C.1, Calvez V.1, Raffi F.2 This study confirms that virological blips or failures observed in naïve patients receiving zidovudine + lamivudine + abacavir were mostly associated with the emergence of WT viruses or M184V mutation alone.
111	3.4/9 - UNIVERSAL PROTEASE ASSOCIATED MUTATIONS (UPAMS) ARE RESPONSABLE FOR LOPINAVIR/RITONAVIR (LPV/R)-BASED HAART-FAILURE - ANALYSIS OF 79 PATIENTS BASED ON GENOTYPING European AIDS Conf 2003 Oct 25-29;9:(abstract no. 111) Postel N.1, Wolf E.2, Ruemmelein N.1, Buchberger A.2, Jaegel-Guedes E.1,2, Jaeger H.1,2,3 Combinations of at least 5 LPV-ass.-mutations lead to reduced efficacy of LPV/r-based HAART. UPAMs are significantly associated with virological failure in a LPV/r-based therapy.
112	3.4/10 - RESISTANCE ANALYSIS HELPS TO SPARE ANTIRETROVIRAL SUBSTANCES IN PRETREATED PATIENTS - SUBANALYSIS OF THE RADATA-PROJECT European AIDS Conf 2003 Oct 25-29;9:(abstract no. 112) Plettenberg A., Meyer P., Graefe K., Stoehr A., Lorenzen T. In the era of multiple drugs available it becomes more difficult to choose adequate ART regimens in pretreated patients. One instrument may be the resistance analysis. Evaluation shows that experts with access to RA recommend not more susceptible but less resistant substances in ART regimens. This may not only decrease costs of ART by sparing inactive substances, but also reduce pill burden and side effects.
113	3.4/11 - THE DEGREE OF VIRAL SUPPRESSION PREDICTS THE PROBABILITY OF ACCUMULATING NEW DRUG-MUTATIONS AT VIROLOGICAL FAILURE TO THE FIRST PI-HAART REGIMEN European AIDS Conf 2003 Oct 25-29;9:(abstract no. 113) d'Arminio-Monforte A.1, Cozzi-Lepri A.2, Balotta C.1, Velleca R.1, Gori C.3, Antinori A.3, Angarano F.4, Mazzotta F.5, Cadeo G.P.6, Maserati R.7, Perno C.F.3, for the ICONA Study Group >1/4 pts failing first HAART do not accumulate new mutations. Pts experiencing <1-log10CI reduction of VL at VF have lower chance of harbouring resistant viruses, thus suggesting that a moderate rather than low pharmacological pressure (partial adherence) is a factor favouring development of mutations.
114	4.1/1 - PHARMACOKINETIC (PK) STUDY OF SAQUINAVIR HARD GELS CAPS/ RITONAVIR (SQV-HGC/ RTV ) IN HIV-1 INFECTED PATIENTS: 1600/100MG QD COMPARED TO 2000/100 QD AND 1000/100MG BID European AIDS Conf 2003 Oct 25-29;9:(abstract no. 114) Autar R.S.1, Ananworanich J.1,2, Apateerapong W.1, Sankote S.1, Hill A.3, Hirschel B.4, Cooper D.5, Lange J.1,2, Phanuphak P.1, Ruxrungtham K.1, Burger D.6 SQV when dosed 2000/100mg qd or 1000/100mg bid shows better PK parameters than 1600/100mg qd.
115	4.1/2 - ONCE-DAILY ANTIRETROVIRAL THERAPY WITH THE BOOSTED PI SAQUINAVIR/RITONAVIR COMBINATION (1600 /100) IN HIV+ NAÏVE PATIENTS. A PHARMACOKINETIC SUBSTUDY European AIDS Conf 2003 Oct 25-29;9:(abstract no. 115) Duque B.1, Frías J.1, González-Garcia J.2, Guerra P.1, Aguilar M.1, Lorenzo A.2, Sanz J.3, Estrada V.4 Despite high variability SQV/r 1600mg administred once a day reach drug plasma concentrations over CI50 for wild-type HIV during the whole dosing interval.
116	4.1/3 - SOFT-GEL SAQUINAVIR AND LOPINAVIR/RITONAVIR DOUBLE BOOSTED PI REGIMEN: A PHARMACOKINETIC STUDY European AIDS Conf 2003 Oct 25-29;9:(abstract no. 116) Duque B.1, Carcas A.J.1, González-García J.2, Arribas J.R.2, Aguilar M.1, Peña J.M.2, Casinello A.1, Frías-Iniesta J.1 Total exposure to saquinavir in this regimen is similar to previously reported for this SQV schedule and C12h were in all patients above the theoretical MIC for HIV. The association of two protease inhibitors pharmacoenhanced with ritonavir may be adequate for those patients with previous treatment failures.
117	4.1/4 - ENFUVIRTIDE PHARMACOKINETIC-PHARMACODYNAMIC (PK-PD) RELATIONSHIP European AIDS Conf 2003 Oct 25-29;9:(abstract no. 117) Zhang X.1, Buss N.2, Salgo M.1, Patel I.H.1 90 mg BID dosage is optimal in combination with other active ARVs. In virtual monotherapy increasing the dose would have a minimal additional impact on efficacy.
118	4.1/5 - AMPRENAVIR PLASMA PROTEIN BINDING IN HIV-INFECTED PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 118) Boffito M. 1,3, Gatti G.2,4, Almond L.3, De Pascalis C.4, Bonora S.1, Bassetti D.4, Back D.3, Di Perri G.1 The overall unbound % of APV in vivo is consistent with in vitro data. However, we here show a [C]-dependent binding with a higher unbound % at 2h compared to through.
119	4.1/6 - INVESTIGATION OF THE INFLUENCE OF FOOD UPON THE PHARMACOKINETICS OF SPD754 European AIDS Conf 2003 Oct 25-29;9:(abstract no. 119) Holdich T., Dennis K. There is no impact of food upon the pharmacokinetics of SPD754. Single doses of 1200mg are well tolerated.
120	4.2/1 - IMPACT OF DRUG LEVELS AND BASELINE GENOTYPIC RESISTANCE ON THE VIROLOGICAL RESPONSE TO AMPRENAVIR/RITONAVIR SALVAGE THERAPY European AIDS Conf 2003 Oct 25-29;9:(abstract no. 120) Valer L., Gonzalez de Requena D., de Mendoza C., Martin-Carbonero L., Gonzalez-Lahoz J., Soriano V. HIV genotyping might help to predict which patients would benefit from a rescue intervention based on APV/rit. In any case, individuals previously treated with lopinavir may have less chances of VR.
121	4.2/2 - THERAPEUTIC DRUG MONITORING (TDM) IN HIV-INFECTED PATIENTS ENROLLED IN THE GENOPHAR STUDY European AIDS Conf 2003 Oct 25-29;9:(abstract no. 121) Bossi P.1, Peytavin G.2, Lamotte C.2, Ait-Mohand H.1, Bonmarchand M.3, Ktortza N.1, Simon A.3, Delaugerre C.4, Calvez V.4, Bricaire F.1, Costagliola D.5, Katlama C.1 72/126 patients (57%) had at W24 adequate Cmin and VL<200 cps/ml. The benefit of TDM in association with GRT and expert advice to optimize therapy appeared crucial in the GENOPHAR study.
122	4.2/3 - INTRA-INDIVIDUAL VARIABILITY IN NEVIRAPINE PLASMA CONCENTRATIONS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 122) Almond L.M.1, Boffito M.1,2, Hoggard P.G.1, Bonora S.2, Raiteri R.2, Sinicco A.2, Di Perri G.2, Back D.J.1 The variability in NVP plasma concentrations within the same patient over time was less than the variability between patients. These data support the use of TDM, although highlight the potential importance of repeated sampling, particularly in patients whose concentrations fall near the boundaries of target concentrations.
123	4.2/4 - CONTRIBUTION OF DIFFERENT FACTORS TO THE VARIABILITY IN EFAVIRENZ PLASMA CONCENTRATIONS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 123) Pereira S.A.1, Côrte-Real R.M.1, Branco T.2, Lampreia F.2, Germano I.2, Caixas U.2, Papoila A.L.3, Monteiro E.C.2 The intra-individual variability found, supports efavirenz as a candidate to TDM. Differences in the time of sample collection may contribute to the high interindividual variability observed.
124	4.2/5 - A POPULATION APPROACH TO STUDY THE INFLUENCE OF HCV OR HBV COINFECTION ON NEVIRAPINE PHARMACOKINETICS IN HIV-1 PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 124) Billaud E.1, Dailly E.1, Reliquet V.1, Breurec S.1, Perré P.2, Léautez S.2, Raffi F.1 The factor which indicates a significant alteration of NVP PK is not HCV or HBV coinfection but rather ASAT level. This result suggests that monitoring of NVP concentrations could be mandatory particularly if ASAT level is 1.5 ULN.
125	4.2/6 - IS LOPINAVIR GENOTYPIC INHIBITORY QUOTIENT (GIQ) A USEFUL DRUG-MONITORING TOOL IN CLINICAL PRACTICE? European AIDS Conf 2003 Oct 25-29;9:(abstract no. 125) Chantret M., Chapplain J.M., Tribut O., Maillard A., Arvieux C., Michelet C., Bentué-Ferrer D., Ruffault A. For therapeutic drug monitoring, GIQ could help in adapting the lopinavir target concentration in order to achieve long-term undetectable VL, especially in genotypic resistant patients.
126	4.2/7 - THERAPEUTIC DRUG MONITORING - LESSONS FROM FOUR YEARS OF RUNNING A CLINICAL SERVICE IN THE UK European AIDS Conf 2003 Oct 25-29;9:(abstract no. 126) Gibbons S.E., Robinson L., Tjia J.F., Back D.J., Khoo S.H. The uptake of TDM in the UK has increased considerably since 1999. Despite this, there is still a lack of clinical studies to assess how TDM should be best utilised and in which patient groups. In the absence of these data, the collection of post reporting patient outcomes assumes critical importance.
127	4.2/8 - EVALUATION OF AN ELISA METHOD FOR MEASURING AMPRENAVIR IN PLASMA European AIDS Conf 2003 Oct 25-29;9:(abstract no. 127) Montagna M.1, Bastiani E.2, Cusato M.1, Benedetti F.3, Rinaldi S.2, Donadel E.2, Berti F.3, Meroni V.4, Regazzi M.1 For routine use in clinical laboratories its performance should be carefully evaluated during extensive use of patient samples that are representative of samples to be routinely assayed.
128	4.2/9 - DETERMINANTS OF ADHERENCE TO HAART IN CLINICAL ROUTINE European AIDS Conf 2003 Oct 25-29;9:(abstract no. 128) Göbels K., Oette M., Feldt T., Kroidl A., Hemker J., Häussinger D. We found a good correlation between self reported adherence and unscheduled therapeutic drug monitoring. Of patients with good self reported adherence there is still a proportion of 13% with suboptimal drug levels. Thus, single unscheduled therapeutic drug monitoring might be a more reliable tool to evaluate effective drug intake and absorption than self reported adherence. In contrast, low self-reported adherence is a good predictor of low drug bioavailability. In conclusion, unscheduled therapeutic drug monitoring may be a good and cost-effective guidance for clinicians to optimize HAART.
129	4.3/1 - CLINICAL AND PHARMACOKINETIC INTERACTIONS BETWEEN METHADONE AND NELFINAVIR (NEMESIA STUDY) European AIDS Conf 2003 Oct 25-29;9:(abstract no. 129) Marco A.1, Cadafalch J.2, Pedrol E.3, Valls I.1, Fuster M.2, Soler A.3, Teixidó N.1, Queraltó J.M.2 These results show a significant reduction of the MTD plasmatic concentration when coadministred with NFV, however there are not any OWS and there is no need of any significant MTD dose adjustment.
130	4.3/2 - NO OUTSTANDING CLINICAL INTERACTIONS BETWEEN BUPROPION AND ANTIRETROVIRAL THERAPHY (AT) European AIDS Conf 2003 Oct 25-29;9:(abstract no. 130) Ribell M., Vidal I., Deig E., Garcia P., Soler A., Pedrol E. Bupropion therapy has been effective in treating HIV smokers under AT, without leading to adverse effects.
131	4.3/3 - SAFETY OF THE COMBINATION OF TENOFOVIR WITH STANDARD DOSE OF DIDANOSINE European AIDS Conf 2003 Oct 25-29;9:(abstract no. 131) Boix V.1, Lopez-Azkarreta I.1, Seguí J.M.1, Polache J.2, Sanchez-Paya J.3, Merino E.1, Reus S.1, Portilla J.1 Coadministration of tenofovir and didanosine at standard dose has not led to a significant increase of toxicity in our series. At least in the short term didanosine toxicity seems not to be increased. These results do not support didanosine dose reduction when coadministered with tenofovir.
132	4.3/4 - RITONAVIR (RTV) TROUGH PLASMA CONCENTRATIONS (CMIN) IN RTV LOW DOSE BOOSTED PROTEASE INHIBITORS (PI) CONTAINING REGIMEN AND THEIR USE FOR THERAPEUTIC DRUG MONITORING IN HIV-INFECTED PATIENTS (PTS) European AIDS Conf 2003 Oct 25-29;9:(abstract no. 132) Lamotte C.1, Reynes J.2, Vildé J.L.3, Yéni P.4, Katlama C.5, Peytavin G.1 The wide interindividual variability of RTV Cmin might result from multiple reciprocal RTV-PI interactions. APV and LPV produced lower RTV Cmin probably due to their induction potency. RTV Cmin might be useful in therapeutic drug monitoring to guide dosage adjustment especially regarding multiple PI combination.
133	4.4/1 - REVERSE-HYBRIDIZATION IN THE DETECTION OF MDR1, CYP2D6, AND CCR5 ALLELIC VARIANTS ASSOCIATED WITH RESPONSE TO ANTIRETROVIRAL THERAPY European AIDS Conf 2003 Oct 25-29;9:(abstract no. 133) Kriegshaeuser G., Kury F., Oberkanins C. The reverse-hybridization assay described here is rapid and linked into a simple format. It is compatible with large-scale screening programmes, and can easily be modified to include additional loci.
134	4.5/1 - ABNORMALITIES AND INTRAUTERINE EXPOSURE TO EFAVIRENZ European AIDS Conf 2003 Oct 25-29;9:(abstract no. 134) Khuong-Josses M.-A.1, Jeantils V.2, Delassus J.-L.3, Bentata M.4, Khelil N.1, Taverne B.1, Méchali D.1 In all cases women received efavirenz early in pregnancy. It is not certain that there is a relationship between efavirenz exposure and the described abnormalities. Nevertheless two cases of myelomeningoceles in children with intrauterine exposure to efavirenz have been recently reported . This cases emphasized the necessity of pharmacovigilance notification in all the possible fetal or children abnormalities possibly related to intrauterine exposure to efavirenz.
135	4.5/2 - THE SCOLTA PROJECT: A METHOD FOR DRUG SAFETY MONITORING OF ANTIRETROVIRALS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 135) Martinelli C., Bonfanti P., Quirino T., Ricci E., Magnani C., Cristina G., Migliorini D., Orofino G., Landonio S., Capetti A., Carradori S., Madeddu G., Sfara C., Miccolis S., Vigevani G.M., for the CISAI Group Since October 1, 2002 to April 30, 2003, 487 patients were enrolled, 355 males, mean age 40.7 years (SD±7.4). LPN cohort is made of 355 patients, TNV cohort of 152, IFN cohort of 18 and finally 6 patients are on ATZ-based therapies; 45 subjects are on treatment with two of the investigated drugs and thus belong to two different cohorts. Up to date 55 adverse events have been reported: 45 were in the LPN-treated group and 5, 3 and 2 were reported in patients assuming TNV, IFN and ATZ, respectively. 24 patients (4.9%) discontinued due to toxicity; 20 of these assumed LPN (5.6%) and 2 TNV (1.3%).
136	6.5/1 - GBV-C VIRUS INFECTION AND PROGRESSION OF HIV DISEASE IN A COHORT OF LONG TERM NON PROGRESSORS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 136) Bagaglio S.1, Ghezzi S.2, Neri F.2, Lodrini S.1, Vicenzi E.2, Santagostino E.3, Carminati G.4, Lazzarin A.1, Poli G.2, Morsica G.1 Maintenance of LTNPs status was related to baseline HIV viremia and CD4 cells count, whereas GBV-C- infection and TREC evaluation were not associated with distinct patterns of HIV disease progression disease. GBV-C infected patients maintained a stable TREC levels during the follow-up.
137	6.9/1 - INCREASED PLASMA INTERLEUKIN-18 IN HIV-1-INFECTED PATIENTS: ASSOCIATION WITH HIV VIRAL BURDEN AND ANTIRETROVIRAL TREATMENT European AIDS Conf 2003 Oct 25-29;9:(abstract no. 137) Jaroszewicz J., Wiercinska-Drapalo A., Prokopowicz D. We confirmed of a relationship between HIV replication and IL-18 concentration, and we showed that antiretroviral treatment and its complications (lipodystrophy syndrome) can affect pro-inflammatory cytokine production, with special respect to IL-18. IL-18 is an important element of HIV-infection pathogenesis.
138	6.10/1 - DISCORDANT PLASMA AND CEREBROSPINAL FLUID VIROLOGICAL FAILURES IN AIDS PATIENTS RECEIVING HAART European AIDS Conf 2003 Oct 25-29;9:(abstract no. 138) Abrescia N.1, Busto A.1, D'Abbraccio M.1, Figoni M.1, Viglietti R.1, Di Nicuolo G.2 The results provide a very strong evidence that plasma and CNS are highly separated compartments with a poor communication between them, coexisting an integrity of blood-brain barrier. Finally, there is a clear evidence that viral mutant strains grow in a compartment and then, spread to the others.
139	6.10/2 - VALIDATION OF A SAMPLING METHOD FOR QUANTIFYING THE VAGINAL HIV-1 VIRAL LOAD European AIDS Conf 2003 Oct 25-29;9:(abstract no. 139) Gimeno A.1, Portilla J.2, Plazas J.1, Sánchez-Payá J.3, Ochando M.1, Boix V.2, Llopis C.1, Merino E.2, Arroyo E.1, Pardo M.A.1 Direct aspiration of vaginal secretions is a reproducible sampling method to assess HIV-1 nucleic acids and HIV-1 RNA loads by RT-PCR after isolation nucleic acids in silica columns.
140	6.11/1 - THE LOW-ALPHA1-ANTITRYPSIN LEVEL IN HIV-INFECTED PATIENTS' SERUM AND ITS ROLE IN THE PROGRESS OF DISEASE COURSE European AIDS Conf 2003 Oct 25-29;9:(abstract no. 140) Papuashvili M. It may be considered the normal ATT concentration remains at the stage of HIV-carrier until the appearance opportunist infections. The patient's clinical condition aggravates as far as this parameter is decreasing. Thus, the low level of ATT concentration in HIV-infected patients' serum in most cases is correlating with progression of HIV-infection and it may be used as a prognostic marker of disease.
141	6.11/2 - ELDERLY AND ANTIRETROVIRAL THERAPY. AN EMERGING RELATIONSHIP NEEDING CAREFUL ATTENTION European AIDS Conf 2003 Oct 25-29;9:(abstract no. 141) Manfredi R., Calza L., Chiodo F. The increase of mean p's age is an emerging feature of HIV. Its pathogenetic, clinical, and therapeutic implications parellel problems in health care and resource allocation.An increased co-morbidity, a more frequent indication to multiple medications, an expected higher rate of toxicity, worsened adherence levels, and a different immunological, virologic, and clinical response, are expected with the increase of mean patients' age.
142	6.11/3 - ANTI-HIV EFFECT OF SOME NEWLY SYNTHESIZED 4-HYDROXYCOUMARINE DERIVATIVES IN CELL CULTURE (PRELIMINARY REPORT) European AIDS Conf 2003 Oct 25-29;9:(abstract no. 142) Manolov I.1, Raleva S.2, Mladenova Z.3, Froloshka L.2, Doundarova D.3, Argirova R.2 These preliminary results showed only weak RT-inhibition effect for three out of 17 derivatives. The effect described does not exclude anti-IN-inhibition. The other compounds have no activity on steps after integration.
143	6.11/4 - HIV-2 VIRAL LOAD - CLINICAL AND IMMUNOLOGICAL CORRELATION European AIDS Conf 2003 Oct 25-29;9:(abstract no. 143) Gomes M.H., Piñeiro C., Tavares M., Serrao R., Araújo F., Mota-Miranda A. HIV-2 viral load was lower than usually observed in HIV-1 patients. Viremia was higher in severely immunosupressed patients and remained detectable in spite of ART. More studies are needed to determine the sensitivity of the tests and its clinical correlation to allow prognosis and therapy monitoring.
144	6.11/5 - VIROLOGICAL QUALITY MANAGEMENT 2003 -A MULTI-CENTRE COMPARISON OF VIROLOGICAL RESPONSE IN DAILY ROUTINE European AIDS Conf 2003 Oct 25-29;9:(abstract no. 144) Knechten H., Höhn C., Yun-Kremer M., Ehret R., Braun P. Regular monitoring of these data and a given feedback for each centre compared to the group should lead to control and thereby improve the quality in the treatment of HIV-disease.
145	7.1/1 - PATIENT ACCEPTANCE WITH SELF-INJECTION OF ENFUVIRTIDE (ENF) FOR HIV OVER 48 WEEKS OF TREATMENT European AIDS Conf 2003 Oct 25-29;9:(abstract no. 145) Cohen C.1, Green J.2, Wintfeld N.2, Patel K.2 Most patients in a clinical trial setting taking ENF for up to 48 weeks are satisfied with the ease of injection and impact on their activities of daily living. Acceptance of self-injection is not associated with baseline clinical characteristics.
146	7.1/2 - DERIVATIVES OF 2,3-DIDEOXY-3-FLUOROTHYMIDINE (FLT) AS POTENT AND SELECTIVE ANTI-HIV-1 AGENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 146) Lipniacki A.1,2, Miazga A.3, Piasek A.1,2, Kulikowski T.3 The presented data show that above mentioned FLT derivatives are potent and selective anti-HIV agents with potency comparable to AZT and it seemed to be of interest to test their antiretroviral activity against AZT resistant viruses.
147	7.2/1 - ATAZANAVIR (ATV) MAINTAINED PATIENT UTILITY AND IMPROVED QUALITY OF LIFE (QOL), COMPARING FAVORABLY TO LPV/RTV: 24-WEEK DATA FROM BMS043 European AIDS Conf 2003 Oct 25-29;9:(abstract no. 147) Mukherjee J., Wu Y., Odeshoo L., Kelleher T., Iloeje U., Cross A., Giordano M. Both utility and QOL data suggest that ATV therapy was associated with clinically relevant QOL improvements.
148	7.2/2 - TIPRANAVIR/RITONAVIR (TPV/R) DEMONSTRATES POTENT EFFICACY IN MULTIPLE PROTEASE INHIBITOR (PI)-EXPERIENCED PATIENTS AT 24 WEEKS: BI 1182.52 European AIDS Conf 2003 Oct 25-29;9:(abstract no. 148) Kohlbrenner V.1, Gathe J.2, Pierone G.3, Arasteh K.4, Rubio R.5, LaLonde R.6, Piliero P.7, McCallister S.1, Garfinkel S.1, Chaves R.1, Mukwaya G.1, Dohnanyi C.1, Shaw S.1, Mayers D.1 All three doses of TPV/r demonstrated potent antiviral efficacy, with an acceptable safety profile during 24 weeks of treatment. Phase III trials at the 500/200 dose are ongoing.
149	7.2/3 - LONG-TERM 80-WEEK FOLLOW-UP OF HIGHLY TREATMENT-EXPERIENCED (HTE) PATIENTS ON TIPRANAVIR-BASED ANTIRETROVIRAL THERAPY (BI 1182.2) European AIDS Conf 2003 Oct 25-29;9:(abstract no. 149) Neubacher D.1, Markowitz M.2, Slater L.3, Curry R.1, Mayers D.1, McCallister S.1 These results indicate that TPV-based therapy can provide a durable response in a majority of HTE patients.
150	7.3/1 - EFFICACY AND SAFETY OF NEVIRAPINE, DIDADOSINE AND LAMIVUDINE AS A ONCE-DAILY HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN ADULT HIV-1-INFECTED NAÏVE PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 150) Ribera E.1, Rodríguez D.1, Soler A.2, Rubio M.3, Pedrol E.2, Blanco J.L.4, Gonzalez A.5, Crespo M.1, Falcó V.1, Ocaña I.1, Deig E.2, Miro J.M.4, Pahissa A.1 The once-daily regimen of didadosine, lamivudine and nevirapine is easy-to-take and demonstrates strong antiretroviral effect in naïve patients with more than 100 CD4 cells at baseline.
151	7.3/2 - SWITCHING TO NEVIRAPINE FROM AN INSUFFICIENT PROTEASE INHIBITOR-CONTAINING REGIMEN OFFERS A THERAPEUTIC OPPORTUNITY European AIDS Conf 2003 Oct 25-29;9:(abstract no. 151) Eskoetter H., Gerken F., Haubrich A., Goldbach J. If a PI-containing HAART has no sufficient virological response switching to a NVP-containing regimen is a therapeutic opportunity. It results in a durable virological and immunological improvement. It is a convenient regimen for clinical practice.
152	7.3/3 - ASSESSING THE IMPACT OF DIFFERENT VIROLOGIC RESPONSE DEFINITIONS ON RESPONSE RATES European AIDS Conf 2003 Oct 25-29;9:(abstract no. 152) Phillips A.N.1, King M.2 It is helpful to be aware of variations in ITT discontinuation / switch=failure response definitions, although differences had relatively little impact on overall response rates at Week 48 in this particular trial. Use of multiple response definitions to present study results should enable more complete interpretation of trial findings.
153	7.3/4 - OUTCOME OF THE FIRST HAART REGIMEN AMONG PATIENTS FROM WARSAW COHORT European AIDS Conf 2003 Oct 25-29;9:(abstract no. 153) Bakowska E., Ignatowska A., Burkacka E., Stanczak J., Pulik P., Swiecki P., Horban A. Outcome of the first HAART regimen in terms of virological results, immunological results and durability of treatment effect was significantly better in naïve patients group
154	7.3/5 - CHANGES IN THE FIRST HAART REGIMEN ADMINISTERED IN YEARS 1995-2002 IN WARSAW COHORT European AIDS Conf 2003 Oct 25-29;9:(abstract no. 154) Bakowska E., Ignatowska A., Burkacka E., Stanczak J., Gizinska J., Higersberger J., Horban A. HAART was introduced in clinical practice in Warsaw in 1997/1998. Antiretroviral treatment first was applied in the most advanced cases. Diminishing number of patients starting treatment in next years reflects changes in recommendations and epidemiological situation. Changes in first line HAART regimens reflects availability of new compounds and recomendation.
155	7.3/6 - CRIXIVAN(R)/RITONAVIR OBSERVATIONS WITH NELFINAVIR (CROWN): COMPARISON OF THE TWICE DAILY REGIMENS OF INDINAVIR (IDV) BOOSTED BY RITONAVIR (RTV) VS NELFINAVIR (NFV) PLUS TWO NEW NRTIS IN THE TREATMENT OF PROTEASE INHIBITOR (PI) NAÏVE PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 155) Mendo F.1, Salazar R.2, Badaro R.3, Andrade Neto J.4, Grinsztejn B.5, Nelson M.6, Keraudren V.7, Shivaprakash M.7, Stek M.7, and the CROWN team Numerically greater proportions on IDV800/RTV100 regimens (A) overall and entering with high VL or low CD4 with VL reductions and CD4 increases were observed than on NFV1250 regimens (B). Generally more AEs, discontinuations, and lower compliance were seen in A than B. These results are indicative of IDV800/RTV100 potency but with decreased tolerability in some patients.
156	7.3/7 - 2 YEAR LONG TERM SAFETY PROFILE OF TENOFOVIR DF (TDF) IN TREATMENT-EXPERIENCED PATIENTS FROM RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIALS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 156) Cheng A., Wulfsohn M., Cheng S.S., Toole J.J. In the placebo-controlled Phase 2-3 studies of tenofovir DF, long-term follow up shows the severity and incidence of AE and LA, as well as the proportion of patients discontinuing tenofovir DF, remain low. With exposure of up to 4 years, there is no indication of clinically significant nephrotoxicity in these highly treatment-experienced patients.
157	7.3/8 - SAQUINAVIR PLUS TWO ITRN IN THE TREATMENT OF naïve HIV MEXICAN PATIENTS FOLLOW UP TO FOUR YEARS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 157) Torres R., Robles M., Cano C. The baseline CD4 cells 216 ± 131 (16-481), at 4 years (13/60) 589 ± 230 (p<0.05). Log viral load basal 4.9 ± .65 (3.1-6.4) at 4 years (13/60) 2.3 ± 1.9(p<0.05). riglycerides 138 ± 83 (30-541) at 4 years 235 ± 190 (p<0.05). With the results, we consider that at 4 years the Saquinavir plus two nucleosides, there was successfully, because any patient developed AIDS, besides there were increase in CD4 cells, and decrease in viral load. The tolerance was adequate.
158	7.3/9 - NEVIRAPINE VERSUS EFAVIRENZ IN DAILY CLINICAL PRACTICE. A PROSPECTIVE, OPEN-LABEL SINGLE-CENTRE STUDY ON OVER 550 PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 158) Manfredi R., Calza L., Cocchi D., Chiodo F. An initial virological advantage among efavirenz-treated naïve patients was demonstrated, while nevirapine and efavirenz paralleled their frequency and duration of efficacy in all other therapeutic scenarios. The different pattern of untoward events deserves attention, due to the varied short- and long-term toxicity. A prolonged follow-up shows a tendency to cumulative hepatotoxicity for nevirapine, while efavirenz may not resolve (or might even prompt) metabolic abnormalities. Pathogenesis of NNRTI toxicity warrants investigation.
159	7.3/10 - NEVIRAPINE-CONTAINING REGIMENS IN HIV-INFECTED naïve PATIENTS WITH CD4 <= 200 CELLS/MICROL European AIDS Conf 2003 Oct 25-29;9:(abstract no. 159) Ferrer E.1, Fumero E.1, Domingo P.2, Ribera E.3, Knobel H.4, Lopez J.C.5, Barrios A.6, Santamariña E.1, Sambeat M.A.2, Crespo M.3, Podzamczer D.1 Nevirapine-containing regimens are effective and well tolerated in a high proportion of immunosuppressed patients. After 24 months more than 80% of patients who continued with a nevirapine regimen had VL < 50 copies/mL and CD4 > 200 cells/µL.
160	7.3/11 - LONG-TERM ASSESSMENT OF CLINICAL STATUS AND QUALITY OF LIFE IN A LARGE COHORT OF PATIENTS WITH NELFINAVIR-BASED THERAPY European AIDS Conf 2003 Oct 25-29;9:(abstract no. 160) Fumaz C.R.1, Aldeguer J.L.2, Lozano F.3, Knobel H.4, Casado J.L.5, Torralba M.6, Canoves L.7, Viciana P.8, García J.9, Ríos J.J.10, Clotet B.1 NFV-containing regimens permit long-term virologic control, good QOL and positive perception of tt that increases with the time. This could lead to question the widely use of simplification strategies and support individualized tt considering the clinical and psychological status of pts.
161	7.3/12 - RELATIONSHIP BETWEEN LOPINAVIR AND EFAVIRENZ PLASMA LEVELS AND THERAPEUTIC EFFICACY/ TOLERABILITY IN A DUAL ANTIRETROVIRAL REGIMEN LOPINAVIR/R-EFAVIRENZ (BIKS STUDY) European AIDS Conf 2003 Oct 25-29;9:(abstract no. 161) Dailly E.1, Allavena C.1, Goujard C.2, Reliquet V.1, Brunet C.1, Valantin M.A.3, Raffi F.1, and the BIKS study group Induction of LPV metabolism by EFV could explain the moderate rise of LPV concentrations compared to standard LPV/r dosage. Our results suggest a relationship between early virological response and LPV/EFV concentrations but have to be confirmed on the whole population after a population pharmacokinetic analysis of the full set of data.
162	7.3/13 - EFFICACY AND SAFETY OF TRIZIVIR IN A CLINICAL SETTING: A NEED FOR CHOOSING THE BEST TREATMENT CANDIDATES European AIDS Conf 2003 Oct 25-29;9:(abstract no. 162) Maida I.1, Barrios A.2, Núñez M.2, González-Lahoz J.2, Soriano V.2 Tolerance and adherence to TZV are quite good, and its efficacy is comparable to other triple regimens in a clinical setting. TZV seems ideal for HIV populations at higher risk for hepatotoxicity (IDUs with hepatitis C) and/or with a need for simple and free-from-interactions regimens (methadone). Prior suboptimal NRTI exposure and/or transmission of drug-resistant viruses negatively impact on TZV success.
163	7.3/14 - EFFICACY AND SAFETY OF ATAZANAVIR (ATV) IN PROTEASE INHIBITOR-EXPERIENCED HIV-INFECTED PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 163) Barrios A.1, Martín-Carbonero L.1, Ríos P.1, Maida I.2, Gallego O.1, Valer L.1, González-Lahoz J.1, Soriano V.1 ATV-based regimens provide a significant virologic response in PI-experienced patients, particularly in subjects lacking primary PRO resistance mutations. Hyperbilirrubinemia is frequent, but only rarely leads to tx discontinuation.
164	7.3/15 - EFFICACY OF ENFUVIRTIDE IN SUBGROUPS OF PATIENTS THROUGH 48 WEEKS OF THERAPY IN THE TORO TRIALS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 164) Walmsley S.1, Clotet B.2, Cooper D.3, Lalezari J.4, Nelson M.5, O'Hearn M.6, Piliero P.7, Reynes J.8, DeMasi R.9, Delehanty J.9, Chung J.10, Salgo M.10 Enfuvirtide is effective across all sub-groups evaluated. The greatest antiviral activity was seen in those patients with lower BL viral loads, higher BL CD4+ cell counts and in patients with increasing numbers of active drugs in the optimized background regimen.
165	7.3/16 - 5-YEAR RESULTS OF LOPINAVIR/RITONAVIR (LPV/R)-BASED THERAPY IN ANTIRETROVIRAL-NAÏVE HIV-INFECTED PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 165) Hicks C.1, Da Silva B.11, King K.R.11, Eron J.2, Benson C.3, Gulick R.4, Glesby M.4, Thompson M.5, Albrecht M.6, Wolfe P.7, Murphy R.8, White A.C.9, Kessler H.10, King M.11, Brun S.11 LPV/r-based therapy demonstrated sustained antiretroviral activity and was generally well tolerated in ARV-naïve patients through 5 years of therapy. Decreases in total cholesterol and triglycerides were observed in patients initiating lipid-lowering agents.
166	7.3/17 - ESPRIT: DEMOGRAPHICS AND INITIAL RESPONSE TO IL-2 European AIDS Conf 2003 Oct 25-29;9:(abstract no. 166) Knysz B.1, Bakowska E.2, Beniowski M.3, Leszczyszyn-Pynka M.4, Aboulhab J.5, Dragsted U.B.6, Bebchuck J.7, on behalf of the ESPRIT study group Treatment with lamivudine/abacavir/efavirenz taking with morning methadone dose can be effective treatment option. Close monitoring liver enzymes is required as well as initial good motivation to antiretroviral treatment.
167	7.3/18 - PRELIMINARY RESULTS OF DOT-POL STUDY-DAILY OBSERVED THERAPY WITH LAMIVUDINE, ABACAVIR, EFAVIRENZ(300/600/600 MG) QD IN HIV-1 INFECTED PATIENTS PARTICIPATING IN METHADONE MAINTENANCE PROGRAMME (MMPT) European AIDS Conf 2003 Oct 25-29;9:(abstract no. 167) Pulik P., Higersberger J., Bednarska A., Burkacka E., Horban A. Treatment with lamivudine/abacavir/efavirenz taking with morning methadone dose can be effective treatment option. Close monitoring liver enzymes is required as well as initial good motivation to antiretroviral treatment.
168	7.3/19 - IMPACT OF ENFUVIRTIDE ON HEALTH-RELATED QUALITY OF LIFE AT 48 WEEKS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 168) Clumeck N.1, Cohen C.J.2, Thompson M.3, Molina J.-M.4, Patel K.5, Wintfeld N.5, Green J.5 Adding enfuvirtide to an OB regimen may improve HRQoL when self-administered for 48 weeks by treatment-experienced, HIV-1-infected individuals. Improvement in quality of life was correlated with virological response.
169	7.3/20 - REAL LIFE EFFECTIVENESS OF ANTIRETROVIRAL THERAPY BASED ON LOPINAVIR/RITONAVIR IN ANTIRETROVIRAL NAÏVE PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 169) Montes M.1, Arribas J.R.1, Pulido F.2, Barros C.3, Dronda F.4, Berenguer J.5, Sanz J.6, Gonzalez J.1, Conde E.3, Rubio R.2 L/r based HAART is well tolerated and has a high effectiveness in antiretroviral naïve patients with advanced HIV infection. Impact on lipid values is complex with modest change in LDL/HDL ratios and an increase of serum triglycerides
170	7.4/1 - DOUBLE PROTEASE INHIBITOR BOOSTING WITH RITONAVIR. RESULTS IN A HEAVILY EXPERIENCED COHORT European AIDS Conf 2003 Oct 25-29;9:(abstract no. 170) Boix V.1, Lopez-Azkarreta I.1, Seguí J.M.1, Polache J.2, Sanchez-Paya J.3, Merino E.1, Reus S.1, Portilla J.1 DB is a useful strategy in heavily treated patients. A successful virologic response can be expected in more than 40% of patients (intention to treat), benefits are long-lived and toxicity is acceptable.
171	7.4/2 - MULTICENTER STUDY OF AN INDINAVIR/LOPINAVIR BASED REGIMEN EXCLUDING NRTIS IN SALVAGE THERAPY OF NUCLEOSIDE-ANALOGUES EXPERIENCED PATIENTS (MILESTONE) European AIDS Conf 2003 Oct 25-29;9:(abstract no. 171) Lauenroth-Mai E.1, Kuhlmann B.2, Esser S.3, Gellermann H.4, Fenske S.5 The simple regimen of IDV + LPV7r provided significant VL suppression and a pronounced increase of CD4 cells, even in the subgroup with ongoing viral replication. The decreased CD38+ expression on CD8+ cells is regarded as a marker of effective response to HAART possibly mediated by a direct PI-effect on T-cell.
172	7.4/3 - DIFFERENCES IN TIME TO TREATMENT CHANGE BY CLASS OF INITIAL REGIMEN European AIDS Conf 2003 Oct 25-29;9:(abstract no. 172) Bhaskaran K., on behalf of the CASCADE Collaboration NNRTI-based regimens have become more popular than PI-based regimens in recent years; individuals on these regimens may be more likely to remain on their first strategy.
173	7.4/4 - THE CRIXILOP COHORT STUDY: PRELIMINARY RESULTS FROM A SALVAGE STUDY OF THE BOOSTED DOUBLE PROTEASE INHIBITOR (PI) REGIMEN CONTAINING INDINAVIR (IDV) PLUS LOPINAVIR/RITONAVIR (LPV/R) WITHOUT THE ADDITION OF REVERSE TRANSCRIPTASE INHIBITORS (RTI) IN HEAVILY THERAPY-EXPERIENCED HIV+ PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 173) Dauer B.1, Von Hentig N.2, Müller A.1, Carlebach A.1, Mösch M.1, Haberl A.1, Gute P.3, Klauke S.4, Stürmer M.5, Staszewski S.1 The boosted double PI regimen of IDV+LPV/r may provide a clinical benefit for patients who have lost their RTI options. It appears possible to combine these two PIs without negative drug interactions. Lower doses of indinavir are needed to minimize intolerance.
174	7.4/5 - TRIZIVIR AND TENOFOVIR AS A SIMPLE SALVAGE REGIMEN European AIDS Conf 2003 Oct 25-29;9:(abstract no. 174) Latham V., Gazzard B., Bower M., Nelson M. Salvage therapy with a simple regimen of Trizivir/ Tenofovir is associated with an improvement in outcome even in heavily pre-treated patients, provided there are less than 3 TAMs in their resistance history. Compliance is still a problem as shown by the number of patients "lost-to-follow-up".
175	7.4/6 - IS THERE AN INCREASED RISK OF TOXICITY IN INDIVIDUALS RECEIVING COMBINATIONS INCLUDING KALETRA / TENOFOVIR? European AIDS Conf 2003 Oct 25-29;9:(abstract no. 175) Rajpopat S., Nelson M. Treatment with T/K was not associated with excess renal toxicity. Although few individuals had a phosphate measured, there was no increase in the rate of hypophosphataemia Despite increased exposure to T in individuals receiving K, there is no excess renal toxicity.
176	7.4/7 - PREDICTIVE FACTORS ASSOCIATED WITH VIROLOGIC SUCCESS IN HIGHLY PRE-TREATED HIV-INFECTED PATIENTS RECEIVING BOOSTED AMPRENAVIR: A PHARMADAPT SUBSTUDY European AIDS Conf 2003 Oct 25-29;9:(abstract no. 176) Clevenbergh P.1,3, Boulme R.2, Kirstetter M.3, Dellamonica P.4 Efficacious APV concentrations need to be determined for ARV experienced patients. Baseline viral load, new drugs and the number of mutations (RT/PRO) were associated with the outcome of APV/rtv based regimen.
177	7.4/8 - SAQUINAVIR/RITONAVIR IN HIV - INFECTED CHILDREN European AIDS Conf 2003 Oct 25-29;9:(abstract no. 177) Jugulete G., Dragan M., Mardarescu M., Petrea S., Luminos M. All antiretroviral combinations containing saquinavir/ritonavir have good efficacy and tolerability. HAART brings one categorically benefit form HIV infected children survival duration and quality of live.
178	7.4/9 - SWITCH FROM IP PLUS TWO ITRN TO NEVIRAPINE PLUS TWO ITRN. FOLLOW UP TO 36 MONTHS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 178) Cano C., Robles M., Torres R. With the results, we consider that with the switch to NEV plus two AN has been successfully, 40 patients continue actives, only 5 developed AIDS, 3 deaths. Iincrement in CD4 cells, decrement in viral load and only 9 with rash. Any patient with hepatic toxicity.
179	7.4/10 - NO BENEFIT OF LONG TREATMENT INTERRUPTION (TI) IN HIV-INFECTED PATIENTS WITH NO THERAPEUTIC OPTIONS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 179) Ghosn J.1, Wirden M.2, Ktorza N.1, Ait-Mohand H.1,3, Dominguez S.1,3, Schneider L.1,3, Pauchard M.1, Calvez V.2, Costagliola D.3, Katlama C.1,3 A long TI in HIV-infected patients with no therapeutic options on genotypic score was first of no virologic benefit and second with deleterious clinical results.
180	7.4/11 - FOSCARNET USED AS A SUPPLEMENT TO HAART IN SALVAGE THERAPY OF HIV-1 PATIENTS HARBOURING MULTIPLE NUCLEOTIDE EXCISION MUTATIONS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 180) Mathiesen S.1, Roge B.T.1, Weis N.2, Lundgren J.2, Obel N.3, Gerstoft J.1 Despite the risk of nephrotoxicity and inconvenience of iv-administration foscarnet could be an important alternative when few other treatment options remain. Further delineation of the mode of action, including the role of multiple nucleotide excision mutations, and optimal dosing regimens are needed.
181	7.4/12 - LOPINAVIR/R-SAQUINAVIR REGIMEN IN PRE-TREATED PROTEASE INHIBITORS AND REVERSE TRANSCRIPTASE INHIBITORS PATIENTS, WITH RESISTANCE OR TOXICITY European AIDS Conf 2003 Oct 25-29;9:(abstract no. 181) Delassus J.L.1, Mansouri R.2, Malbec D.1, Touitou H.3, Maisonneuve L.4 At week 24, double PI regimen is an alternative for patients who present a resistance or a toxicity with RTI. TF is mainly due to bad compliance (due to side effects and number of capsule). We will assess the results at 48 weeks.
182	7.4/13 - USE OF LOPINAVIR/RITONAVIR IN HIGHLY IMMUNOCOMPROMISED HIV-INFECTED PATIENTS: RESULTS AFTER 18 MONTHS OF FOLLOW UP European AIDS Conf 2003 Oct 25-29;9:(abstract no. 182) Bongiovanni M.1, Bini T.1, Adorni F.2, Meraviglia P.3, Capetti A.4, Testa L.5, Di Biagio A.6, Cicconi P.1, Tordato F.1, Melzi S.1, Chiesa E.1, Schiavini M.3, Landonio S.4, d'Arminio Monforte A.1 LPV/RTV showed to be highly effective also as part of a salvage regimen in heavily immuno-compromised HIV-infected patients. The rate of discontinuation of LPV/RTV in our cohort was higher than observed in the available studies.
183	7.4/14 - RESISTANCE PROFILES AND ADHERENCE AT PRIMARY VIRAL FAILURE IN THREE DIFFERENT HAART REGIMENS: ANALYSIS OF FAILURES WITHIN TWO RANDOMISED STUDIES European AIDS Conf 2003 Oct 25-29;9:(abstract no. 183) Roge B.T.1, Barfod T.S.1, Kirk O.2,3, Katzenstein T.L.2, Obel N.4, Nielsen H.5, Pedersen C.6, Mathisen L.2 The majority of primary failures could be attributed to weak adherence or unsanctioned treatment interruptions, often attributed to side effects. PI mutations were extremely rare.
184	7.4/15 - NNRTI SALVAGE THERAPY WITH NELFINAVIR IN PI NAÏVE PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 184) Viciana P.1, Pérez R.2, Hernández Quero J.3, Hernández Burruezo J.4, Labarga P.5, Vergara A.6, and the NNIP study group After a low pill count regimen the initiation of a NFV-containing regimen could be a handicap for some patients to be adherent, however this will change with the new 625mg-NFV tablet. NFV is an efficacious and safe option for PI naïve patients after initial NNRTI therapy ensuring a good lipidic and hepatic profile, this is a very important fact for specific populations like cardiovascular risk factor's or HCV co-infected patients.
185	7.4/16 - IMPROVED VIROLOGICAL AND IMMUNOLOGICAL RESPONSE TO EFAVIRENZ (EFV)-BASED THERAPY IN PATIENTS HARBORING SELECTED NRTI MUTATIONS AFTER GENOTYPE RESISTANCE TEST (GRT): A HINT OF HYPERSUSCEPTIBILITY? European AIDS Conf 2003 Oct 25-29;9:(abstract no. 185) Tozzi V., Zaccarelli M., Ceccherini-Silberstein F., De Longis P., D'Offizi G., Forbici F., D'Arrigo R., Boumis E., Bellagamba R., Bonfigli S., Carvelli C., Narciso P., Antinori A., Perno C.F. Several NRTI mutations (M41L, M184V, L210W, and T215Y, alone or in combination) are associated with better virological and immunological outcome in EFV-treated patients, thus suggesting possible NNRTI hypersusceptibility.
186	7.4/17 - TENOFOVIR IN CLINICAL PRACTICE - FIRST, SECOND, THIRD LINE? European AIDS Conf 2003 Oct 25-29;9:(abstract no. 186) Mauss S.1, Holm S.2, Wolf E.3, Kuhlmann B.2, Bellmunt A.2, Jaeger H.3, Berger F.1, Schmutz G.1 TDF shows good short term tolerance. Efficacy of TDF-containing regimens is better and more durable in patients with at least one active antiretroviral class left. In clinical practice, presence of highly resistant HIV has an impact on TDF-efficacy as shown previously in controlled studies.
187	7.4/18 - RADATA - EXPERT ADVICE CONDUCTED SWITCH OF ANTIRETROVIRAL THERAPY European AIDS Conf 2003 Oct 25-29;9:(abstract no. 187) Lorenzen T., Meyer P., Graefe K., Stoehr A., Plettenberg A. Radata is a well established system to provide expert advice to primary care physicians. So far, 193 patients have been included and 663 recommendations concerning a new ART have been given. Newest data will be presented. Radata is suitable to support decisions in ART in network setting.
188	7.4/19 - FINAL RESULTS OF A PHASE II RANDOMIZED, CONTROLLED STUDY OF EXTRACORPOREAL WHOLE-BODY HYPERTHERMIA (EWBH) AS SALVAGE THERAPY FOR HIV/AIDS PATIENTS WITH MULTI-DRUG RESISTANT (MDR-) HIV European AIDS Conf 2003 Oct 25-29;9:(abstract no. 188) Blick G.1, Greiger-Zanlungo P.1,2, Garton T.1, Ahern M.3, Simons P.3, Westerbeck T.3, McCartney C.D.3 EWBH was generally well-tolerated in advanced HIV/AIDS pts and associated with no new OIs, 1 EWBH-related death, initial CD4% increase followed by CD8+ cell increase, inability to culture HIV in PBMCs for 6mos, and genotypic reversion through wk24. Further studies are warranted in HIV, HCV, HIV/HCV pts.
189	7.5/1 - THE SIMPLIFICATION OF THE ANTIRETROVIRAL THERAPY WITH ABACAVIR-A RETROSPECTIVE STUDY European AIDS Conf 2003 Oct 25-29;9:(abstract no. 189) D'Arminio Monforte A.1, Tordatto F.1, Cîrciumaru B.2 Whereas, the simplification of the ARV therapy was mainly necessary, as the previous HAART regimens were bad tolerated, this method should be individualized balancing the risk/benefit ratio, in specialized infectious diseases clinics.
190	7.5/2 - EFFECT OF SWITCHING PI AND NNRTI BASED HAART TO ABACAVIR BASED HAART European AIDS Conf 2003 Oct 25-29;9:(abstract no. 190) Roca B., Perez A.P., Ventura J.M., Ferrero J.A. In poorly adherent populations, a simplified HAART may be more effective than a stronger but more complex HAART.
191	7.5/3 - EFFICACY AND SAFETY OF TRIZIVIR MAINTENANCE TREATMENT OVER 48 WEEKS AFTER QUADRUPLE INDUCTION THERAPY : AZLF30004/TRISUD TRIAL European AIDS Conf 2003 Oct 25-29;9:(abstract no. 191) Reynes J.1, Ragnaud J.M.2, Delmas B.3, Gallais H.4, Peyramond D.5, Laurichesse H.6, Dellamonica P.7, Pellegrin J.L.8, Allegre T.9, Thiaux C.1, on behalf of InfectioSud group Simplification with Trizivir following initial 48 week treatment with a protease inhibitor containing regimen, is well tolerated and maintains viral load suppression.
192	7.5/4 - RITONAVIR/INDINAVIR 100/400 MG BID : A SIMPLE, POTENT AND WELL-TOLERATED PI-CONTAINING REGIMEN European AIDS Conf 2003 Oct 25-29;9:(abstract no. 192) Ghosn J.1, Duvivier C.1,4, Peytavin G.2, Marcelin A.-G.3, Ait-Mohand H.1,4, Astriti M.1, Agher R.1, Costagliola D.4, Calvez V.2, Katlama C.1,4 RTV/IDV 100/400 bid is a simple potent ARV regimen with excellent tolerability. Moreover, RTV/IDV 100/400 bid costs 50% less than the standard IDV regimen, a major advantage in countries with limited resources.
193	7.5/5 - ONCE DAILY STAVUDINE (D4T PRC) VERSUS TWICE DAILY STAVUDINE; A COMPARISON OF THE EFFICACY, TOLERABILITY, SAFETY AND ADHERENCE European AIDS Conf 2003 Oct 25-29;9:(abstract no. 193) Portsmouth S., Osorio J., McCormick K., Gazzard B., Moyle G. D4T PRC is as effective, safe and tolerable as D4T twice daily. Adherence to the once daily formulation was as good as the twice daily drug.
194	7.5/6 - A PILOT STUDY OF ONCE DAILY SAQUINAVIR/ RITONAVIR MINIDOSIS: 52 WEEKS RESULTS IN ANTIRETROVIRAL-naïve PATIENTS WITH ADVANCED HIV INFECTION COMPARED TO CONVENTIONAL DOSING OF SAQUINAVIR European AIDS Conf 2003 Oct 25-29;9:(abstract no. 194) Hidalgo J., Castillo R., Villena J., Sanchez C., Salazar R. The association of low dose ritonavir and saquinavir-SGC in a single daily dose as part of antiretroviral therapy showed similar efficacy to a conventional regimen in patients with advanced HIV infection and no prior therapy. This regimen was well tolerated. Additional studies to evaluate once daily ritonavir/saquinavir-SGC combinations are granted.
195	7.5/7 - ANTIRETROVIRAL TREATMENT SIMPLIFICATION IN HIV-INFECTED INDIVIDUALS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 195) Plachouras D., Poulakou G., Antoniadou A., Panagopoulos P., Papadopoulos A., Koratzanis G., Kanellakopoulou K., Giamarellou H. ART simplification appears equally effective at viral suppression with the possible advantage of improved adherence and maintaining future treatment options. Possible improvement in lipodystrophy syndrome needs further evaluation in long-term studies.
196	7.5/8 - 52 WEEKS EVALUATION OF THREE DIFFERENT DOSES OF ZIDOVUDINE AS PART OF ANTIRETROVIRAL THERAPY IN LIMA, PERU European AIDS Conf 2003 Oct 25-29;9:(abstract no. 196) Chumpitaz R., Rodríguez L., Claros J., Gutiérrez L., Hidalgo J., Collins J., Illescas R., Castillo R., Villena J., Salazar R. Virological and immunological responses after one year therapy were similar in groups 1 and 2. Group 3 showed the biggest increase in CD4+, although it had a bigger proportion of virological failure. The potential use of smaller doses of AZT could be evaluated in patients not tolerating conventional doses.
197	7.5/9 - EVALUATION OF SUSTAINED VIROLOGICAL AND IMMUNOLOGICAL RESPONSE AND LIPID ABNORMALITIES AFTER SWITCH THERAPY IN HIV/AIDS PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 197) Bonasser F.F.1, Atomiya A.N.1, Leite A.G.B.1, Kalmar E.M.N.2, Waghabi G.R.2, Magri M.C.M.2, Nogueira R.S.1,2 Switching to a regimen containing efavirenz is safe and effective. The better outcomes occurred in patients naïve before HAART.
198	7.5/10 - SWITCHING TO HU PLUS DDI AFTER SUCCESSFUL HAART SUSTAINS VIRUS REPLICATION AND IMPROVES METABOLIC AND MORPHOLOGIC TOXICITY European AIDS Conf 2003 Oct 25-29;9:(abstract no. 198) Barreiro P., de Mendoza C., Camino N., Blanco F., García-Benayas T., González-Lahoz J., Soriano V. HU-ddI may be a maintenance therapy for subjects having good response to HAART, especially in those with lower set-points of viremia, limited CD4 cell depletion and no ddI exposure. HAART induced lipid and morphologic disturbances significantly improved after moving to HU-ddI.
199	7.5/11 - EVALUATION A SIMPLE ONCE DAILY HAART (QD) REGIMEN IN PATIENTS (PTS) AT HIGH RISK OF NON ADHERENCE: A PILOT ISTAR STUDY (IMEA 018) European AIDS Conf 2003 Oct 25-29;9:(abstract no. 199) Landman R.1, Detruchis P.2, Peytavin G.3, Benalycherif A.1, Yeni P.3, Bentata M.4, Jarrousse B.4, Lang J.M.5, Descamps D.3, Flandre P.6 In this population, simple QD regimen is well accepted and tolerated. In experienced pts only 1/3 achieved an undetectable VL, possibly due to poor adherence and/or resistance. In naïve pts, treatment efficacy was considerably higher.
200	7.5/12 - AN OPEN-LABEL STUDY TO EVALUATE LONG TERM (96 WEEKS ) SAFETY AND EFFICACY OF SWITCH TO TRIZIVIR AFTER FIRST LINE QUADRUPLE INDUCTION THERAPY : AZLF3006-SUBURBS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 200) de Truchis P.1, Rouveix E.1, Zucman D.1, Chemlal K.1, Mathez D.1, Devidas A.1, Welker Y.1, Leibowitch J.1, Khuong A.1, Force G.1, Praindhui D.2 After potent induction therapy for 48 W with quadritherapy, simplification with Trizivir® was safe and not associated with viral rebound, as measured by plasma VL, proviral DNA, or infectious cell frequency.
201	7.5/13 - RECENT PATTERNS IN ANTIRETROVIRAL THERAPY INITIATION IN THE UNITED STATES AND THE NETHERLANDS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 201) Le Fevre A.M.1, Ghani A.C.1, Donnelly C.A.1, Bartley L.M.1, Gras L.2, van Valkengoed I.2, de Wolf F.2, Anderson R.M.1 Although complex patterns of antiretroviral therapy initiation were found, similar patterns were observed in the US and the Netherlands.
202	7.5/14 - BRITISH HIV ASSOCIATION NATIONAL CLINICAL AUDIT OF PATIENTS STARTING FIRST LINE ART European AIDS Conf 2003 Oct 25-29;9:(abstract no. 202) Tang A., Brook M.G., Curtis H., Johnson M. British HIV units show a high level of adherence to ART guidelines although there are unexplained delays in starting therapy and omissions in pre-treatment tests.
203	7.5/15 - EFFICACY AND TOLERABILITY OF SUBSTITUTION OF EFAVIRENZ (EFV) FOR PROTEASE INHIBITORS (PI) IN VIROLOGICALLY SUPPRESSED PATIENTS HAVING FAILED A PRIOR PI BASED REGIMEN European AIDS Conf 2003 Oct 25-29;9:(abstract no. 203) Baril J.G.1, Thomas R.2, Longo N.3 Substitution of EFV for PI in virologically suppressed patients is a safe and effective alternative even for patients with a prior PI failure.
204	7.5/16 - SAFETY AND EFFICACY OF A QD SIMPLIFICATION REGIMEN (DIDANOSINE PLUS TENOFOVIR PLUS EFAVIRENZ) European AIDS Conf 2003 Oct 25-29;9:(abstract no. 204) Barrios A.1, Maida I.2, Vilaró-Rodríguez J.3, Negredo E.4, Domingo P.3, Estrada V.5, Asensi V.6, Labarga P.7, Gálvez J.8, Santos J.9, Terrón J.10, Morales D.8, Riera M.11, Vergara A.12, Martín-Carbonero L.1, Barreiro P.1, García-Benayas T.1, Núñez M.1, Blanco F.1, González-Lahoz J.1, Clotet B.4, Soriano V.1 Simplification with qd ddI+TDF+EFV is relatively safe and potent. Co-administration of TDF and ddI does not seem to enhance the risk of ddI toxicity, at least during the first 6 months of therapy.
205	7.5/17 - SUBSTITUTION OF NEVIRAPINE FOR EFAVIRENZ IN VIROLOGICALLY CONTROLLED PATIENTS INTOLERANT OF EFAVIRENZ European AIDS Conf 2003 Oct 25-29;9:(abstract no. 205) Ward D.J., Kantor T.A. NVP can be successfully substituted for EFA in patients unable to tolerate the side effects of EFA, with maintenance of virologic control and improvement of lipid profiles.
206	7.5/18 - HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN HIV-INFECTED PATIENTS RECEIVING TWO EFAVIRENZ-BASED REGIMENS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 206) Ribera E.1, Soriano V.2, Alvarez C.3, Rivero A.4, Martinez- Lacasa J.5, Torres R.6, Del Castillo R.7, Valencia E.2, on behalf of ESTRATEGO Study Group EFV-based therapies as part of either rescue or simplification interventions result in a significant improvement in QoL.
207	7.5/19 - SIMPLIFICATION OF ANTIRETROVIRAL TREATMENT AT A HOSPITALARY HIV CARE UNIT European AIDS Conf 2003 Oct 25-29;9:(abstract no. 207) Redondo C., Galera C., Poza G., Fernandez A., Aguayo C., Bermejo M., Martinez J. 1. Simplification of antiretroviral treatment with NNRTIs or abacavir seems to be safe in clinical practice. 2. Virological failure is related to NRTIs treatment prior to HAART.
208	7.5/20 - EFFICACY AND TOLERANCE OF TREATMENT SIMPLIFICATION WITH TRIZIVIR® European AIDS Conf 2003 Oct 25-29;9:(abstract no. 208) Vergas J.1, Tellez M.J.1, Fernandez C.2, Roca V.1, Estrada V.1 Trizivir® is a useful to maintain the virological and immunologic success with more complex ART. - Virological failure increases with previous mono- o bi-therapy. - Withdrawal due to hypersensitivity is similar to other series. - Lipid profile improves significantly after switching to Trizivir®.
209	7.6/1 - RISKS OF CLINICAL PROGRESSION, GENOTYPIC EVOLUTION AND FAILURE OF RETREATMENT AFTER A NON-PROGRAMMED HAART INTERRUPTION European AIDS Conf 2003 Oct 25-29;9:(abstract no. 209) Sánchez R., Portilla J., Gimeno A., Boix V., Llopis C., Merino E., Reus S. HAART can usually be safely interrupted if necessary in "real world" patients. Concerns remain about developing resistance or symptoms related to immune reconstitution.
210	7.6/2 - COMPARISON OF THE DYNAMICS OF RESISTANCE-ASSOCIATED MUTATIONS TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AND PROTEASE INHIBITORS AFTER CESSATION OF ANTIRETROVIRAL COMBINATION THERAPY European AIDS Conf 2003 Oct 25-29;9:(abstract no. 210) Wirden M.1, Delaugerre C.1, Marcelin A.G.1, Ktorza N.2, Ait-Mohand H.2, Pauchard M.2, Katlama C.2, Calvez V.1 This prospective study demonstrated that the order of resistance mutation disappearance is PI, NNRTI and NRTI. Thus, in subsequent regimen, it would be interesting to use multiple PIs whose the resistance mutations disappeared significantly faster than NRTIs.
211	7.6/3 - CD4-GUIDED INTERRUPTION OF THERAPY IN PATIENTS WITH CHRONIC INFECTION European AIDS Conf 2003 Oct 25-29;9:(abstract no. 211) Boschi A., Ortolani P., Moscatelli G., Morigi G., Mori F., Arlotti M. The suspension of therapy in patients with high CD4, if monitored, is clinically safe, decrease the exposition to the therapy and do not reduce the efficacy of therapy when re-started.The duration of first interruption and the duration of total suspension of therapy is correlate with Nadir CD4 count.
212	7.6/4 - EVOLUTION OF HIV INFECTED PATIENTS FOLLOWING ANTIRETROVIRAL TREATMENT WITHDRAWAL European AIDS Conf 2003 Oct 25-29;9:(abstract no. 212) Carrillo R.1, Jiménez C.1, Arranz A.2, Peñalver R.2, Santos I.1, Sanz J.1 Withdrawal of HAART in selected patients with regular follow-up can be a reliable strategy that would avoid side effects.
213	7.6/5 - HAART INTERRUPTION IN VIROLOGICALLY CONTROLLED PATIENTS WHO STARTED TREATMENT AT AN EARLY STAGE OF HIV-INFECTION European AIDS Conf 2003 Oct 25-29;9:(abstract no. 213) Cotte L., Lebouche B., Miailhes P., Schlienger I., Augustin-Normand C., Trepo C. HAART interruption in virologically controlled patients who started treatment at an early stage of HIV-infection appears safe under strict monitoring. Based on CD4 levels, 85% of patients remained off treatment after 1 year interruption.
214	7.6/6 - HEPATITIS B VIRUS RECTIVATION AFTER WITHDRAWAL OF LAMIVUDINE IN HIV-HBV COINFECTED PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 214) del Río M.1, Murillas J.1, Tur S.2, Riera M.1, Villalonga C.1 Current status of HBV infection should be tested in HIV/HBV coinfected patients before withdrawal of lamivudine. It seems to be wise to keep lamivudine if HBV active replication can not be ruled out.
215	7.6/7 - PERSISTENCE OF HIV DRUG-RESISTANT STRAINS AFTER TREATMENT INTERRUPTION IN A PUBLIC REFERENCE AIDS CLINIC - SAO PAULO - BRAZIL European AIDS Conf 2003 Oct 25-29;9:(abstract no. 215) Kalmar E.M.N.1,2, Barreto C.C.3, Ferreira S.C.3, Sabino E.3 Stable resistant strains that do not disappear after interruption of antiretroviral selective pressure are frequent. This may be a problem since individuals harboring these strains are at risk for transmitting these viruses. A larger set of this type of samples should be evaluated to determine if a specific patterns of drug resistance mutation are associated with persistence and apparent fitness of HIV.
216	7.6/8 - TWO MONTHS OF NNRTI INTERRUPTION HAS NO EFFECT ON HIV-1 RNA PLASMATIC LEVEL IN PATIENTS HARBORING VIRUSES WITH RESISTANCE-ASSOCIATED MUTATIONS FOR THIS CLASS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 216) Wirden M.1, Simon A.2, Schneider L.3, Paris L.3, Marcelin A.G.1, Delaugerre C.1, Legrand M.4, Peytavin G.5, Katlama C.3, Calvez V.3 This study demonstrated that the antiviral activity is totally lost when viruses harboring NNRTI resistance mutations are selected.
217	7.6/9 - DISCONTINUATION OF HAART IS SAFE IN PATIENTS WITH A HIGH CD4 CELL COUNT AFTER A LONG-TERM CONTROL OF VIRAL REPLICATION European AIDS Conf 2003 Oct 25-29;9:(abstract no. 217) Hernangomez S., Lopez J.C., Cosin J., Berenguer J., Miralles P., Padilla B. Discontinuation of HAART is a safe therapeutically approach in patients with a good control of viral replication and immunological reconstitution after HAART. The early reintroduction of HAART is associated with a lower nadir CD4, a lower CD4 cell counts at the beginning of HAART, and a higher viral load after 4 weeks of discontinuation.
218	7.6/10 - TREATMENT INTERRUPTION (TI) IN PATIENTS WITH PERSISTENT SUPPRESSION OF VIRAL REPLICATION : PREDICTIVE FACTORS TO RESUME THERAPY. A 18-MONTHS STUDY European AIDS Conf 2003 Oct 25-29;9:(abstract no. 218) Prazuck T.1, Hocqueloux L.1, De Luca K.1, Mille C.1, Barthez J.P.2 TI in pts with long term viral suppression is safe. As CD4 nadir is a key issue, HAART should not be introduced below 350 CD4 cells/mm3, as well as HAART re-introduction after TI.
219	7.6/11 - DO COFACTORS MODELL THE OVERALL RESPONSE TO STRUCTURED TREATMENT INTERRUPTIONS (STI) IN THE ACUTE HUMAN IMMUNODEFICIENCY VIRUS (HIV)-INFECTED PATIENT? - RESULTS FROM THE BONN COHORT European AIDS Conf 2003 Oct 25-29;9:(abstract no. 219) Vogel M.1, Voigt E.1, Wasmuth J.C.1, Stroms A.2, Kupfer B.1, Rockstroh J.K.1 STI in acute HIV-infection enables patients to control HI-viremia below 5000 copies/ml at a rate higher than reported in untreated seroconversion studies. No clear distribution of immunogenetic host factors suggesting a determinant role regarding STI was found.
220	7.6/12 - INFLUENCE OF PRIOR STRUCTURED TREATMENT INTERRUPTIONS (STI) IN THE LENGTH OF TIME WITHOUT ANTIRETROVIRAL TREATMENT IN CHRONICALLY HIV-INFECTED SUBJECTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 220) Molto J., Romeu J., Martinez-Picado J., Negredo E., Tural C., Sirera G., Clotet B., Ruiz L. Our results show that previous STIs do not influence the time off-therapy when HAART is definitively discontinued. CD4 nadir may be an important factor for treatment discontinuation decision.
221	7.6/13 - TREATMENT INTERRUPTION (TI) IN CHRONICALLY INFECTED PATIENTS AFTER THERAPY FAILURE INDUCED BY MULTI-DRUG-RESISTANT (MDR) HIV-STRAINS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 221) Kroidl A.1, Balduin M.2, Feldt T.1, Goebels K.1, Däumer M.2, Kaiser R.2, Oette M.1, Häussinger D.1 TI in patients with MDR-HIV may result in occurrence of predominating susceptible virus and a new successful therapy leading to immunological-
222	7.7/1 - SUSTAINED EFFECT OF KALETRA CONTAINING HAART REGIMEN ON LYMPHOCYTE SUBPOPULATIONS FOLLOWING ONE YEAR TREATMENT IN EXPERIENCED HIV-1 INFECTED PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 222) Vigklis V., Lelekis M., Boti S., Chini M., Siorenta A., Stephanou J., Karachaliou V., Gargalianos P. The initial increase of CD45RA+CD62L+ on CD4 T cells could be at clinical importance for intervention with immunomodulation for a short period of time.
223	7.7/2 - LACK OF IMMUNOLOGIC PROGRESSION IN A COHORT OF PATIENTS WITH PERSISTENT LOW VIREMIA European AIDS Conf 2003 Oct 25-29;9:(abstract no. 223) Dyner T., Cafaro V., Chow V. Of these 18 patients on a stable HIV regimen, immunologic competence was maintained despite the presence of persistent low level viral replication. Attention is directed to patients on long term stable regimens because we need to anticipate maintaining therapy and controlling medication side-effects for decades. Our cohort is part of a growing group delaying switches in therapy simply to maintain viral control below the level of detection.
224	7.7/3 - NOT DETERMINED LEUKOENCEPHALOPATHY (NDLE): POSSIBLE HAART FAILURE IN THE CENTRAL NERVOUS SYSTEM European AIDS Conf 2003 Oct 25-29;9:(abstract no. 224) Sotgiu G.1, Maserati R.2, Marchioni E.3, Franciotta D.3, Del Bue S.4, Ferrante P.4, Minoli L.1 No etiology was identified. Median CD4+ value was more elevated than during opportunistic infections, like PML. This disorder may be linked to the incomplete suppression of HIV by antiviral drugs in the CNS and to the long time between diagnosis of HIV-seropositivity and NDLE. It may suppose a direct role of HIV in the pathogenesis of NDLE.
225	7.7/4 - P300 EVOKED POTENTIEL AND ELECTROENCEPHALOGRAM (EEG) IN HIV-INFECTED TREATED PATIENTS WITH COGNITIVE IMPAIRMENT European AIDS Conf 2003 Oct 25-29;9:(abstract no. 225) Milon M.P.1, Poizot Martin I.2, Blanquet F.1, Dinh T.2, Drogoul M.P.2, Gastaut J.A.2, Planche D.1, Vion-Dury J.1 The cognitive troubles displayed by HIV infected treated patients are related to a significant modification of cortical electrogenesis, and are frequently associated with abnormal cognitive EP. The increase of P3B latency is in ingreement with a moderate bradypsychism. The viral and/or iatrogenic origin of such abnormalities has to be investigated.
226	7.7/5 - BRAIN METABOLIC SPECTRUM IN HIV-INFECTED TREATED PATIENTS WITH COGNITIVE IMPAIRMENT European AIDS Conf 2003 Oct 25-29;9:(abstract no. 226) Milon M.P.1, Poizot Martin I.2, Michotey P.3, Dinh T.2, Drogoul M.P.2, Gastaut J.A.2, Vion-Dury J.1 Brain metabolic status is frequently abnormal in HIV-infected treated patients presenting minor cognitive impairment. Furthermore, these abnormalities are not associated with WM hyperintensities as it is usually observed during HIV encephalopathy
227	7.7/6 - DIFFERENCES IN VIROLOGIC AND IMMUNOLOGIC RESPONSE TO HIGHLY ACTIVE ANTIRETROVIRAL THERAPY BY AGE AND GENDER European AIDS Conf 2003 Oct 25-29;9:(abstract no. 227) Touloumi G.1, Pantazis N.1, Antoniou A.1, Sambatakou H.2, Sipsas N.3, Mangafas N.4, Katsarou O.5, Paparizos V.6, Antoniadou A.7, Gargalianos P.2, Kordossis T.3, Lazanas M.4, Karafoulidou A.5, Stavrianeas N.6, Giamarellou H.7, Hatzakis A.1 Women may achieve faster and more durable virologic response than men. Older subjects had better initial VR than their younger counterparts and similar rates of IR.
228	7.7/7 - LATER PRESENTATION FOR EMIGRANT POPULATIONS WITH HIV INFECTION AND LESS SUSTAINED RESPONSE TO HAART DESPITE SIMILAR INITIAL BENEFIT European AIDS Conf 2003 Oct 25-29;9:(abstract no. 228) Ripamonti D., Arici C., Maggiolo F., Gregis G., Quinzan G., Suter F. Non-EEC citizens present with a more advanced disease. The initial response to HAART is similar to EEC subjects, but with a higher risk of failure in the mid- and long-term, suggesting insufficient adherence. Cultural and language barriers may require a different approach in such populations.
229	7.7/8 - CHARACTERISTICS OF PATIENTS WITH DISCORDANT IMMUNOLOGIC RESPONSE AND VIRAL SUPPRESSION AFTER HAART European AIDS Conf 2003 Oct 25-29;9:(abstract no. 229) Popescu G.A., Popov V., Tone A., Gavriliu L., Popescu C., Ivan M., Benea E. We confirmed that, in general, IR and VS were associated. However, isolated VS could be related to female gender, naïve or less experienced HAART, lower CD4 at baseline, indinavir-containing regimens. Multiple HAART-experienced patients tended to have often isolated IR.
230	7.8/1 - DETECTABLE PLASMA VIRAL LOAD ON HIV-2 INFECTED PATIENTS IS A MARKER OF DISEASE PROGRESSION European AIDS Conf 2003 Oct 25-29;9:(abstract no. 230) Gomes P. 1, Abecasis A.1, Almeida M.1, Lobo M.C.1, Carvalho P.1, Gonçalves M.F1, Diogo I. 1, Cabanas J.1, Mansinho K.2, Camacho R.1 In contrast to infection by HIV-1, the majority of HIV-2 infected individuals have undetectable levels of viral RNA in the plasma. The group of individuals with CD4+ T cells counts<200 is the one with the highest percentage of detectable and high plasma viremias. Therefore we conclude that, in HIV-2 infection, detectable plasma VL is a marker of disease progression.
231	7.8/2 - NO GENDER DIFFERENCE IN VIRAL REPLICATION IN HIV-2 INFECTION European AIDS Conf 2003 Oct 25-29;9:(abstract no. 231) Gomes P.1, Arroz M.J.2, Freire M.2, Abecasis A.1, Pinto, L.2, Almeida M.1, Carvalho P.1, Gonçalves M.F.1, Diogo I.1, Cabanas J.1, Lobo M.C.1, Camacho R.1 In this study, when controlling for relevant factors such as age and CD4+ T cells counts, we found no evidence that the course of infection was different according to gender. However the number of patients with detectable plasma viral load was very low, so more studies with patients in a more advanced stage of disease are needed.
232	8.2/1 - THERAPEUTIC VACCINATION IN HIV-INFECTION: TRIALS IN EUROPE European AIDS Conf 2003 Oct 25-29;9:(abstract no. 232) Wienold M., on behalf of the Vaccine Working Group Key data on ongoing efforts can be recruited through voluntary reporting. A Lack of legal requirements for registration of such trials in Europe precludes completeness of a database. Efforts to increase transparency in this field should be supported. An update on trials registered in ETAV-db will be prepared for presentation.
233	8.3/1 - GENE THERAPY FOR HIV INFECTION WITH ENTRY INHIBITORS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 233) Brandenburg G.1, Martinius H.1, Egelhofer M.1, Schult-Dietrich P.1, Tarimoradi S.1, Koopmann G.2, Schiedlmeier B.3, Baum C.3, Schweizer M.4, Schilz A.5, Alexandrov A.6, von Laer D.1 For toxicity and efficacy studies in mouse and rhesus macaque animal models, we established transduction protocols. C46 was highly expressed on the surface of murine (>30 %) and rhesus macaque lymphocytes (>50 %). No side effects were observed in any animal model. In the latter, the transgene did not induce a cellular or a humoral immune response. In conclusion, there was no evidence for acute or chronic toxicity of gene-modified T cells in vivo. A clinical phase I trial in humans and efficacy studies for the transfer of gene-modified T cells in SIV infection in rhesus macaques have been initiated.
234	9.1/1 - LOPINAVIR/RITONAVIR VS INDINAVIR/RITONAVIR IN HIV INFECTED PATIENTS naïve FROM ANTIRETROVIRAL TREATMENT: IMMUNO-VIROLOGICAL OUTCOME AND SIDE EFFECTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 234) Bongiovanni M.1, Bini T.1, Adorni F.2, Cicconi P.1, Tordato F.1, Melzi S.1, Chiesa E.1, d'Arminio Monforte A.1 In our setting, LPV/RTV and IDV/RTV shown the same effectiveness as first-line HAART. Patients receiving IDV/RTV had a higher risk of stopping therapy for drug-related adverse events.
235	9.1/2 - HIV INFECTION IN OLDER ADULTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 235) Redondo C., Poza G., Galera C., Martinez J., Aguayo C., Bermejo M. 1. Diagnosis of HIV infection is delayed in older patients, usually at an advance clinical status. 2. Co-morbilities are usual. 3. HAART efficacy is high although toxicity is frequent.
236	9.1/3 - PERFORMANCE OF BUFFERED VERSUS ENTERIC DIDANOSINE IN HIV+ PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 236) Barreiro P., Corbatón A., Núñez M., González-Lahoz J., Soriano V. Enteric released ddI is associated with lower gastrointestinal toxicity than the buffered formulation.
237	9.1/4 - IDENTIFICATION OF NRTI TREATMENT LIMITING TOXICITIES AND DRUGS INVOLVED (RECOVER STUDY) European AIDS Conf 2003 Oct 25-29;9:(abstract no. 237) Palacios R.1, Santos J.1, Camino X.2, Arazo P.3, Torres R.4, Echevarría S.5, Ribera E.6, Moreno S.7, Mallaina P.8 and the RECOVER study group Abnormal fat distribution is the main toxic effect attributed to NRTI leading to discontinuation of the drug. Other events in which mitochondrial toxicity is involved (neuropathy, lactic acidosis,#) account for a significant number of NRTI withdrawals. In this serie, the drug which was most frequently withdrawn due to toxicity was stavudine.
238	9.1/5 - COMPARATIVE HEALTH-RELATED QUALITY OF LIFE OF HIV-INFECTED PATIENTS AND INSULIN-DEPENDENT DIABETICS (IDD) PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 238) Prazuck T.1, Ruiz A. 1, Emy P.2, Hocqueloux L. 1, Barrande G.2, Villeneuve A.2, Mille C. 1, Chadenas D.2 Assessement of HRQL is useful to provide specific care and optimize the durability of response to HAART
239	9.1/6 - INCIDENCE OF LYPODYSTROPHY IN CHILDREN RECEIVING FIRST LINE ANTIRETROVIRAL THERAPY (LINUSIN) European AIDS Conf 2003 Oct 25-29;9:(abstract no. 239) Fortuny C.1, Sánchez E.2, Ciria L.3, Dueñas J.3, Mellado M.J.4, Ramos J.T.5, Navarro M.L.6 These findings do not support the association between stavudine and lipodystrophy in pediatric patients on HAART.
240	9.1/7 - IMPACT OF ANTIRETROVIRAL TOXICITY ON HOSPITAL ADMISSIONS AMONG HIV-INFECTED PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 240) Nuñez M.J., Martin-Carbonero L., Valencia M.E., Garcia-Samaniego J., González del Castillo J., Soriano V., Gonzalez-Lahoz J. Currently, 9% of hospital admissions in HIV+ patients are due to HAART toxicity. Liver toxicity is the main one and mainly occurs in HCV-coinfected patients.
241	9.1/8 - ACUTE RENAL FAILURE IN HIV PATIENTS IN INTENSIVE CARE European AIDS Conf 2003 Oct 25-29;9:(abstract no. 241) Spichler A., Andrade L., Seguro A.C. ARF mortality in the ICU is very high and occurs most frequently in patients with a mean 75 months of HIV infection. Surviving patients presented lower levels of urea and creatinine and lower CD4 cells count at admission than did non-survivors.
242	9.1/9 - STAVUDINE HAS AN EXCELLENT LONG-TERM SAFETY AND TOXICITY PROFILE WHEN USED AS A FIRST- OR SECOND-LINE AGENT EARLIER IN DISEASE WITH HIGHER NADIR CD4 CELL COUNTS AND PERCENTAGES European AIDS Conf 2003 Oct 25-29;9:(abstract no. 242) Blick G.1, Greiger-Zanlungo P.1,2, Garton T.1, Arzu Z.1,2 Preliminary results demonstrate d4T has an excellent safety/toxicity profile with less LD and PN when used as the first-line thymidine ARV earlier in HIV disease with higher nadir CD4%/CD4#>350. When used as a second-line ARV following AZT, LD was increased and associated with lower nadir CD4%/# and HIV/HCV. British and US Guidelines may be contributing to increased d4T toxicities by delaying HAART initiation.
243	9.2/1 - RISK OF HYPERTRIGLICERIDEMIA IN 247 HIV INFECTED PATIENTS RECEIVING LOPINAVIR/RITONAVIR AS PART OF A SALVAGE REGIMEN European AIDS Conf 2003 Oct 25-29;9:(abstract no. 243) Bongiovanni M.1, Bini T.1, Meraviglia P.2, Capetti A.3, Testa L.4, Di Biagio A.5, Cicconi P.1, Tordato F.1, Melzi S.1, Chiesa E.1, Schiavini M.2, Landonio S.3, d'Arminio Monforte A.1 LPV/RTV showed a high effectiveness also as part of a salvage regimen. It was usually well tolerated. The main side effect observed was hypertrygliceridemia.
244	9.2/2 - CHANGES IN CHOLESTEROL LEVELS FOLLOWING TREATMENT SIMPLIFICATION TO TRIZIVIR® European AIDS Conf 2003 Oct 25-29;9:(abstract no. 244) McQuillan O., Prasad N., Day J. An additional benefit of switching to Trizivir is a reduction in cholesterol levels, particularly in those switching from a PI based regime.
245	9.2/3 - ATORVASTATIN AND PRAVASTATIN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA IN HIV POSITIVE PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 245) Smith N., Nelson M., Moyle G., Gazzard B. Both A and P decrease serum cholesterol in HIV-positive patients receiving HAART. The decrease was negligible as the majority of patients still had a cholesterol level above the upper limit of normal on treatment. There was no clear difference in effect on PI containing regimes as compared to non-PI regimes between treatment groups.
246	9.2/4 - ATORVASTATIN & PRAVASTATIN FOR HYPERCHOLESTEROLEMIA IN HIV-POSITIVE PATIENTS RECEIVING HAART European AIDS Conf 2003 Oct 25-29;9:(abstract no. 246) Smith N., Nelson M., Moyle G., Gazzard B. Both A and P decrease serum cholesterol in HIV-positive patients receiving HAART. The decrease was negligible as the majority of patients still had a cholesterol level above the upper limit of normal on treatment. There was no clear difference in effect on PI containing regimes as compared to non-PI regimes between treatment groups.
247	9.2/5 - INCIDENCE AND TREATMENT OF HYPERGLYCEMIA IN A COHORT OF 221 HIV-INFECTED PATIENTS RECEIVING A PROTEASE INHIBITOR-BASED ANTIRETROVIRAL THERAPY European AIDS Conf 2003 Oct 25-29;9:(abstract no. 247) Calza L., Manfredi R., Borderi M., Colangeli V., Farneti B., Tampellini L., Freo E., Chiodo F. In our study, a small but unnegligible incidence (6.3%) of HY has been reported in HIV-positive individuals receiving HAART, and oral antidiabetic agents revealed a similar, significant efficacy in the treatment of HY.
248	9.2/6 - HYPERLIPIDEMA IN HIV-INFECTED INDIVIDUALS RECEIVING ANTIRETROVIRAL THERAPY WITH INDINAVIR OR NELFINAVIR + 2NRTIS FOR 2 YEARS IN LIMA, PERU European AIDS Conf 2003 Oct 25-29;9:(abstract no. 248) Claros J., Hidalgo J., Collins J., Chumpitaz R., Rodriguez L., Vega J., Salazar R. We found a high prevalence of hyperlipidemia after 2 years of antiretroviral therapy in this Peruvian population. The most frequent disorder was HTG. Nelfinavir and indinavir-based regimens were associated to similar proportions of HCT and HTG. Age modified risk for mixed HLP.
249	9.2/7 - SHORT-TERM LIPID CHANGES ASSOCIATED WITH HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN NAÏVE HIV-INFECTED PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 249) Palacios R., Santos J., González M., Ruiz J., Márquez M., González P. As soon as 24 weeks after starting HAART, the prevalence of dyslipemias in our HIV-patients is high, with an increase of TC, LDL-C and Lp(a). Our results suggest that the aetiology of dyslipemias in HIV patients is multifactorial and mainly depends on host factors, disease stage and PI use.
250	9.2/8 - HIV-1 INFECTION, HAART AND METABOLIC DISORDERS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 250) Olczak A., Grabczewska E. Metabolic complication are frequent in patients receiving antiretroviral therapy. The difference in lipid profile of NNRTI and PI should have the influence on choice antiretroviral regimen.
251	9.2/9 - RISK OF HAART-ASSOCIATED HYPERGLYCAEMIA IN HIV/HCV CO-INFECTED PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 251) Ferreira A., Tavares M., Marques R., Piñeiro C., Silva S., Xeringa S., Mota Miranda A. HCV co-infection was not found to significantly increase the risk of HAART associated hyperglycaemia.
252	9.2/10 - COMPARATIVE ANALYSIS OF DYSLIPIDAEMIA IN PTS RECEIVING LONG TERM THYMIDINE ANALOGUE BASED HAART European AIDS Conf 2003 Oct 25-29;9:(abstract no. 252) Swiecki P., Firlag-Burkacka E., Horban A. Both analysed groups achieved similar treatment efficacy. Serum TG and cholesterol elevations were more frequent in D4T/3TC group. Due to high prevalence of dyslipidaemia patients should be routinely monitored for possible consequences.
253	9.2/11 - THE INFLUENCE OF HCV CO-INFECTION AND LIVER FUNCTION ON THE RISK OF LIPID ABNORMALITIES IN A COHORT OF HIV-1-INFECTED PATIENTS AFTER INITIATION OF HAART European AIDS Conf 2003 Oct 25-29;9:(abstract no. 253) Di Giambenedetto S.1, Baldini F.1,2, Fantoni M.1, Ammassari A.1, Murri R.1, Cingolani A.1, Cauda R.1, De Luca A.1, for the Rome CUSH HIV cohort HCV co-infection and liver enzyme alterations are associated with reduced probability of TChol elevations, relevant for CVD risk. Age, type of HAART and virological suppression are also significant predictors of dyslipidaemia.
254	9.2/12 - ATHEROGENIC LIPID PROFILE IN HIV-INFECTED WOMEN RECEIVING COMBINED ANTIRETROVIRAL TREATMENT European AIDS Conf 2003 Oct 25-29;9:(abstract no. 254) Leszczyszyn-Pynka M., Bander D., Boron-Kaczmarska A. 1.Undesirable serum lipids' levels (in context of CVR), especially LDL, in our female pts treated 3 years, require further permanent control and diet guidance at least. 2. HDL level remained the only protective factor as regards CVR.
255	9.2/13 - DYSLIPIDEMIA IN HIV INFECTED PATIENTS ON NELFINAVIR (NFV) COMPARED TO LOPINAVIR/RITONAVIR (LPV/R) European AIDS Conf 2003 Oct 25-29;9:(abstract no. 255) Dufresne S.1, Côté P.1, Baril J.-G.1, Junod P.1, Laplante F.1, Vandervliet W.2 NFV patients showed less new-onset dyslipidemia than patients on LPV/r. Lack of fasting data impaired the determination of statistical significance for hypercholesterolemia. The benefits of NFV on TG was greatest at 8 wks. Two-thirds fewer NFV patients required agents to control hyperlipidemia.
256	9.3/1 - FACIAL LIPOATROPHY IN HIV+ PATIENTS: QUALITY OF LIFE, ADHERENCE TO TREATMENT, PSYCHOPATHOLOGY AND STIGMATIZATION European AIDS Conf 2003 Oct 25-29;9:(abstract no. 256) Barata A.1, Domingo P.2, Sambeat M.A.2, Fuster M.2, Cadafalch J.2, Wulff J.1 Only State Anxiety is higher in the FLa group. The PSICOSOM test results point out the negative influence of facial lipoatrophy in personal and social adaptation.
257	9.3/2 - BODY FAT DISTRIBUTION CHANGES IN HIV PATIENTS RECEIVING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) European AIDS Conf 2003 Oct 25-29;9:(abstract no. 257) Madeddu G.1, Spanu A.2, Solinas P.2, Calia G.M.1, Lovigu C.1, Chessa F.2, Mannazzu M.1, Falchi A.2, Mura M.S.1, Madeddu G.2 In HAART-treated HIV patients fat loss with distribution changes may occur, significantly higher in FC than in NFC. The longer PI and NRTI therapy duration and the better immune recovery in FC, both conditions affecting adipocyte metabolism, seem the most probable risk factors in our cases, to be considered in patient management.
258	9.3/3 - BONE MASS LOSS IN HIV PATIENTS RECEIVING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY WITH FAT MASS CHANGES European AIDS Conf 2003 Oct 25-29;9:(abstract no. 258) Madeddu G.1, Spanu A.2, Solinas P.2, Calia G.M.1, Lovigu C.1, Chessa F.2, Mannazzu M.1, Falchi A.2, Mura M.S.1, Madeddu G.2 Bone mass loss, even osteoporosis, may occur in HIV patients on HAART, particularly when lipodystrophy is present and PI are included. An inverse correlation seems to exist between low BD and high T-FM; it is unclear whether their pathogenetic mechanism is common.
259	9.3/4 - ASSESSMENT OF ABDOMINAL FAT BY COMPUTED TOMOGRAPHY, ULTRASONOGRAPHY AND ANTHROPOMETRY IN HIV-INFECTED PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 259) Padilla S.1, Gallego J.A.2, Gutiérrez F.1, Masiá M.1, Escolano C.1, Ramos J.M.1, Ardoy F.2, Pascual J.1, Martín-Hidalgo A.1 These findings enhance the potential use of ultrasonography and anthropometric measurements to assess abdominal fat in HIV-infected patients. High agreement between sonographic and anthropometric assessments, and CT was found.
260	9.3/5 - QUANTITATIVE L4-MRI EVALUATION OF FAT REDISTRIBUTION SYNDROME (FRS): A CASE-CONTROL STUDY European AIDS Conf 2003 Oct 25-29;9:(abstract no. 260) Salomon J.1, de Truchis P.1, Carlier R.1, Clarissou1, Billy C.1, Michel A.L.2, Watissee M.2, Melchior J.C.1 Quantitative L4-MRI evaluation of FRS with VAT/TATindex is a reproductive and efficient method, except in patients with high BMI, and in women where VAT represents a better index.
261	9.4/1 - A 13C-METHIONINE BREATH TEST TO MONITOR MITOCHONDRIAL TOXICITY IN ANTIRETROVIRAL TREATED HIV INFECTED PATIENTS WITH HYPERLACTATAEMIA European AIDS Conf 2003 Oct 25-29;9:(abstract no. 261) Milazzo L., Piazza M., Sangaletti O., Moroni M., Riva A. 13C-methionine breath test showed mitochondrial function impairment in HIV patients on ART with hyperlactataemia. Drug suspension or regimen modification determined an amelioration of symptoms and of the mithocondrial respiratory chain as shown by blood tests and by the 13C exhalation test. This non-invasive test is useful to monitor ART mitochondrial toxicity in vivo.
262	9.4/2 - LOWERING STAVUDINE DOSAGES DOES NOT COMPROMISE ANTI-VIRAL EFFICACY IN HIV-1 INFECTED PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 262) Delpierre C., Cuzin L., Alvarez M., Khatibi S., Bonnet E., Obadia M., Massip P. Reduced-dose stavudine containing regimens maintained virologic suppression and CD4 increase on a 12-months period. Further studies are needed to assess the improvement of the long term
263	9.5/1 - PREVALEAT STUDY (PREMATURE VASCULAR LESIONS AND ANTIRETROVIRAL THERAPY). A COLOR-DOPPLER ULTRASONOGRAPHIC COMPARATIVE STUDY BETWEEN PATIENTS TREATED WITH PI-INCLUDING REGIMENS VS NNRTI-INCLUDING REGIMENS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 263) Maggi P.1, Epifani G.1, Lillo A.2, Perilli F.2, Ladisa N.1, Chirianni A.3, Gargiulo M.3, Ferraro S.4, Grisorio B.5, Ferrara S.5, Maserati R.6, Ravasi G.6, Martignoni A.7, Regina G.2, Pastore G.1 These data in our ongoing study show an higher prevalence of acquired carotid lesions even when compared with patients treated with NNRTI-including regimens. No statistical difference resulted when this latter group was compared with patients naïve
264	9.5/2 - PREVALEAT STUDY (PREMATURE VASCULAR LESIONS AND ANTIRETROVIRAL THERAPY). PATIENTS TREATED WITH NELFINAVIR-INCLUDING REGIMENS VS IDV-INCLUDING REGIMENS: A COLOR-DOPPLER ULTRASONOGRAPHIC COMPARATIVE STUDY European AIDS Conf 2003 Oct 25-29;9:(abstract no. 264) Maggi P.1, Epifani G.1, Lillo A.2, Perilli F.2, Ladisa N.1, Chirianni A.3, Gargiulo M.3, Ferraro S.4, Grisorio B.5, Ferrara S.5, Regina G.2, Pastore G.1 In conclusion, these data show a higher prevalence of acquired carotid
265	9.5/3 - SELECTED HOSPITAL ADMISSION RATES FOR PATIENTS WHO RECEIVED HAART European AIDS Conf 2003 Oct 25-29;9:(abstract no. 265) Fichtenbaum C.1, Lee D.2, Broderick W.2, Emons M.2, Goldberg G.2, Haberman M.2, Vendiola R.2 These results confirm a shift (as compared to the Pre-HAART era) in the reasons for hospitalization in persons exposed to HAART. Adverse effects associated with HAART may be an increasingly important explanation for non-infectious conditions resulting in hospitalization.
266	9.5/4 - LIPOPROTEIN (A), ANOTHER ATHEROGENIC FACTOR, AND HAART: PROSPECTIVE ANALYSIS IN NAÏVE HIV PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 266) Palacios R., Santos J., González M., Ruiz J., Márquez M., González P. Lp(a) levels in HIV-patients prior to start HAART are higher than in the general population. HAART induces an increase of Lp(a), reaching an atherogenic range in a third of cases. A high level of Lp(a) at 24 weeks was associated with a better immunologic response to HAART. Our results suggest that besides the traditional cardiovascular risk factors - hyperlipemia, hypertension, diabetes - another atherogenic lipid, Lp(a), may be increased in HIV patients on or prior
267	9.5/5 - HIGH PREVALENCE OF HYPERTENSION IN HIV-INFECTED PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 267) Santos J., Palacios R., Ruiz J., González M., Márquez M. The prevalence of SH and DH in our HIV-patients is high. SH and DH are associated with classic risk factors. It is important to measure blood pressure in these patients periodically. Although we have not observed any relation between HIV infection and/or HAART and SH/DH, prospective studies with a better analyse of their influence on blood pressure, are needed.
268	9.5/6 - DOPPLER TISSUE IMAGING PATTERN AND ANALYSIS IN HIV POPULATION AND ITS RELATION WITH CLINICAL DATA European AIDS Conf 2003 Oct 25-29;9:(abstract no. 268) Custódio H., Galeano A., Monge J., Galvao J., Bronze L., Arroja I., Azevedo J., Aleixo A. In our young assymptomatic HIV population, DTI analysis revealed an early stage of segmental LV myocardial dysfunction directly related with the time of infection and degree of CDC class.
269	9.6/1 - LIVER TOXICITY OF LOPINAVIR/RITONAVIR-CONTAINING REGIMENS IN HIV-INFECTED PATIENTS WITH OR WITHOUT HEPATITIS C VIRUS (HCV) CO-INFECTION European AIDS Conf 2003 Oct 25-29;9:(abstract no. 269) Gonzalez de Requena D., Nuñez M., Gonzalez-Lahoz J., Soriano V. The incidence of severe liver toxicity attributable to LPV/rit is low, although this complication may be more frequent among HCV+ patients. In contrast with other side effects associated to PI use, Kaletra liver toxicity does not seem to be related with LPV plasma levels.
270	9.6/2 - HEPATOTOXICITY ASSOCIATED WITH DUAL NUCLEOSIDE ANALOGUE ANTIRETROVIRAL THERAPY IN PATIENTS WITH HIV-1 INFECTION European AIDS Conf 2003 Oct 25-29;9:(abstract no. 270) Calza L., Verucchi G., Manfredi R., Chiodo F. In our study, an unnegligible frequence of transaminase elevation has been reported in HIV-1-infected patients receiving an isolated dual NRTI therapy of at least 12-month duration. Occurrence of liver toxicity was significantly more frequent in subjects treated with a stavudine-containing antiretroviral regimen.
271	9.6/3 - HEPATOTOXICITY AFTER HARRT IN HAEMOPHILIA PATIENTS HCV/HIV COINFECTED European AIDS Conf 2003 Oct 25-29;9:(abstract no. 271) Ioannidou P.1, Katsarou O.1, Touloumi P.2, Pantazis N.2, Kouramba A.1, Hatzakis A.2, Karafoulidou A.1 In this group of HIV/HCV coinfected haemophilia men, hepatotoxicity is common with mild severity, appearing soon after HAART initiation. Severe hepatotoxicity is a relatively rare event and it seems to be related to NVP.
272	9.6/4 - HEPATOTOXICITY ASSOCIATED WITH ANTIRETROVIRAL THERAPY IN ADULT HIV-1 INFECTED PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 272) Olczak A., Grabczewska E., Nowak W. Severe hepatotoxicity associated with HAART is uncommon. HCV infection and persistently elevated aminotransferases activity before treatment increases the risk of hepatotoxicity.
273	9.6/5 - ALT AND AST CHANGES OVER 48 WEEKS IN HIV- INFECTED THERAPY-NAÏVE ADULTS WITH HEPATITIS B (HBV) AND/OR C (HCV) CO-INFECTION TREATED WITH 908/R QD European AIDS Conf 2003 Oct 25-29;9:(abstract no. 273) Clumeck N.1, Faetkenheuer G.2, Halota W.3, Vera J.4, Flamm J.5, Stark T.6, Sexton A.7 HBV and/or HCV co-infected subjects receiving 908/r QD had a median decrease from baseline in ALT and AST levels. Less than 25% of the co-infected subjects had treatment emergent Grade 3/4 elevations in either AST or ALT levels. Overall, for subjects co-infected with HBV and/or HCV, hepatotoxicity was limited and comparable between the 908/r QD and NFV BID groups.
274	9.7/1 - SERUM LEPTIN (LP) LEVELS RELATED TO BONE MINERAL DENSITY IN HIV PATIENTS TREATED WITH HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) European AIDS Conf 2003 Oct 25-29;9:(abstract no. 274) Madeddu Gr.1, Spanu A.2, Solinas P.2, Calia G.M.1, Lovigu C.1, Chessa F.2, Mannazzu M.1, Falchi A.2, Mura M.S.1, Madeddu G.2 A significant negative relationship seems to exist between Lp and BMD in HIV males on HAART, suggesting a Lp and HAART effect on bone mass loss associated with HIV infection.
275	9.7/2 - BONE MASS LOSS RISK AND VITAMIN D METABOLISM IMPAIRMENT IN HIV PATIENTS TREATED WITH HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) European AIDS Conf 2003 Oct 25-29;9:(abstract no. 275) Madeddu Gr.1, Spanu A.2, Solinas P.2, Calia G.M.1, Lovigu C.1, Chessa F.2, Mannazzu M.1, Falchi A.2, Mura M. S.1, Madeddu G.2 HAART, especially when including PI, can be associated to bone mass loss, even to osteoporosis, and could also aggravate bone mass loss due to HIV infection itself. Hypotheses can be made concerning HAART effect directly on bone remodelling or indirectly on vitamin D metabolism.
276	9.7/3 - DYSLIPIDEMIA AND/OR GYNECOMASTIA OCCURRED OR WORSENED AFTER EFAVIRENZ INTRODUCTION European AIDS Conf 2003 Oct 25-29;9:(abstract no. 276) Manfredi R., Calza L., Chiodo F. Switching from PI-based regimens to those containing EFZ may not guarantee significant benefits on serum lipid abnormalities and/or gynecomastia, since an appreciable number of p developed these disturbances only after EFZ adjunct or initiation. Pathogenetic mechanisms underlying both dyslipidemia and gynecomastia and the eventual relationship with lipodistrophy are still unknown, especially for NNRTI, which were suggested as alternative agents for p who developed metabolic abnormalities while on HAART.
277	9.7/4 - HYPOPHOSPHATAEMIA IN PATIENTS TAKING TENOFOVIR European AIDS Conf 2003 Oct 25-29;9:(abstract no. 277) Day S.1, Leake Date H.1, Hankins M.2, Bannister A.1, Lambert N.1, Fisher M.1 The utility of routine phosphate monitoring in patients taking TDF is as yet unproven. The clinical significance of HP remains to be determined. Clinicians should exert caution before discontinuing TDF in patients with this biochemical abnormality.
278	9.7/5 - EMERGENCE OF SJOGREN SYNDROME DURING HAART European AIDS Conf 2003 Oct 25-29;9:(abstract no. 278) Mastroianni A. Rheumatic signs and symptoms have been increasingly reported in the setting of HIV infection, and the association between rheumatic diseases and HAART is clinically important. The pathogenesis of rheumatologic diseases induced by HAART is still unclear.We suggest that SS may be a new and an important side effect of HAART.
279	9.7/6 - EVOLUTION OF PERIPHERAL NEUROPATHY IN HIV-1-INFECTED PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 279) Haslinger B.A., Arendt G. This clear increase of the axonal type independent from neurotoxic medication indicates an evolution of polyneuropathy in the course of disease towards axonal degeneration.
280	9.8/1 - GENETIC VARIATIONS IN HLA-B REGION AND HYPERSENSITIVITY TO ABACAVIR IN AN OUTPATIENT POPULATION IN NORTHERN ITALY European AIDS Conf 2003 Oct 25-29;9:(abstract no. 280) Giola M.1, Rinaldini P.2, Basilico C.1, Foglia E.1, Rossi D.2, Grossi P.1 Our findings highlight that predictive values of HLA-B region typing vary among different populations, even within the Caucasoid subgroups. Thus, if a positive result for the hypersensitive aplotype HLA-B57, DR7 and DQ3 may allow clinicians to reduce the risk of hypersensitivity reaction withholding abacavir from such patients, a negative result cannot completely rule out a possible hypersensitivity reaction.
281	9.8/2 - EVALUATION OF EFFICACY AND SAFETY OF TENOFOVIR DF (TDF) AFTER SWITCH FROM STAVUDINE (D4T) IN 93 CHRONICALLY HIV-1 INFECTED PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 281) Schewe C.K.1, Adam A.1, Weitner L.1, Meyer T.2 Switching from d4T to TDF in intensively pretreated patients maintains antiviral control and immunological effect, and appears to be safe. The switch resulted in significant improvements of liver function and lipid profile.
282	9.8/3 - RECOVERY FROM HIV-ASSOCIATED ANEMIA AFTER INITIATION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) European AIDS Conf 2003 Oct 25-29;9:(abstract no. 282) Wyen C., Schmeisser N., Woehrmann A., Schmitz K., Balthesen H., Faetkenheuer G. In treatment-naïve patients with HIV-related anemia, hemoglobin levels increased significantly after initiation of HAART. Treatment with Zidovudine was the only independent risk factor for developing anemia under HAART.
283	9.8/4 - SWITCH TO TENOFOVIR IN PATIENTS WITH SUPPRESSED HI-VIRAEMIA European AIDS Conf 2003 Oct 25-29;9:(abstract no. 283) Haberl A.1, Müller A.1, Mösch M.1, Gute P.2, Klauke S.3, Staszewski S.1 Switching to tenofovir in pretreated patients with suppressed viraemia is effective. However virological failure should be observed carefully during the first weeks after therapy change.
284	9.8/5 - LOW DOSE STAVUDINE: AS EFFECTIVE AS STANDARD DOSE BUT LESS SIDE EFFECTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 284) Koegl C.1, Wolf E.1, Postel N.2, Buchberger A.2, Ruemmelein N.2, Jaegel-Guedes E.1,2, Jaeger H.1,2,3 D4T as part of HAART is effective in reducing viral load and in increasing CD4-count independent of low or standard dosage. PNP occured more often on standard dose than on low dose. In order to reduce side effects like PNP slight underdosage of d4T may be a reasonable approach.
285	9.8/6 - GENDER, ETHNIC, AND GEOGRAPHIC ASSOCIATIONS WITH QUALITY OF LIFE (QOL) IN PATIENTS BEFORE AND AFTER PI/NNRTI SUBSTITUTION WITH LOPINAVIR/RITONAVIR European AIDS Conf 2003 Oct 25-29;9:(abstract no. 285) Israelski D.M.1, Shen Y.2, Traves M.1, Sylte J.2, Tressler R.2, Rode R.2, for the M00-267 (PLATO) Study Group. Results suggest an association between gender, race, and geographic region and overall state of well-being; however, improvements in QOL were associated with BL substitution of the PI/NNRTI with lopinavir/ritonavir.
286	10.1/1 - STRATEGY FOR INCREASING ADHERENCE AMONG PATIENTS TREATED WITH HAART AT THE ACUTE STAGE OF HIV-INFECTION European AIDS Conf 2003 Oct 25-29;9:(abstract no. 286) Belyaeva V., Kravchenko A., Miroschnichenko A. The preparation of patients for the commencement of treatment for acute in-fection requires that adherence to HAART becomes an essential part of their coping behavior.
287	10.1/2 - PATIENTS ON HAART TRAVELLING THE USA - WHAT DO THEY DO? European AIDS Conf 2003 Oct 25-29;9:(abstract no. 287) Ponnusamy K., Lambert N., Perry N., Johnson D., Churchill D.R. Most HIV positive patients who travel to the USA have no visa waiver or HIV inclusive medical insurance. A significant number of patients on HAART stop medication, often in an unplanned way, and with adverse effects on their health.
288	10.1/3 - STARTING OR CHANGING HAART: READINESS OF PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 288) Fehr J.1, Nicca D.2, Spirig R.2, Wagels T.3, Kiss A.5, Bregenzer T.6, Vernazza P.4, Sendi P.1, Wolf E.7, Jäger H.7, Battegay M.1, and the the Swiss HIV Cohort Study Clinical decision-making depends strongly on patients readiness and on a shared decision. Readiness for therapy and a shared decision regarding start or change of therapy may impact on adherence.
289	10.1/4 - ADHERENCE OF FORMER DRUG ADDICTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 289) Deulina M., Yourin O., Narsiya R., Pokrovsky V. Perhaps the decreased efficacy and the reduced duration of therapy in the first group are related to insufficient adherence to therapy. The adherence of former drug addicts was lower but not without hope as a majority (88,2%) often completed 48 weeks of treatment in the trial. We suggest that more attention be paid to such patients through counselling for increased adherence
290	10.1/5 - THE CHANGING ACTIVITY PROFILE OF NURSES IN AN INPATIENT INFECTIOUS DISEASES UNIT European AIDS Conf 2003 Oct 25-29;9:(abstract no. 290) O'Doherty E., Charlier M., Clumeck N. The activity profile of nurses has predictably changed and evolved now integrating skills of education and counselling thus responding to different challenges seen with chronic HIV while maintaining their role of caring bedside professionals for those with acute nursing needs.
291	10.1/6 - THE IMPACT OF DEPRESSION ON HAART EFFECTIVENESS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 291) Mostaza J.L., Arias M.C., Bahamonde A., Prieto M., Rodriguez R. We found high incidence of DS in HIV infected patients. Depression seems to have a negative impact on HAART effectiveness. We have found a non significant tendency to a worse adherence and lower CD4 cell count in patients with DS. We think it's very important to identify all HIV infected patients with depression and further studies should examine if depression therapy could contribute to better control of HIV infection.
292	10.1/7 - RELATIONSHIP BETWEEN ADHERENCE, VIROLOGICAL OUTCOME AND QUALITY OF LIFE IN A COHORT OF PATIENTS ON TREATMENT WITH NELFINAVIR FOR MORE THAN 1 YEAR European AIDS Conf 2003 Oct 25-29;9:(abstract no. 292) Fumaz C.R.1, Aldeguer J.L.2, Lozano F.3, Knobel H.4, Casado J.L.5, Torralba M.6, Canoves L.7, Viciana P.8, García J.9, Ríos J.J.10, Clotet B.1 High values of ADH were observed in p taking NFV for at least 1 year. Its was confirmed again that virological outcome and ADH are strongly related as well as QOL and ADH. PE and ET play an important role in ADH and could be taken as predictors of ADH in future research.
293	10.1/8 - ADHERENCE TO ANTIRETROVIRAL THERAPY - INFLUENCE OF PATIENTS' PERSONALITY TRAITS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 293) Sucena S., Sargento P., Castro V., Gonçalves G., Vera J. No significant differences in ART adherence were observed between male and female patients.Medical evaluation of adherence to ARV based on patients' responses is influenced by the patients' need of social acceptance, and is therefore subject to patient lying. This can explain the discrepancy between estimated adherence levels results.
294	10.1/9 - DO AFRICAN PATIENTS ACCEPT AND ADHERE TO HAART? European AIDS Conf 2003 Oct 25-29;9:(abstract no. 294) Weeler H., Leventis P., Adewakun A., Fakoya A. There is no difference in uptake and adherence between the African and non-African groups.
295	10.1/10 - CD4 RESPONSE IN ELDERLY PATIENTS WITH AIDS RECEIVING HAART European AIDS Conf 2003 Oct 25-29;9:(abstract no. 295) Likatavicius G.1, Gravenstein S.2, Oldfield E.2 At least by laboratory parameters on post-hoc analysis, CD4 recovery appeared to be better among the Oldest patients, both in absolute and relative CD4 counts and viral copies, after controlling for drug dose and duration of therapy differences among observed groups. That the older patient achieved better response to therapy was counterintuitive, and may be due to social differences, such as better compliance with age. HAART appears to overcome age and viral effect of immune senescence as well as the negative selection of older populations that normally results in attrition due to other infections (such as influenza).
296	10.1/11 - 'YOU DON'T HAVE ANY PROBLEMS TAKING YOUR MEDICATIONS, RIGHT?' - A QUALITATIVE OBSERVATIONAL AND INTERVIEW STUDY OF PHYSICIANS' COMMUNICATION WITH PATIENTS ABOUT ADHERENCE TO HAART European AIDS Conf 2003 Oct 25-29;9:(abstract no. 296) Barfod T.S.1, Rubow C.2, Gerstoft J.1 Physicians seldom engaged in dialogue about patients' resources or adherence strategies. When adherence was addressed, most physicians did so relatively repetitively in their individual favourite way. This suggests that adherence communication can be improved if physicians learn a broader spectrum of communication strategies and topics.
297	10.1/12 - VIROLOGICAL SUCCESS >90% - CAN IT BE CHALLENGED? European AIDS Conf 2003 Oct 25-29;9:(abstract no. 297) Pehrson P.O., Darlington P., Ahlquist M., Halvarsson M. These results were also achieved in groups often regarded as more difficult to treat- intravenous drug users, people of non-European origin or who have a treatment history of mono or dual therapy. The success is probably due to a well-developed clinical stucture leading to knowledgable and well-motivated staff and patients.
298	10.1/13 - TRIPLE-NUC-THERAPY WITH TRIZIVIR® (ZIDOVUDINE 300MG, LAMIVUDINE 150MG, ABACAVIR 300MG) IN ANTIRETROVIRAL NAÏVE HIV-INFECTED INTRAVENOUS DRUG USERS (IDUS): WEEK 48 RESULTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 298) Jablonka R.1, Esser S.1, Körber A.1, Haberl A.2, Staszewski S.2 Exceeding our study continuation expectations the bid Trizivir® regimen shows efficacy in IDUs and demonstrates the usefulness and practicability of a simple ART regimen.
299	10.1/14 - ADHERENCE TO HAART AND SHORT-TERM OUTCOMES IN NAÏVE PATIENTS WITH RECENTLY DIAGNOSED HIV INFECTION European AIDS Conf 2003 Oct 25-29;9:(abstract no. 299) Ocana I., Feijoo M., LLinás M., Gómez R.M., Ribera E., Falcó V., Pahissa A. Adherence to HAART > 95% optimized the immuno-virologic outcome for HIV- infected patients, even in a short-term follow-up.This is particularly important in pregnant women, in order to avoid vertical transmission.
300	10.1/15 - ATAZANAVIR (ATV) IS ASSOCIATED WITH BETTER PATIENT ADHERENCE (AD): LONG-TERM FOLLOW-UP DATA FROM BMS 041 AND 044 STUDIES European AIDS Conf 2003 Oct 25-29;9:(abstract no. 300) Wu Y., Odeshoo L., Iloeje U., Mukherjee J., Cross A., Giordano M. AD to ATV appears to be high and durable compared to NFV in 041. Switching from NFV to ATV maintained high AD in 044.
301	10.1/16 - PROSPECTIVE EVALUATION OF INFLUENCE OF ART ON ADHERENCE FROM 1997-2001 European AIDS Conf 2003 Oct 25-29;9:(abstract no. 301) Lorenzen T., Meemken L., Graefe K., Meyer P., Fehr J., v. Krosigk A., Stoehr A., Plettenberg A. In the evaluated period virologic and immunologic response increased while intake modalities became easier. Reduced tablet-counts and minimized dosing schedule were associated with improved adherence. Additional substances for once-daily use are currently being investigated. The influence of once-daily therapy on adherence remains to be seen.
302	10.1/17 - IMPACT EVALUATION IN ADHERENCE THROUGH PARTICIPATION IN SUPPORT WORKSHOPS IN MEXICO European AIDS Conf 2003 Oct 25-29;9:(abstract no. 302) López P.1, Vázquez R.M.2, Gómez J.M.3 As far as the evaluations made over the 12 weeks and in accordance with the results obtained. The adherence workshops as an education method focused on covering specific necessities using previously proven isolated form methods demonstrated a positive impact in patient adherence to their anti-retroviral treatment
303	10.1/18 - THE LOW INCIDENCE OF RESISTANCE MUTATIONS IN NAÏVE PATIENTS RECEIVING 908/R QD COMPARED TO NFV BID CANNOT BE EXPLAINED BY ADHERENCE DIFFERENCES European AIDS Conf 2003 Oct 25-29;9:(abstract no. 303) Quattek K.1, Kotsopoulos N.1, Garris C.2, Elston R.3 Among NFV failures, a bell-shaped relationship between resistance and adherence appears to exist, with mutations occurring at all levels of adherence. In contrast, when patients are adherent to 908/r QD, virological failure and resistance mutations are rare, suggesting high potency and genetic resistance barrier.
304	10.1/19 - RELATIONSHIP BETWEEN FOUR ADHERENCE MEASUREMENTS AND CD4 COUNT RESPONSE European AIDS Conf 2003 Oct 25-29;9:(abstract no. 304) Trotta M.P.1, Ammassari A.2, Cozzi-Lepri A.3, Marconi P.1, Melzi S.4, Zaccarelli M.1, Murri R.2, De Longis P.1, Bontempo G.1, Ladisa N.5, Sighinolfi L.6, Castelli F.7, Madeddu G.8, Abrescia N.9, Lichtner M.10, Vecchiet J.11, Orofino G.12, d'Arminio Monforte A.4, Antinori A.1, for the AdICoNA2 Study Group Systematic non-adherence behaviours, such as prescription deviation and interruption in drug supply, are strongly associated with CD4 count and need to be investigated also.
305	10.1/20 - ADHERENCE AND PSYCHOLOGICAL IMPACT OF HAART IN A COHORT OF 112 HIV POSITIVE PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 305) Compostella S., Zeni C., Antonelli S., Lottieri S., Moretti E., Casari S., Torti C., Forleo M.A., Uccelli M.C., Lapadula G., Carosi G. Most pts showed GA, with a negative effect of the complexity of the therapy. Exhaustive medical information is related to less psychological distress and depression has a negative impact on the adherence. Male pts tolerate less than female the body changes due to HAART.
306	10.3/1 - ISS-QOL: QUALITY OF LIFE SELF-ADMINISTERED QUESTIONNAIRE FOR HIV INFECTED PEOPLE IN THE HAART ERA European AIDS Conf 2003 Oct 25-29;9:(abstract no. 306) Bucciardini R.1, Lorenzetti D.2, Grisetti R.3, Guarinieri M.4, Martini M.5, Murri R.6, Starace F.7, Vatrella A.8, Vella S.9 The direct involvement of HIV-positive people in all the phases of the project was an innovative characteristic of this work and resulted in high levels of efficiency. This new questionnaire can be a realistic tool for both clinical and practical research, identifying the actual needs of people living with HIV in the era of HAART.
307	10.3/2 - THE IMPORTANCE OF POTENCY AND DURABILITY IN HIV PATIENT ANTIRETROVIRAL THERAPY PREFERENCES European AIDS Conf 2003 Oct 25-29;9:(abstract no. 307) Sherer R.1, Fath M.2, da Silva B.2, Nicolau A.2, Gaultier I.2, Shabo V.3 When asked to make trade-offs, 90% chose a more durable BID ART over a less durable QD ART. HIV+ patients view ART potency and durability as being more important than dosing frequency or pill burden. These results may be of use to clinicians when discussing ART options with their patients.
308	10.3/3 - AIDS METAPHORS AND NURSING CARE IN PREGNANT WOMEN OF DIFFERENT CULTURES WHOSE HAVE JUST BEEN DIAGNOSED POSITIVE TO HIV European AIDS Conf 2003 Oct 25-29;9:(abstract no. 308) Feijoo M., Barrio A., Carballo M., Llinás M. Culture bacground was not a factor which marked differences by the time they were diagnosed as positive. Counselling and health education helped those women by reducing suffering and shame.
309	11.1/1 - DESCRIPTIVE ANALYSIS OF 868 BONE MARROW ASPIRATED IN HIV INFECTED PATIENTS IN SPAIN European AIDS Conf 2003 Oct 25-29;9:(abstract no. 309) Valencia M.E.1, Martínez P.2, Moreno V.1, González Lahoz J.M.1 Bone marrow aspirated (without biopsy) continue being a rapid and accurate method for diagnosing opportunistic infections and lymphomas in HIV-infected subjects. In patients with FUO and/or unexplained cytopenia, the more frequent problem in Spain are visceral leishmaniasis, disseminated mycobacteriosis and, recently, lymphomas. However, near 50% are non diagnostic and more aggressive explorations are needed.
310	11.1/2 - ADVERSE EFFECTS AND HEPATOXICITY IN THE TREATMENT OF LATENT TUBERCULOUS INFECTION (LTI) IN HIV (+) PATIENTS AND DRUG USERS HIV (-). ITS RELATIONSHIP WITH HEPATITIS C VIRUS (VHC) AND ANTIRETROVIRAL TREATMENT European AIDS Conf 2003 Oct 25-29;9:(abstract no. 310) Portu J.J., Aldamize M., Grivé N., Aizpuru F., Gómez M., Izaguirre M. 1) The adverse effects in the treatment of latent tuberculous infection are related to HIV infection and VHC. 2) In HIV + patients hepatoxicity is related to hepatitis C virus and not to the antiretroviral treatment nor to the CD4 values.
311	11.1/3 - COST-EFFECTIVENESS ANALYSIS OF SUPERVISED TREATMENT OF LATENT TUBERCULOUS INFECTION IN HIV PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 311) Portu J.J., Aldamize M., Aizpuru F., Gómez M., Erdozain M.A., Tarabini-Castellani P. 1) Treatment is cost-effective in relation to the free development of the tuberculous disease. 2) If the group given the non-supervised treatment is well selected this is cost-effective.
312	11.1/4 - DRUGS RESISTANCE IN TUBERCULOSIS IN HIV PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 312) González-Castillo J., Lozano M.A., Roca V., Tellez M.J., Vergas J., Estrada V. Tuberculosis is still an important disease in Spain due to HIV infection and immigration, mostly from South America. There is a high number of primary resistences to Isoniazid, so a 4 regimen drugs treatment must be prescribed initially while resistance test is done.
313	11.4/1 - UNUSUAL ORAL MANIFESTATIONS IN AIDS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 313) Crivello S.M.A.C., Furtado J.D., Thimermann A., Vipich R., Tardochi S., Cavalcante J.W.A. All of these infections 'ditto' opportunistics are well defined and during many years have been described in different AIDS stadium evolution. Neverthless, some of them merit notability owing their singularity and scarce frequency. Oral manifestations deserve distinction specially when are virotic and fungal ethiologies.
314	11.4/2 - SYMPTOMATIC AND ASYMPTOMATIC PNEUMOCYSTIS JIROVECI INFECTIONS IN HIV-POSITIVE PATIENTS: MOLECULAR EVALUATION European AIDS Conf 2003 Oct 25-29;9:(abstract no. 314) Golab E.1, Bednarska A.2, Bitkowska E.1, Horban A.2, Dzbenski T.1 1. P. jiroveci infections occurred more frequently among HIV-infected (59,75%) than among non-infected patients with immunosuppression (10%). 2. More than 50% of patients with HIV and CD4 count >200/mm3 had asymptomatic Pneumocystis infection. 3. Lungs could be cleared from Pneumocystis - 3 of 6 patients had different PCR results on examination of consecutive excretion samples obtained during two episodes of lung infections.
315	11.4/3 - DETECTION OF PNEUMOCYSTIS JIROVECI BY SIMPLE AND NESTED PCR IN BRONCHOALVEOLAR LAVAGE SPECIMENS AND SERUM FROM HIV-INFECTED PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 315) Golab E.1, Bednarska A.2, Horban A.2, Dzbenski T.1 1. sPCR with BAL samples is proved suitable for the routine diagnosis of acute PCP infections - giving 68,75% positive results for symptomatic patients. 2. nPCR with BAL samples, being more sensitive than sPCR, detected DNA in 20 asymptomatic patients and appeared is useful to confirm low levels of Pneumocystis jiroveci infections . 3. The nPCR test turned out to be of little value when used for serum DNA in PCP patients, showing positive results only in 4 (33,3%) symptomatic cases and 8 (66.7%) asymptomatic.
316	11.5/1 - BORDETELLA BRONCHISEPTICA IN PATIENTS WITH AIDS IN SPAIN European AIDS Conf 2003 Oct 25-29;9:(abstract no. 316) Valencia M.E.1, Enríquez A.2, Camino N.2, Moreno V.1, García Benayas T.1, Blanco F.1, Barreiro P.1, González Lahoz J.M.1 Bordetella bronchiseptica may be associated with pneumonia in HIV infected patients, especially those with severe immunodepression. The infection is recognised by standard bacteriologic culture of sputum and treatment should be based on the results of susceptibility testing. Although all the patients had low CD4 lymphocyte count, all were cured and discharged.
317	11.5/2 - FACTORS RELATED WITH NASOPHARYNGEAL CARRIER STATE OF S. AUREUS AND S. PNEUMONIAE IN HIV-INFECTED PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 317) Payeras A.1, Martínez P.2, Riera M.3, Milà J.2, Pareja A.1, Lladó B.1, Casal J.4, Matamoros N.2 The exact reasons for the carriage state in HIV-infected patients remain unclear. It may be studied specific immunological responses to one's own isolates, adherence of bacteria via non-specific and specific binding of adhesins to host cell receptors, or the role of some toxics on that interplay.
318	11.5/3 - HAVE HIV ASSOCIATED BACTEREMIAS CHANGED IN THE LAST YEARS? European AIDS Conf 2003 Oct 25-29;9:(abstract no. 318) Galera C., Poza G., Bermejo M., Aguayo C., Redondo C. The incidence of bacteremia has decreased. Staphylococci were the most common agent, but a significant increased in Gram - bacteremia and reduction in mycobacteremias has succeded. The outcome of bacteremias has improved.
319	11.5/4 - CONSIDERATIONS UPON THE RESULTS OF BLOOD CULTURES OBTAINED FROM HIV POSITIVE PATIENTS ADMITTED AT OUR INSTITUTE DURING A 6 YEAR PERIOD: 1997-2002 European AIDS Conf 2003 Oct 25-29;9:(abstract no. 319) Podani M., Benea E.O., Badea G., Necsoi C.V., Arama V., Botea S., Streinu-Cercel A. 33 (of 67) identified pathogens were considered as the actual cause;the rest of the bacteremias were not considered significant for sepsis but transient bacteremias with comensal pathogens of no clinical impact.
320	12.1/1 - HUMAN HERPESVIRUS 8 SEROPREVALENCE AND ONCOLOGIC DISEASES INCIDENCE IN HIV-POSITIVE INDIVIDUALS AND IVDU POPULATION: RELEVANCE FOR PREVENTION European AIDS Conf 2003 Oct 25-29;9:(abstract no. 320) Orofino G.C.1, Gennero L.1, De Vivo E.2, Pistono P.G.3, Teta E.2, Bignamini E.2, Bossi V.3, Carosella S.1, De Santis G.1, Caramello P.1 IVDU had lower HHV8+ prevalence than HIV+ group (p=0.04) and controls(p<0.05), but higher HCV and HBV prevalence. HHV8+HIV+ status and displastic diseases seem to be a relevant problem. Counselling and prevention of HHV8 transmission in the HIV+ pts is priority way.
321	12.1/2 - EFFECT OF NNRTI-BASED REGIMENS ON AIDS ASSOCIATED KAPOSI'S SARCOMA European AIDS Conf 2003 Oct 25-29;9:(abstract no. 321) Sotgiu G.1, Maserati R.2, Ravasi G.1, Gulminetti R.2, Zucchi P.1, Minoli L.1 In this group of patients NNRTI-based therapies showed no benefit on prognosis of KS lesions (60 % had a clinical progression), despite a significant immunologic recovery. This suggests the importance of PI both for the improvement of cellular immunity and for the inhibition of angioproliferative KS lesions.
322	12.2/1 - TRENDS IN KAPOSI'S SARCOMA AND NON-HODGKIN LYMPHOMAS INCIDENCE AS INDICATIVE DISEASES IN AIDS PATIENTS IN GREECE FROM 1981 THROUGH 2002 European AIDS Conf 2003 Oct 25-29;9:(abstract no. 322) Masgala A., Nikolopoulos G., Arvanitis M., Paraskeva D., Eleni E. The decline over time of the number of S.Kaposi cases as indicative disease in AIDS patients is attributed to the reduction of the total number of AIDS cases. The incidence of S.Kaposi in AIDS patients remains steady. In contrast, the total incidence of NHL, shows an increasing time trend in AIDS patients, but there is considerable differentiation between the NHL subtypes
323	12.2/2 - FIRST REPORT OF RITUXIMAB ALONE AS RESCUE THERAPY OF NON-HODGKIN LYMPHOMA RELATED TO CONGENITAL HIV DISEASE European AIDS Conf 2003 Oct 25-29;9:(abstract no. 323) Manfredi R., Chiodo F. Preliminary reports showed the potential of combined R therapy in HIV-related CD20 NHL in adults, although drug safety was of concern. Since no experience is described in the field of pediatric AIDS, our report suggests a promising potential of R alone in treating HIV-related, highly malignant, advanced,and refractory NHL.In our p, a 2nd cycle of R alone tested successfully in consolidating a sustained disease remission.
324	12.2/3 - HIV-ASSOCIATED SYSTEMIC NON HODGKIN'S LYMPHOMA (SNHL) OF GASTROINTESTINAL ORIGIN IS ESSENTIALLY AN INTESTINAL LYMPHOMA: A CASE SERIES IN LIMA, PERU European AIDS Conf 2003 Oct 25-29;9:(abstract no. 324) Collins J., Villena J., Hidalgo J., Hernández A., Castillo R., Salazar R. HIV-associated PGITL is our most common extra-nodal lymphoma, presenting with non-specific symptoms and at advanced stage. Origin was mainly intestinal, cellular types were B and T cell with similar frequency.
325	12.2/4 - T CELL PHENOTYPE IS A PROTECTIVE FACTOR FOR SURVIVAL IN HIV- RELATED SYSTEMIC NON-HODGKIN'S LYMPHOMA European AIDS Conf 2003 Oct 25-29;9:(abstract no. 325) Collins J., Villena J., Hidalgo J., Hernández A., Gutiérrez L., Salazar R. Survival of patients with HIV-related sNHL is much lower than described in North American and European series. Factors associated with a poor prognosis were CD4+ < 100 cel/ul and clinical stage IV lymphoma. T cell phenotype was associated with a decresed risk of death.
326	12.3/1 - PAPILOMAVIRUS TYPIFICATION AS A SCREENING METHOD FOR CERVICAL PATHOLOGY IN WOMEN WITH VIH European AIDS Conf 2003 Oct 25-29;9:(abstract no. 326) Santos J.1, Pujol E.3, Palomeque F.1, Borrero J.2, Ruano A.1, Rodriguez-Gomez F.J.3, Conde J.2 HPV detection, used with cytology, increase sensitivity for SIL screening in HIV infected women. Low CD4 counts were associated with HPV infection and cervical lesions. High viral load levels were associated with HPV infection but a non-significant trend was observed with cervical lesions.
327	13.1/1 - PYO-INFLAMMATORY PROCESSES IN SOFT TISSUES AMONG HIV-POSITIVE INJECTING DRUG USERS CO-INFECTED WITH HEPATITIS B AND C VIRUSES European AIDS Conf 2003 Oct 25-29;9:(abstract no. 327) Popov A.V.1, Cherkasov V.A.1, Palatova L.F.1, Zverev S.Y.2 Spreading of pathological process and its duration at pyo-inflammatory complications in soft tissues among HIV-infected IDUs depend on presence with co-infection hepatitis B and C viruses
328	13.1/2 - EVOLUTION OF HEPATITIS B VIRUS IN HUMAN IMMUNODEFICIENCY VIRUS COINFECTED PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 328) Tellez M.J.1, Vergas J.1, Fernandez C.2, Suarez A.3, Roca V.1, Estrada V.1 It is necessary to investigate for replication in all cases of HBV-HIV coinfection including HbeAb patients. Patients with transaminasitis after HAART have more probability of seroconversion. HAART including Lamivudin is effective against HBV in HBV-HIV patients.
329	13.2/1 - EFFECT OF HAART ON HCV VIRAL LOAD IN THE FIRST THREE YEARS OF FOLLOW-UP European AIDS Conf 2003 Oct 25-29;9:(abstract no. 329) Tornero C.1, Gimeno C.2, Santamaria A.1, Gil E.1, Sanchis-Bayarri V.1, Rull S.1 Although globally patients who respond to HAART maintain stable HCV-VL, some subjects may exhibit HCV RNA clearance in the first two years of treatment - maintaining this situation after three years. This should be taken into account when evaluating the already adjusted percentage responses to HCV specific therapies, when both types of treatment are administered concomitantly.
330	13.2/2 - HCV-INFECTION AMONG HIV-1-INFECTED NONIDUS IN RUSSIA European AIDS Conf 2003 Oct 25-29;9:(abstract no. 330) Bobkova M.1, Buravtsova E.1, Sukhanova A. (1,2), Kazennova E.2, Bobkov A.2, Pokrovsky V.1 Prevalence of HCV in HIV-infected nonIDUs seems to be extraordinarily high. The most possible explanation is that many nonIDUs actually have drug usage experience in their past and later on prefer to conceal or just attach no significance to it. Prevalence of subtype A HIV-1 typical for IDUs in Russia confirms this suggestion. Presence of antiHCV may play a role of surrogate marker and be considered when HIV-infected individuals are classified into main risk groups.
331	13.2/3 - SEROPREVALENCE OF HIV, HBV AND HCV AMONG BLOOD DONORS IN AND AROUND CALCUTTA (KOLKATA), STATE-WEST BENGAL, INDIA European AIDS Conf 2003 Oct 25-29;9:(abstract no. 331) Dey S.K.1, Senbarat P.K.2, Pal N.K.3 Baseline HCV prevalence is alarming. HIV prevalence is low in blood donors but increasing gradually & consistent with ANC-HIV sentinel surveillance -0.3% in Calcutta, Westbengal after 6 rounds as against 0.7% estimation of UNAIDS for India. Effective interventions to to prevent transfusion transmitted diseases urgently needed. Compulsory HCV, HBV screenig in HIV+ves requiring ARV drugs, whose use is incresing in india with drastic price reductions. (ARV drugs 3TC, d4t, Nevirapine-1 Euro./day).
332	13.2/4 - TREATMENT COMBINATION WITH PEGYLATED-INTERFERON AND RIBAVIRIN IN CRHONIC HEPATITIS OF HIV-HCV COINFECTED PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 332) Santos I., Zabaleta J.P., Rodríguez-Serrano D.A., Sanz J. Our results show that combination therapy is effective in 43% of the cases in clearing serum HCV-RNA, especially in genotype 3 (77,7%).
333	13.2/5 - THYROID DISFUNCTION DURING TREATMENT OF CHRONIC HEPATITIS C WITH INTERFERON IN PATIENTS CO-INFECTED BY HUMAN IMMUNODEFICIENCE VIRUS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 333) Laguno M.1, Mallolas J.1, Naf S.2, Leon A.1, Biglia A.1, Loncá M.1, Blanco J.L.1, Larrouse M.1, Martinez E.1, Gatell J.M.1 Thyroid dysfunction occurred in 9% of HIV patients treated for chronic hepatitis C with INF. The PEG-INF formulation seems to be related with higher incidence of thyroid dysfunction. Regular monitoring of TSH/fT4 concentration is essential for early diagnosis and treatment of thyroid complications.
334	13.2/6 - THE TREATMENT OF ACUTE HEPATITIS C INFECTION IN HIV-COINFECTED PATIENTS - A RETROSPECTIVE ANALYSIS OF 8 CASES IN A MULTICENTER SETTING European AIDS Conf 2003 Oct 25-29;9:(abstract no. 334) Vogel M.1, Bieniek B.2, Jessen H.3, Schewe C.K.4, Lutz T.5, Kroidl A.6, Bogner J.7, Spengler U.1, Rockstroh J.K.1 Treatment with interferon +/- ribavirin initiated during the acute phase of HCV-infection in HIV-positive patients appears to be very effective. Further trials are needed, however, to validate these findings.
335	13.2/7 - LONG-TERM OBSERVATION OF CHANGES IN HAZARD FUNCTION AND CAUSES OF DEATH IN JAPANESE HEMOPHILIACS INFECTED WITH HIV-1 European AIDS Conf 2003 Oct 25-29;9:(abstract no. 335) Tatsunami S.1, Taki M.2, Mimaya J.3, Shirahata A.4, Kuwabara R.5, Yamada K.2 The striking decline in the hazard function correlates with protease inhibitors becoming available in Japan. A survival fraction > 60% at the end of 2002 will most likely be related to the young ages of the subjects during the period of HIV-1 infection. The slight rise in hazard function in 2000 seems to parallel the recent increase of serious liver disease originating from HCV in these patients.
336	13.2/8 - METABOLIC DISTURBANCES IN LIVER 1H MR SPECTROSCOPY IN HIV AND HCV COINFECTED PATIENTS AS A POTENTIAL MARKER OF HEPATOCYTE ACTIVATION European AIDS Conf 2003 Oct 25-29;9:(abstract no. 336) Wiercinska-Drapalo A.1, Tarasów E.2, Jaroszewicz J.1 Our finding suggest clinical usefulness of liver 1H MR spectroscopy in detecting even slight disturbances in liver metabolism despite the lack of other markers of liver injury and regeneration in HIV/HCV coinfected patients.
337	13.2/9 - HEPATITIS C VIRUS GENOTYPES IN HIV-INFECTED PATIENTS OF SPAIN European AIDS Conf 2003 Oct 25-29;9:(abstract no. 337) Roca B.1, Suarez I.2, Gonzalez J.3, Garrido M.4, Galindo M.J.5, Domingo P.6, Ribera E.7, Viciana P.8, Lozano F.9, Teira R.10, Vergara A.11, Geijo P.12, Sanchez T. (13), Cosin J. (14), Terron A. (15), Garcia-Alcalde M.L. (16) In HIV-infected people of Spain, HCV genotype 1 is the predominant, although major discrepancies exist among different cities.
338	13.2/10 - EFFECT OF INTERFERON ALPHA ON CD4, CD8, AND CD45RO AND CD45RA SUBPOPULATIONS T CELLS IN HCV AND HIV-COINFECTED PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 338) Arizcorreta A., Brun F., Montes de Oca M., Martin M., Soto M.J., Martin A., Perez E., Giron J.A. A significant diminution of CD4 and CD8 T cells, and of their naïve and memory subpopulations in HIV-HCV coinfected patients in treatment with interferon. Higher decrease is expected in those treated with PEG-Interferon.
339	13.2/11 - LIVER BIOPSY IN HIV AND HEPATITIS C VIRUS CO-INFECTED PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 339) Mendes-Corrêa M.C., Martins-Filho L.G., Guastini C., Brussi M.L., Gutierrez E., Carrasco R., Barbosa H.M., Barone A.A. In co-infected patients: 1- Transaminase level does not accurately reflect the degree of fibrosis or inflammatory activity of the liver; 2- Liver biopsy may help in the diagnosis of other liver diseases and it should be carried out in order to establish a correct management of liver disease.
340	13.2/12 - DEPRESSIVE SYMPTOMS AFTER INITIATION OF INTERFERON IN HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENTS WITH CRONIC HEPATITIS C European AIDS Conf 2003 Oct 25-29;9:(abstract no. 340) Laguno M.1, Mallolas J.1, Blanch J.2, Leon A.1, Biglia A.1, Loncà M.1, Blanco J.L.1, Larrousse M.1, Milinkovich A.1, Martinez E.1, Gatell J.M.1 The incidence of depressive symptoms in patients with HIV/HCV co-infection treated with interferon alpha is high. Most of the depressive symptoms were mild to moderate and improved with antidepressant therapy, without reduction or cessation of IFa therapy. During the first weeks after initiating IFa therapy in HIV/HCV co-infection, close assessment of psychiatric symptoms is recommended. Premature treating of these side effects with antidepressants would avoid early dropouts of interferon therapy.
341	13.2/13 - INCREASED RANTES STEADY STATE MRNA LEVELS IN LIVER BIOPSIES OF HIV/HCV-COINFECTED PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 341) Kuntzen T.1, Tural C.3, Feldmann G.1, Leifeld L.1, Wolff M.2, Dumoulin F.L.1, Nischalke H.D.1, Clotet B.3, Sauerbruch T.1, Spengler U.1, Rockstroh J.1 We here report increased intrahepatic RANTES levels in HIV/HCV-coinfected patients as compared to patients with HCV infection alone, which may importantly contribute to enhanced hepatic inflammation and accelerated progression towards cirrhosis in double infected patients.
342	13.2/14 - FACTORS ASSOCIATED TO PROGRESSION OF HCV LIVER DISEASE IN HIV/HCV CO-INFECTED PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 342) Lomas J.M., Rodríguez-Gómez F.J., * Pérez S., Merino D., Pujol E. 1. Among the variables related to VIH infection we did find that > 50 g/ethanol/day consumption, the time of addiction to drugs by parenteral route and ALT levels do not have significant association with the VHC chronic liver disease progression in our VIH population. These results can be influenced by the small sample size. 2. Our analysis either allows to draw conclusions of the possible association between VHC chronic liver disease and the immunovirologic situation of VIH patients or HCV RNA at the time of the biopsy realization.
343	13.2/15 - IMMUNE DEACTIVATION AND APOPTOSIS AFTER STARTING HAART: DELETERIOUS EFFECT OF HIV/HCV COINFECTION European AIDS Conf 2003 Oct 25-29;9:(abstract no. 343) Macias J. (1,2), Maldonado R.3, Miñano J.3, Merchante N.1, Corzo J.E.2, Garcia-Garcia A.1, Vegara S. (1,2), Mira J.A.1, Gomez-Mateos J.2, Pineda J.A.2 HIV/HCV-coinfected patients show a worse immune deactivation and higher levels of apoptosis after starting HAART than patients without HCV coinfection.
344	13.2/16 - THE PRESCO STUDY: PEGINTERFERON-(ALPHA)2A PLUS RIBAVIRIN FOR THE TREATMENT OF CHRONIC HEPATITIS C IN HIV-COINFECTED PATIENTS IN SPAIN European AIDS Conf 2003 Oct 25-29;9:(abstract no. 344) Nuñez M.1, Camino N.1, Ocampo A.2, Miralles C.2, Barreiro P.1, Prieto A.3, Losada E.3, Martín-Carbonero L.1, Garcia-Samaniego J.1, Romero M.1, Hernández-Burruezo J.J.4, Soriano V.1 PegIFN-α2a plus RBV is relatively safe in HCV/HIV-coinfected patients. In contrast with previous trials, the early virological response seems to be similar to that seen in HCV-monoinfected patients.
345	13.2/17 - TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS COINFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 345) Lozano M.A., Rojano B., Candel F.J., Caminero R., Vergas J., Tellez M.J., Estrada V., Roca-Arbones V. The efficacy of the treatment with PegIFNa-RBV in patients co-infected is lesser than observed in non-HIV patients. HCV genotype being the main factor predicting the good response to therapy. The treatment with HAART would determine some additional risk of AE in patients on anti-HCV therapy.
346	13.2/18 - WHAT PROPORTION OF HIV-INFECTED PATIENTS WITH ANTIBODIES TO HEPATITIS C VIRUS (HCV) HARBOUR ACTIVE HCV REPLICATION? European AIDS Conf 2003 Oct 25-29;9:(abstract no. 346) Toro C., Ríos P., Bassani S., Soriano V. Similar to what is seen in HCV-monoinfected individuals, nearly 1/6 of anti-HCV Ab positive individuals with HIV coinfection show no active HCV replication. Therefore, our data do not support a higher rate of chronification of HCV in the setting of HIV infection. Alternatively, prior exposure to HCV in subjects who thereafter become infected with HIV could explain our findings.
347	13.2/19 - PREVALENCE OF NON-ADVANCED LIVER FIBROSIS AMONG HIV/HCV-COINFECTED PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 347) Merchante N.1, Macías J.1,2, Palacios R.B.3, Mira J.A.1, Castellanos V.4, Sáez C.5, García A.1, Lozano F.2, Corzo J.E.2, Pineda J.A.1,2 There is a considerable proportion of coinfected patients with non-advanced liver fibrosis. Therefore, LB is necessary as a pre-therapy test in this setting.
348	13.2/20 - HAART NON-ADHERENCE AND HCV/HIV CO-INFECTION European AIDS Conf 2003 Oct 25-29;9:(abstract no. 348) Ammassari A.1, Trotta M.P.2, Cozzi-Lepri A.3, De Luca A.1, Melzi S.4, Zaccarelli M.2, Castelli F.5, Narciso P.2, Soscia F.6, Murri R.1, Scasso A.7, Izzo C.M.8, Baldelli F.9, d'Arminio Monforte A.4, Antinori A.2, for the AdICoNA Study Group HIV+ pts with chronic HCV infection and abnormal ALT reported poorer HAART adherence compared to those HCV+ with normal ALT or not co-infected. This effect was independent from active IDU and might be due to a lower HAART tolerability. Adherence measurement should be included as cofactor in longitudinal investigations of clinical progression in HIV+/HCV+ co-infection.
349	13.2/21 - INFLUENCE OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY FOR HIV ON COMBINED HEPATITIS C THERAPY European AIDS Conf 2003 Oct 25-29;9:(abstract no. 349) De Paula Bueno J.M., Moll A., Gölz J., Schleehauf D., Klausen G., Prizwara D., Nzimegne-Gölz S. Parallel treatment of HIV and HCV results in higher discontinuation rates than treatment of HCV alone. Therefore, therapy for HCV should be given on ist own in co-infected patients if this is immunologically feasible.
350	13.2/22 - FACTORS ASSOCIATED TO PROGRESSION OF HCV LIVER DISEASE IN HIV/HCV CO-INFECTED PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 350) Lomas J.M., Rodríguez-Gómez F.J., Pérez S., Merino D., Pujol E. > 50 g/ethanol/day consumption, the time of addiction to drugs by parenteral route and ALT levels do not have significant association with the VHC chronic liver disease progression in our VIH population. Our analysis either allows to draw conclusions of the possible association between VHC
351	13.4/1 - OBSTACLES TO HCV CLINICAL CARE AMONG HCV AND HCV-HIV INFECTED PATIENTS: GYMKHANA SURVEY European AIDS Conf 2003 Oct 25-29;9:(abstract no. 351) Bentata M.2, Aubert J.P.2, Bouee S.1, Compagnon S.2, ElghoziI B.2, Livrozet J.M.2, Mechali D.2, Perdieau J.F.2, Py A.M.2, Rozenbaum W.2, Taulera O.2, Wajsbrot A.2 and the GYMKHANA study group Efforts for a better screening of patients at risk for, resolution of social or addictive problems, a better relationship between patients and practitioners, could enhance optimal clinical care. In co-infected patients the main obstacle remains physical impairment.
352	13.4/2 - IMIQUINOD CREAM 5% IN THE TREATMENT OF MOLLUSCUM CONTAGIOSUM. OUR EXPERIENCE European AIDS Conf 2003 Oct 25-29;9:(abstract no. 352) Arcidiacono I.1, De Filippi C.2, Cerri C.1, Bazzigaluppi F.2, Tinelli M.1 We want the present our experience in order to add more data as the efficacy of imiquinod in the treatment of viral diseases other than anogenital warts.
353	13.4/3 - INFLAMMATORY CYTOKINES IN CEREBROSPINAL FLUID OF PATIENTS WITH AIDS-ASSOCIATED PML IN THE ERA OF HAART: HARMFUL OR BENEFICIAL IMMUNE REACTION? European AIDS Conf 2003 Oct 25-29;9:(abstract no. 353) Marzocchetti A.1, Cingolani A.1, Di Giambenedetto S.1, Giancola M.L.2, Antinori A.2, De Luca A.1 Selected markers of immune response/activation may be favourable prognostic indicators in AIDS-associated PML in the HAART era.
354	13.4/4 - HCV-RNA DETECTION IN BRONCHOALVEOLAR LAVAGE OBTAINED FROM HIV AND HCV COINFECTED PATIENTS WITH CONFERMED OR SUSPECTED TUBERCULOSIS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 354) Bednarska A.1, Zalewska-Schonthaler N.1, Horban A.1, Radkowski M.2 The presence of HCV-RNA in BAL cells is frequent. The correlation between tuberculosis and HCV replication seems to be possible. This phenomenon can be due to immune cell activation and propagation of the HCV replication.
355	13.4/5 - CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA IN HIV-INFECTED PATIENTS NOT RECEIVING ANTIBACTERIAL THERAPY: COMPLICATION OR COINFECTION? European AIDS Conf 2003 Oct 25-29;9:(abstract no. 355) Burke M., Werner B., Vardinon N., Mardkhah E., Yust I. CDAD in patients with AIDS may be due to other factors than antibiotic therapy. Coinfection during receptive anal intercourse, CD4 count, viral load and non-antibacterial agents, including HAART and Fluconazole, should be considered.
356	13.4/6 - ADDITION OF RIBAVIRIN AT THIRD MONTH OF PEG-IFN MONOTHERAPY IN HIV-HCV COINFECTED PATIENTS WITH POSITIVE HCV VIREMIA European AIDS Conf 2003 Oct 25-29;9:(abstract no. 356) De Bona A.1, Ciuffreda D.2, Gallotta G.3, Sagnelli C.4, Lazzarin A.5, Uberti-Foppa C.6 Our data indicate that, in HIV-HCV coinfected subjects without an HCV-RNA decrease of 2 log during IFN-αlpha monotherapy, the addition of ribavirin at third month is not associated with significant advantage of tolerability (drop-out 34.7%); the drop-out is associated with a concomitant HAART. Moreover this drugs schedule is associated with a low sustained virological response (23.8%).
357	13.4/7 - INFLUENCE OF HTLV-II INFECTION ON HEPATITIS C VIRUS CLEARANCE IN HIV-POSITIVE PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 357) Toro C., Bassani S., Ríos P., Rodés B., Soriano V. Although HTLV-II infection is frequently found in coinfection with HIV and HCV, it does not seem to modify the natural clearance of HCV in these patients.
358	13.4/8 - MODIFICATIONS OF SENV REPLICATION AND/OR SENV SUBTYPES OVER A PROSPECTIVE FOLLOW-UP IN A COHORT OF HIV-POSITIVE PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 358) Quiros-Roldan E., Moretti F., Torti C., Nasta P., Giovanelli G., Carosi G. We have demonstrated high degree of instability of both SENV viremia and subtype in a cohort of HIV-infected patients and this may have important implications in further studies on both SENV epidemiology and its clinical impact.
359	14.1/1 - VERTICALLY TRANSMITTED HIV PRESENTING IN ADULTHOOD European AIDS Conf 2003 Oct 25-29;9:(abstract no. 359) Hay P.1, Majewska W.2, Railton J.2, Sharland M.3, Scullard G.4, Pakianathan M.2 Children with vertically acquired HIV infection may survive to adulthood without symptoms. Healthcare workers should actively seek screening for HIV in all children of seropositive women regardless of age.
360	14.1/2 - MOTHER TO CHILD TRANSMISSION: EPIDEMIOLOGY OF VERTICAL TRANSMISSION IN DEMOCRATIC REPUBLIC OF CONGO (DRC) European AIDS Conf 2003 Oct 25-29;9:(abstract no. 360) Lutete A., Kipulu G., Faray D. The D.R.Congo with 60,000,000 people, country in war since 1996; 700 to 1,000 rape of women per day; positive prevelence is 5% betwen 15 to 49 years and 3% to pregnancy women.
361	14.2/1 - HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)IN PREGNANT HIV-INFECTED WOMEN. EFFICACY AND SAFETY FOR THE MOTHERS AND INFANTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 361) Abarzúa F. 1, Hubinont C. 1, Bernard P. 1, Debiève F. 1, Goubau P.3, Benoit K.3, Brichard B.4, Vandercam B.2 No case of MCT was observed with HAART. The viral load was undetectable or less of 250 c/ml at delivery in 96.6% of cases.
362	14.2/2 - THE RISK OF VERTICAL HIV TRANSMISSION IN POLAND European AIDS Conf 2003 Oct 25-29;9:(abstract no. 362) Marczynska M., Szczepanska-Putz M., O'dakowska A. Lack of offering testing for HIV infection to all pregnant women in Poland results in high HIV vertical transmission rates. On the other hand the risk of transmission among children who received prophylaxis is low and similar to transmission rates in west European countries.
363	14.3/1 - THE EFFECT OF HIGHLY ACTIVE ANTIRETROVIRAL TREATMENT (HAART) ON BREAST MILK : A VIROLOGIC AND PHARMACOKINETIC STUDY European AIDS Conf 2003 Oct 25-29;9:(abstract no. 363) Colebunders R. (1,2), Hodossy B.1, Van Bulck B.3, Pelgrom Y.1, Burger D.3, Fransen K.1 In all women treated with HAART during pregnancy and post-natally the viral load was < 400 copies/ml plasma in plasma and breast milk. This pilot study suggests that, in low income countries, through the treatment of women with HAART during breast feeding, the child's infection risks will be very low.
364	15.1/1 - BOTULINUM TOXIN IN THE TREATMENT OF HIV-RELATED SPASTICITY IN CHILDREN European AIDS Conf 2003 Oct 25-29;9:(abstract no. 364) Noguera A.1, Fortuny C.1, Pérez-Dueñas B.2, Póo P.2 Although highly active antiretroviral therapies (HAART) may halt or even partially reverse HIV-associated progressive encephalopathy (PE) in vertically infected children, sequelae similar to those observed in static encephalopathies, including limb spasticity, usually with normal or mildly affected cognition are often observed. Botulinum toxin type A (BT-A) injection has been proved to be a well tolerated, safe and effective procedure in the treatment of children with cerebral palsy.
365	15.2/1 - TREATMENT OF HIV INFECTED CHILDREN IN POLAND European AIDS Conf 2003 Oct 25-29;9:(abstract no. 365) Marczynska M., Szczepanska-Putz M., Oldakowska A. No 'the best' therapeutic antiretroviralscheme exist. Before starting the treatment resistance tests should be performed.
366	15.2/2 - OUTCOME OF EARLY HAART IN INFANTS: A MULTICENTER SPANISH AUDIT European AIDS Conf 2003 Oct 25-29;9:(abstract no. 366) Ramos J.T.1, Manso B.1, Otero M.C.2, De José M.I.3, González Montero R.4, León J.A.5, Navarro M.L.6, Beceiro J.7, Ciria L.8, Roa M.A.9, Rubio B.10 Despite an overall suboptimal virological response in infants treated early in life, HAART is associated with an absence of clinical or immunologic progression.
367	15.2/3 - OUTCOME OF PROTEASE INHIBITOR SUBSTITUTION WITH NEVIRAPINE IN HIV-INFECTED CHILDREN European AIDS Conf 2003 Oct 25-29;9:(abstract no. 367) González-Tomé M.I.1, Mellado Peña M.J.2, Martín-Fontelos P.1, Navarro M.L.3, Ramos J.T.1 PI substitution with nevirapine improves total cholesterol and HDL cholesterol. Switching to a nevirapine-containing regimen is safe and successfully maintained virological suppression in most children. No significant changes in fat distribution or BMD has been observed in this study. Larger studies with longer follow up are necessary the assess the convenience of simplification strategies in HIV-infected children.
368	15.2/4 - MULTIRESISTANT CONGENITAL HIV INFECTION TREATED SHORTLY AFTER BIRTH: AN INCREASING THERAPEUTIC CHALLENGE European AIDS Conf 2003 Oct 25-29;9:(abstract no. 368) Manfredi R., Calza L., Chiodo F. Initial suboptimal treatments, late availability of most anti-HIV agents for pediatric administration, and low adherence, become responsible for the development of a very extensive viral resistance pattern, and the tendency to repeated failure of salvage regimens, with increasing consequences on clinical progression of HIV disease. Clinicians facing congenital HIV infection treated since birth and overcoming adolescence, now rely on either mega-HAART regimens, or structured therapeutic interruptions, or have to wait for a rapid approval of novel compounds.
369	15.4/1 - USEFULNESS OF ABDOMINAL ULTRASOUND IN DIAGNOSIS OF LIPODYSTROPHY IN HIV-INFECTED CHILDREN European AIDS Conf 2003 Oct 25-29;9:(abstract no. 369) Mellado M.J.1, De José M.I.2, Bellón J.M.3, Navarro M.L.3, Casanova A.3, Prieto C.2, Serrano C.4, Babé J.1, Sánchez-Torres A.M.1, Muñoz M.A.3 The abdominal ultrasound is a usefulness technique, non-invasive and without any adverse effect for diagnosis and control of LD in HIV-infected children. The most sensible section for the diagnosis of LD was that performed at level of coeliac trunc. Therefore, it would be necessary to provide ultrasound reference parameters in healthy pediatric population and to perform developmental studies in order to validate these data.
370	15.5/1 - PATTERN OF SEXUALLY TRANSMITTED DISEASES IN ADOLESCENTS IN A DEVELOPING COUNTRY European AIDS Conf 2003 Oct 25-29;9:(abstract no. 370) Olasode O.A. Sexually transmitted diseases do occur in adolescents in developing cuontries with candida infections being very common. Females may be more conscious of their sexual health. Great attention should be placed on adolescent sexual healthcare in the tropics.Sexual habit modification is essential.Std prevention and early treatment is neccessary to prevent the epidemic of HIV/AIDS in adolescents.
371	15.5/2 - PROBLEMS ENCOUNTERED BY ORPHANED SCHOOL DROPOUTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 371) Mayengo A. In conclusion, we discovered that poverty, disappointments in life, lack of jobs and involvement in prostitution and drugs, have increased the rate of HIV/AIDS.
372	16.2/1 - USE OF PRESERVATIVES BY PEOPLE WITH HIGH RISK BEHAVIOR FOR INFECTION BY HIV: REGULAR MEDICAL FOLLOW UP AND OWN AND PARTNER HIV STATE AS ADHESIVE MARKERS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 372) Saperas M., Fernandez L., Soler A., Llargués E., Pedrol E., Montull S. 1. In high risk HIV behavior people don't usually use preservatives. 2. Its use depends
373	16.2/2 - INTRODUCING SOMATIC CULTURE AS A FACTOR IN THE EXPLANATION OF HIV PROTECTION BEHAVIOUR European AIDS Conf 2003 Oct 25-29;9:(abstract no. 373) Gredig D., Parpan A., Nideroest S. By introducing somatic culture in explanations of HIV protection behaviour, this study represents an addition to the socio-cognitive explanation models of protection. It makes a contribution to a theoretically more comprehensive and better targeted prevention for heterosexual men.
374	16.3/1 - IMPACT OF RECOMMENDATIONS ON THE MANAGEMENT OF ACCIDENTAL EXPOSURE TO BLOODBORNE PATHOGENS IN A GENERAL HOSPITAL CENTER European AIDS Conf 2003 Oct 25-29;9:(abstract no. 374) David-Ouaknine F., Vidal P., Froguel E., Simon P., Augustin-Bourgeois M., Costa Y. The local information campaign led to decrease of severe occupational exposures, nevertheless continuing information on the use of gloves and other standard précautions is needed in order to mainted this good result.The increase of high risk sexual exposure is probably due to a better information. Specific intervention strategies are needed to limit high risk exposures in IVDU and sexual exposures.
375	16.5/1 - TOPICAL ISSUES IN THE DESIGN OF PHASE III CLINICAL TRIALS OF MICROBICIDES European AIDS Conf 2003 Oct 25-29;9:(abstract no. 375) Stone A.B. Another central issue concerns various alternative options for the control arm in Phase III trials, including the challenges posed by using a placebo in the control group and problems of interpretation if a no-treatment arm is included in the design. This presentation will include a critical analysis of these and other central dilemmas.
376	17.1/1 - WHO AND HOW DO WE TREAT HIV INFECTED PATIENTS IN 2003? A PROSPECTIVE MULTICENTRE COHORT OF FRENCH PATIENTS BASED ON THE NADIS 2000 ELECTRONIC MEDICAL RECORD (EMR) European AIDS Conf 2003 Oct 25-29;9:(abstract no. 376) Cuzin L.1, Pugliese P.2, Billaud E.3, Lançon F.4, Barone M.2, Bugnon F.3, Salmi D.4, Raffi F.3, Massip P.1, Dellamonica P.2 This study shows that the Nadis 2000 electronic medical record produces a valuable database from which information can be obtained rapidly. The differences between centres reflect regional strategies.
377	17.1/2 - CLINICAL OUTCOME OF HIV/HCV COINFECTION IN A LARGE COHORT OF HEMOPHILIAC PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 377) Qurishi N.1, Lichterfeld M.1, Schmeisser N.4, Voigt E.1, Brackmann H.2, Effenberg W.2, Kupfer B.3, Rockstroh J.1 After two decades of follow up in our hemopilia cohort one third of the patients were still alive with only two long-term nonprogressors remaining.
378	17.1/3 - EPIDEMIOLOGICAL, CLINICAL, AND THERAPEUTIC FEATURES IN A POPULATION OF HIV-INFECTED IMMIGRANTS COMING FROM OUTSIDE THE EUROPEAN UNION: A GENDER COMPARISON European AIDS Conf 2003 Oct 25-29;9:(abstract no. 378) Manfredi R., Calza L., Chiodo F. Epidemiological and surveillance studies, and prospective therapeutic trials, are strongly warranted in order to have a reliable assessment of immigrated HIV-infected people, to check the efficacy of preventive measures, to have validated data about clinical, virologic, and immunological evolution and outcome of HIV infection undergoing HAART, to measure drug adherence degree, and to evaluate frequency, severity, and consequences of eventual untoward effects.
379	17.1/4 - DIFFERENCES IN HIV-1 INFECTION IN PORTUGUESE IMMIGRANTS TO LUXEMBOURG AND IN LUXEMBOURG NATIVES: IMPLICATIONS FOR PREVENTION AND TREATMENT? European AIDS Conf 2003 Oct 25-29;9:(abstract no. 379) Schmit J.C.1, Goedertz H.2, Arendt V.1, Staub T.1, Schneider F.3, Hemmer R.1 In conclusion, HIV infection in Portuguese immigrants reflects closer the situation in Portugal (presence of HIV-2, subtype G, IVDU, increasing incidence) than in Luxembourg. As most immigrants will continue to live in Luxembourg, HIV prevention has to take into account the specificity of the epidemic in population subgroups.
380	17.2/1 - GENETIC CHARACTERIZATION OF THE IDUS OUTBREAKS OF HIV-1 INFECTION IN THE URALS (RUSSIA) European AIDS Conf 2003 Oct 25-29;9:(abstract no. 380) Kazennova E.V.1, Bobkova M.R.2, Zemerov V.B.3, Shantseva N.A.3, Fedotova T.A.3, Kiva L.D.3, Fedotova T.T.3, Kapizov A.S.3, Bagautdinov A.T.4, Gerasimov V.E.4, Selutina L.I.5, Kostyan I.R.5, Raspopin V.I.5, Pokrovsky V.V.2, Bobkov A.F.1 The IDU-A variant dominates in the largest HIV-1 outbreaks in Russia. The rapid spread of this highly homogeneous strain may influence vaccine development strategies in Russia and must be taken into account for the quality control of Nucleic Acid Tests for HIV-1 diagnostics.
381	17.2/2 - HIV OUTBREAK INVESTIGATION AMONG ILLICIT DRUG USERS AND THEIR CONTACTS DURING 2001-2002 IN STOCKHOLM, SWEDEN European AIDS Conf 2003 Oct 25-29;9:(abstract no. 381) Sylvan S.P.E., Ramstedt K., Rado G., Leitner T. New subtypes of HIV-1 were detected but no further spread of these genotypes within the IDU communities of Stockholm was observed.
382	17.2/3 - NEWLY IDENTIFIED RECOMBINANT AND UNCLASSIFIED HIV-1 STRAINS IN GREECE European AIDS Conf 2003 Oct 25-29;9:(abstract no. 382) Magiorkinis G.1, Paraskevis D.1, Magiorkinis E.1, Sapounas S.1, Margaritis E.1, Lazanas M.2, Paparizos V.3, Gargalianos P.4, Antoniadou A.5, Karafoulidou A.6, Hatzakis A.1, for the Hellenic Multicenter Study on HIV-1 Heterogeneity
383	17.3/1 - LOW PLASMA LEVELS OF DEHYDROEPIANDROSTERONE-SULPHATE IN HIV-POSITIVE WOMEN CO-INFECTED WITH HEPATITIS C VIRUS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 383) Peyrière H.1, Mahamat A.2, Mauboussin J.-M.1, Rouanet I.1, Fabbro-Peray P.2, Daures J.-P.2, Vincent D.1 This is the first report of determination of DHEAs plasma levels in HIV-HCV co-infected patients. DHEAs plasma levels are significantly lower in HIV-HCV coinfected women. The pathophysiology of such results is unknown.
384	17.4/1 - DOES THE RT-M184V AFFECT THE FIDELITY OF THE HIV-1 REVERSE TRANSCRIPTASE IN VIVO? European AIDS Conf 2003 Oct 25-29;9:(abstract no. 384) Micheli V.1, Benatti S.1, Beretta R.1, Meraviglia P.1, Drago L.2, Gismondo M.R.2, Cargnel A.1 Our results suggest that the presence of M184V may decrease viral variability, independently from its effect on VL.
385	18.1/1 - KNOWLEDGE, ATTITUDE & BEHAVIOR STUDY REGARDING HIV/AIDS AMONG HIGH RISK GROUP OF COALMINE WORKERS IN MACH & DUKI BALOCHISTAN European AIDS Conf 2003 Oct 25-29;9:(abstract no. 385) Ahmad R. Considering the suspected high prevalence of HIV/AIDS & the relative lack of knowledge the authorities may start a public health campaign in these areas on firm footing save to these vulnerable group which are at high risk.
386	A COMPARATIVE CLINICAL AND EPIDEMIOLOGICAL STUDY OF HIV INFECTION IN SPANISH VS. IMMIGRANT PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 386) Cervero M., Torres R., Jusdado J., Marco J., Castilla V., Solís J. For this time, we identified in 2003 more new cases in immigrants than in Spanish population. Heterosexual contact was the main transmission in both groups. Immigrants were younger, specially in women. Mean relative ratio of AIDS was higher during six months of follow-up in immigrants.
387	18.1/3 - DESCRIPTIVE STUDY OF HIV PATIENTS ADMITTED TO THE INTENSIVE CARE UNIT: A 9 YEAR EXPERIENCE European AIDS Conf 2003 Oct 25-29;9:(abstract no. 387) Cervero M., Heras G., Marco J., Jusdado J., Torres R., Solís J., Del Nogal F. An increase in mortality and number of admittances is observed in the last year of the study period. HAART does not seem to reduce mortality in critcal HIV infected patients. The most frequent cause of ICU admittance was pneumonia with respiratory failure. All patients with pneumonia were severely immunosupressed and were not receiving HAART.
388	18.1/4 - CHARACTERISTICS OF HIV INFECTION AND RESPONSE TO HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN THE ELDERLY European AIDS Conf 2003 Oct 25-29;9:(abstract no. 388) Brañas F., Sánchez-Conde M., Miralles P., Cosín J., López Bernaldo de Quirós J.C., Vidán M., Serra J.A., Berenguer J. We found that HIV infection in the elderly was commonly acquired sexually and was frequently diagnosed in an advanced stage. HCV infection and psychiatric disorders were frequent comorbidities. We found evidences suggesting a relationship between lower CD4+ cell increase following HAART and advanced age.
389	18.1/5 - STATE AND DYNAMICS OF THE HIV-INFECTION SPREAD IN THE CENTRAL FEDERAL DISTRICT OF RUSSIAN FEDERATION European AIDS Conf 2003 Oct 25-29;9:(abstract no. 389) Mazus A.1, Pankova G.1, Olshansky A.1, Martynav J.2, Golohvastova E.1 In some regions the epidemic has passed its peak. The tendency to the decrease of newly detected cases of HIV-infection is observed in these regions. The increase of newly detected cases of HIV-infection is observed in the other regions.
390	18.1/6 - TREATMENT OUTCOME AND SURVIVAL IN HIV PATIENTS IN A SPARSELY POPULATED AREA WITH FREE ACCESS TO HAART: AN OBSERVATIONAL COHORT STUDY FROM GREENLAND European AIDS Conf 2003 Oct 25-29;9:(abstract no. 390) Lohse N.1, Ladefoged K.2, Jensen-Fangel S.1, Obel N.1 The incidence and prevalence of HIV in Greenland is higher than in the Southern part of the Danish Kingdom, and the patients are older at diagnosis. A relatively high proportion developed AIDS. Furthermore, the mortality remained high after the introduction of HAART.
391	18.1/7 - STUDY ON HIVAB, HCVAB, HBSAG SEROPREVALENCE AMONG PRISON INMATES IN BOLOGNA (ITALY) European AIDS Conf 2003 Oct 25-29;9:(abstract no. 391) Sabbatani S.1, Giuliani R.1, Fulgaro C.1, Baldi E.2, Paolillo P.3, Chiodo F.1 In prison, DA combined with Italian nationality is an important risk factor for HIV+ and HCVAb+.
392	18.1/8 - ABSENCE OF HIV-2 INFECTION IN PORTUGUESE INDIVIDUALS WHO LIVED IN GUINEA-BISSAU AFTER 1940 European AIDS Conf 2003 Oct 25-29;9:(abstract no. 392) Almeida M.1, Abecasis A.1, Lobo M.C.1, Gonçalves M.F.1, Diogo I.1, Mansinho K.2, Camacho R.1, Gomes P.1 Due to the fact that most of these candidate blood donors were sexually active when in Guinea-Bissau, some HIV-2 infections should be expected. The fact that none was found infected argue against sexual transmission as the initial main route of spread for the HIV-2 infection. This observations fit with our knowledge that sexual transmission of HIV-2 is less efficient than for HIV-1; other routes of transmission should be responsible for the HIV-2 epidemics.
393	18.1/9 - PATTERNS OF HIV-2 INFECTION IN SOUTHERN PORTUGAL European AIDS Conf 2003 Oct 25-29;9:(abstract no. 393) Gomes P.1, Abecasis A.1, Almeida M.1, Lobo M.C.1, Carvalho P.1, Gonçalves M.F1, Diogo I.1, Cabanas J.1, Mansinho K.2, Camacho R.1 HIV-2 patients have advanced age for an HIV infection, affects equally men and women. A large proportion of these patients have high numbers of CD4+ T cells counts and undetectable HIV-2 plasma viral load.
394	18.2/1 - PREVALENCE OF SEXUALLY TRANSMITTED INFECTIOUS AMONG SEX WORKERS IN PARIS, FRANCE European AIDS Conf 2003 Oct 25-29;9:(abstract no. 394) Bary M., Asselah K., Catrix S., Djuric M., Boukhemair A., Gentilini M., and the Moulin Joly Team The frequent obstetrical realise the difficulties in prevention among these populations and menace increase of prevalence. Strategies for adapted prevention must be urgently intensified.
395	18.2/2 - USE OF AND RESPONSE TO ANTIRETROVIRAL THERAPY IN REGIONS OF EUROPE. THE EUROSIDA STUDY European AIDS Conf 2003 Oct 25-29;9:(abstract no. 395) Horban A.1, Mocroft A.2, Ledergerber B., Johnson A., Chaplinskas S., Gatell J.M., Chiesi A., Phillips A.N.2, Lundgren J.D.3, Kirk O.3, for the EuroSIDA study group HAART was less commonly used in EE compared to other regions of Europe, primarily explained by regional differences in patient characteristics. Use of HAART varied substantially across the individual countries within EE. On a regional level, there were no differences in response to HAART at present, neither in laboratory response nor clinical outcome. Continuous follow-up is warranted.
396	18.2/3 - REGIONAL DIFFERENCES IN CHARACTERISTICS OF HIV-PATIENTS FROM ACROSS EUROPE. THE EUROSIDA STUDY European AIDS Conf 2003 Oct 25-29;9:(abstract no. 396) Viksna L.1, Mocroft A.2, Knysz B.3, Viard J.-P.4, Dietrich M.5, Duiculescu D.6, Blaxhult A.7, Antunes F.8, Lundgren J.D.9, Kirk O.9, for the EuroSIDA Study Group Substantial regional differences in demographic and clinical characteristics were observed within EuroSIDA. In EE, a higher proportion was infected by IVDU, were coinfected with HCV, were younger, had a higher nadir CD4 cell count and a shorter history of known HIV-infection.
397	18.3/1 - KNOWLEDGE ABOUT HIV IN SEROPOSITIVE PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 397) Roca B., Miguel A., Cabestany B., Perez A.P., Ventura J.M. Among seropositivos patients, there is insufficient knowledge on HIV, especially on the meaning of viral load. An association exists between adequate information and adequate control of HIV infection.
398	18.3/2 - TIMES HAD CHANGED: EVOLUTION OF HIV EPIDEMIC IN WOMEN AND MEN (SPANISH VACH COHORT) European AIDS Conf 2003 Oct 25-29;9:(abstract no. 398) Suárez-Lozano I.1, Fajardo J.M.1, Garrido M.2, Viciana P.3, Lozano F.4, Terrón A.5, Galindo M.J.6, González J.7, Domingo P.8, Ribera E.9, Vergara A.10, Teira R.11, Geijo P.12, Cosín J.13, Roca B.14, de la Fuente B.15, Sánchez T.16, Lacalle J.R.17 The prevalence of parenteral drug use has dramatically decreased among new HIV-infection diagnosis, although the decrease in women is greater than in men, while sexual transmission has greatly increased. The age of patients at the time of diagnosis is increasing, but it is very important to remark that these changes have happened at different time in women than in men.
399	18.3/3 - DIFFERENCES IN HIV-RNA LEVELS DURING TREATMENT FREE PERIOD OF HIV-1 INFECTION AMONG 1864 INDIVIDUALS WITH KNOWN DATES OF SEROCONVERSION European AIDS Conf 2003 Oct 25-29;9:(abstract no. 399) Touloumi G.1, Pantazis N.1, Hatzakis A.1, Katsarou O.2, Karafoulidou A.2, Porter K.3, Babiker A.G.3, on behalf of the CASCADE collaboration As HIV-RNA levels at the same stage of HIV-1 infection differ significantly by gender, risk group and age at SC, these factors should be considered before the initiation of any ART.
400	18.4/1 - NATURAL HISTORY OF HIV INFECTION IN THE COMMUNITY EVOLUTIONAL RISK IN AN INFECTED COHORT European AIDS Conf 2003 Oct 25-29;9:(abstract no. 400) Sola J.1, Bermejo B.2, Uriz J.1, Castiello J.1, Reparaz J.1, Sola O.3 HIV and AIDS diagnose coincide in 25 % of our patiens. An statistically significant change in total survival rates is noticeable since HAART therapy was introduced.
401	18.4/2 - AIDS INDICATOR DISEASES AMONG HIV POSITIVES IN LITHUANIA European AIDS Conf 2003 Oct 25-29;9:(abstract no. 401) Uzdaviniene V., Likatavicius G., Treciokas A., Caplinskas S. Most frequent AIDS indicative diesease among the patients were PCP and oesophageal candidiasis.
402	18.4/3 - SURVIVAL ANALYSIS OF CASES PRESENTING AIDS FROM TIME OF DIAGNOSIS TO DEATH European AIDS Conf 2003 Oct 25-29;9:(abstract no. 402) Arvanitis M., Nikolopoulos G., Masgala A., Paraskeva D., Eleni E. The effect of HAART therapies in survival time was confirmed in our epidemiological data. In addition to this, age at time of diagnosis and mode of transmission seem to modify the survival time.
403	18.4/4 - AIDS DEFINING ILLNESSES (ADIS) IN POLAND IN 2000-2002 European AIDS Conf 2003 Oct 25-29;9:(abstract no. 403) Podlasin R.1, Beniowski M.2, Cholewinska G.1, Gasiorowski J.3, Juszczyk J.4, Mach T.5, Malolepsza E.6, Mian M.7, Olczak A.8, Pynka-Leszczyszyn M.9, Smiatacz T.10, Wiercinska-Drapalo A.11, Horban A.1 The incidence of ADIs was 6.8; 6.5 and 4.8/100person/year in 2000-2002, respectively. The most common diagnosed OIs were: mycosis, tuberculosis, recurrent pneumonia, PCP, toxoplasmosis. In pts receiving HAART (HAART+) incidence of ADIs amounted 4.8; 2.4; 2.2 ADIs/100 person/year and was significantly lower than in all HIV+ (p <0.02, p<0.001, p<0.001 - respectively). Additionally, there was significant decrease in incidence of ADIs in HAART+ pts between 2000 and 2002 (p<0.0001). Twenty five to thirty per cents of ADIs were diagnosed in 3 months from starting HAART. Table 1. shows CD4+ cells count and VL at ADI dgn in HAART+pts. In HAART+pts the most common ADIs were: mycosis and tuberculosis. The dgn of ADIs resulted in recognition of HIV status in 8.7-8.9%pts.
404	18.4/5 - OLDER AGE AND HIGHER CD4 COUNT ARE PREDICTIVE OF HIV-ENCEPHALOPATHY (HIVE) IN HAART EXPERIENCED PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 404) Larussa D.1, Uccella I.1, Lorenzini P.1, Tozzi V.1, Bongiovanni M.2, Bossolasco S.3, Moretti F.4, Zannoni P.5, Foresti S.6, Mazzarello G.7, Artioli S.8, d'Arminio Monforte A.3, Cingolani A.9, Cinque P.2, Antinori A.1 In HAART treated pts, developing dementia was related to older age and higher CD4 count, even though duration of treatment could have a protective role. In pts with neurocognitive disorders, developing dementia does not influence response to HAART but negatively affects survival.
405	18.4/6 - EVOLUTION OF HOSPITALARY ADMISSIONS OF HIV INFECTED PATIENTS IN A UNIVERSITY HOSPITAL: 1989-2002 European AIDS Conf 2003 Oct 25-29;9:(abstract no. 405) Poza G., Redondo C., Galera C., Bermejo M., Aguayo C., Furones M. 1. Pneumonia, respiratory infection and tuberculosis are the most frequent cause of admission. 2. In the HAART period nearly half of admissions didn't receive any medical follow up and the proportion of patients who didn't know the diagnosis of HIV infection remains similar in the two periods. 3. Hospitalization rates have decreased in the HAART period, but haven't changed in the recent years.
406	19.1/1 - ARE THERE GENDER DIFFERENCES IN UTILIZATION OF HEALTH CARE SERVICES IN HIV PATIENTS IN THE HAART ERA? (SPANISH VACH COHORT) European AIDS Conf 2003 Oct 25-29;9:(abstract no. 406) Suárez-Lozano I.1, Fajardo J.M.1, Garrido M.2, Vergara A.3, González J.4, Cosín J.5, Domingo P.6, Galindo M.J.7, Viciana P.8, Roca B.9, Geijo P.10, Terrón A.11, Lozano F.12, Teira R. (13), García-Alcalde M.L. (14), Sanchez T. (15), Ribera E. (16), Lacalle J.R. (17) The way of living seems to be different by gender, no differences were found in utilization of health care services. Important remark was found in men, HIV diagnose is made in more advanced phase of the infection and age at diagnose is higher.
407	19.1/2 - BRIDGING THE GAP IN PRISON?: EFFECTIVENESS OF AN INNOVATIVE HIV PROGRAMME European AIDS Conf 2003 Oct 25-29;9:(abstract no. 407) Suárez-Lozano I.1, Fajardo J.M.1, Chacon J.A.1, Barón B.1, Menchero A.1, Morejon J.2, Castro J.M.2, Sánchez A.2, Campos E.2 Establish a "visit programme to prison" results in an earlier diagnoses of the disease, less needs for hospitalisation, better access to antiretroviral treatment and less progression to death.
408	19.1/3 - IS THERE DIFFERENTIAL FIRST PRESCRIPTION OF HAART BY GENDER AND TRANSMISSION GROUP AND WHAT ARE THE CONSEQUENCES ON IMMUNO-VIROLOGICAL AND CLINICAL EVOLUTION? European AIDS Conf 2003 Oct 25-29;9:(abstract no. 408) Fardet L.1, Mary-Krause M.1, Heard I.2, Partisani M.3, Costagliola D.1 When the first HAART is not prescribed in clinico-biological emergency, no difference by gender was evidenced. However, homosexual men received HAART earlier and at higher CD4 counts than patients belonging to other exposure category which could likely be explained by a better knowledge of the pathology and its treatments by these patients. Whether the better immuno-virological prognosis in homosexual men is explained by the earlier prescription or by higher compliance or both remained to be explored.
409	19.1/4 - HAART LESSONS FROM AMRITSAR, A SIKH MAJORITY BORDER TOWN OF INDIA European AIDS Conf 2003 Oct 25-29;9:(abstract no. 409) Bharti R. One young boy had fatal side effects of DDI-pancreatitis and lactic acidosis. Out of those who could not afford treatment 20 % are still alive even after 5 years or more .While developed talk about testing drug resistance the developing can not even think of doing PCR.The cost of getting mRNA, Cd4 etc varies from 60-120$. The author found 40-70% of HIV +ve patients in whom ART failed to achieve complete viral suppression despite months or years of treatment.
410	19.1/5 - MODIFIED DIRECT OBSERVED THERAPY (MDOT) AMONG ACTIVE INTRAVENOUS COCAINE USERS IN MONTREAL : PARTNERSHIP, ADHERENCE AND REASONS OF NON-ADHERENCE European AIDS Conf 2003 Oct 25-29;9:(abstract no. 410) Therrien R., Rouleau D., Côté P., Beauchamp S., Vézina S., Maari F., Lahaie C., Dufresne S. In order to be successful a MDOT project must use sites in the natural trajectory of participants and adapt itself to their mobility and educate them to facilitate adherence. The partnership also requires a mutual recognition of expertise. Adherence rate in participants under treatment is encouraging with cocaine abuse, psychosocial distress and drug side effects being main reasons for non-adherence.
411	19.1/6 - IMPLEMENTATION OF A HYBRIDIZATION MICROTITER PLATE ASSAY FOR THE DETECTION OF THE HIV-1 OR HIV-2 GENOME FOR NEONATAL DIAGNOSIS OF HIV INFECTION IN BAMAKO (MALI) European AIDS Conf 2003 Oct 25-29;9:(abstract no. 411) Marcelin A.G.1, Ait Arkoub Z.1, Coulibaly A.2, Sylla M.3, Keita T.3, Coulibaly H.3, Cisse B.3, Keita M.3, Traore M.3, Tubiana R.1, Carcelain G.1, Simon A.1, Kameleddine F.4, Pichard E.5, Bougoudogo F.2, Katlama C.1, Calvez V.1, on behalf of the ESTHER program We demonstrated the feasibility of a low cost, simple and efficiency qualitative PCR for neonatal diagnosis of HIV infection in Bamako (Mali).
412	19.1/7 - SOCIAL NEEDS OF HIV-INFECTED PATIENTS IN SOUTH EAST LONDON European AIDS Conf 2003 Oct 25-29;9:(abstract no. 412) Thevarajan I., Mvere M., Easterbrook P. These findings show that HIV-infected patients in South East London, especially asylum seekers, experience a wide range of social problems especially in immigration, finance, housing and mental health. Insights into the range of our patients social needs can help guide the delivery and targeting of local social services.
413	19.3/1 - A COMPARISON OF THE THERAPEUTIC PLAN (TP) COSTS IN THE TREATMENT OF HIV-POSITIVE PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 413) Sabbatani S., Dentale N., Chiodo F. This study demonstrated that, starting with decisions that take into account the efficacy of the therapy and the compliance, and ethical protocols,costs reduction is possible
414	19.3/2 - COST IMPACT OF STRATEGIES FOR MANAGEMENT OF PROTEASE INHIBITOR (PI)-ASSOCIATED DYSLIPIDEMIAS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 414) Berzon R. These results suggest that a switch to nevirapine may provide a low-cost option for management of dyslipidemia in patients on PI-based therapy.
415	19.5/1 - COST-EFFECTIVENESS OF ENFUVIRTIDE FROM UK HEALTH PAYER PERSPECTIVE European AIDS Conf 2003 Oct 25-29;9:(abstract no. 415) Hornberger J.1,2, Youle M.3, Beck E.J.4, Mandalia S.4, Green J.5, Lewis G.6 ENF+OB is predicted to delay onset of ADEs and increase life expectancy by >1.5 years. Adding ENF to OB results in a cost-effectiveness ratio less than the £30,000 generally considered an affordable technology recommended by health policy makers in the UK.
416	19.5/2 - A PHARMACOECONOMIC BALANCE OF EIGHT YEARS OF HAART: 1996 TO 2003 European AIDS Conf 2003 Oct 25-29;9:(abstract no. 416) Manfredi R., Calza L., Chiodo F. During the last decade, we observed a significant change of health care requirements for HIV disease, characterized by reduction of frequency, duration, and intensity of inpatient care, and shift to a outpatient management strategies. Thanks to the drop of hospitalization expenditures, also increasing costs of HAART and laboratory monitoring seem to remain cost-effective, although mathematical models do not allow a mid-long-term pharmacoeconomic forecast, due to the continuing changes of assitance needs, and concurrent variations of the natural history of HIV disease. The obtained chronicization of a formerly life-threatening disease, seems to justify the resort to all available assistential tools, from ethical more than pharmacoeconomic reasons.
417	19.8/1 - HEALTH-RELATED QUALITY OF LIFE AND PATIENT-PROVIDER RELATIONSHIP IN HIV-INFECTED PATIENTS AFTER STARTING PI CONTAINING ANTIRETROVIRAL TREATMENT European AIDS Conf 2003 Oct 25-29;9:(abstract no. 417) Préau M.1,2 Spire B.1, Bazin C.3, Raffi F.4, Carrieri M.P.1, Chene C.5, Cassuto J.P.6, Fournier I.7, Morin M.1,2, Leport C.7 Our results underline the need for improving patient-provider relationship to achieve higher HRQL in the long-term. Socio-behavioural interventions should also focus the patient-provider relationship in order to improve HRQL.
418	19.9/1 - THE PSYCHOLOGICAL ASPECTS OF HIV TESTING IN AFRICAN CHILDREN European AIDS Conf 2003 Oct 25-29;9:(abstract no. 418) Kwalombota M.K., Shumba C.D. Testing of HIV in children is complex because it affects the entire family structure. The full value of the test is not apparent. Good social and psychological support is required for families that have HIV positive children.
419	20.3/1 - HIV SEROPREVALENCE AND RISK BEHAVIORS IN THREE UKRAINIAN CITIES European AIDS Conf 2003 Oct 25-29;9:(abstract no. 419) Booth R.E., Corsi K.F., Salomonsen S., Brewster J.T., Semeryk O. Drug injectors in this study had very high rates of HIV-related risk behaviors and HIV-infected IDUs engaged in the highest rate of risk behaviors, thus ensuring the continued epidemic of HIV in this region of the world. Interventions are needed to prevent the further spread of this disease to those who are vulnerable.
420	20.3/2 - SOSIODEMOGRAPHIC PROFILE OF INJECTING DRUG USERS IN HIV OUTBREAK IN HELSINKI REGION European AIDS Conf 2003 Oct 25-29;9:(abstract no. 420) Kivelä P.1, Krol A.2, Simola S.1, Tuomola P.3, Ristola M.1 The outbreak of HIV in Helsinki region occurred among very marginalized IDUs. Currently HIV incidence among IDU's is decreasing in Helsinki region. Also recent cases are marginalized IDUs with a long history of injecting drug use. The declining trend in HIV cases among IDU's is confirmed by the national register of communicable diseases in Finland.
421	20.5/3 - ENHANCE SOCIAL SECURITY FOR PEOPLE LIVING WITH HIV/AIDS (PLWHA) IN BRAZIL European AIDS Conf 2003 Oct 25-29;9:(abstract no. 421) Ahrens M.H., Ferreira de Souza J.F.E., Doneda D. We analyzed the psychological, social and economic aspect of HIV/aids vulnerability and promote the integration and complementation of these policies, seeking a holistic approach. Access to social services and benefits are investigated and publicized. PLWHA need access to work, housing, healthy nutrition, equal retirement conditions and should be directly involved in the formulation of these integrated social policies.
422	LBF4/1 - DISRUPTION OF SPECIFIC CROSSTALK BETWEEN VIRAL ACCESSORY PROTEIN AND MITOGENIC SIGNALING CASCADE ABROGATES ACUTE RETROVIRAL PATHOGENESIS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 422) Tschulena U., Sanzenbacher R., Plesker R., Coulibaly C., Raupp S., Wenig R., Cichutek K., Flory E. Histopathological analysis revealed that animals inoculated with wildtype virus showed characteristic blunting and fusion of intestinal villi, whereas animals inoculated with point-mutant virus showed no pathological changes. Taken together, our results show for the first time that acute pathogenesis of this retrovirus infection can be linked on the molecular level to the capability of Nef to interact with distinct cellular MAPK signaling pathways.
423	LBF6/1 - DRUG SUSCEPTIBILITY PATTERNS IN 195 EUROPEAN PATIENTS DE NOVO INFECTED WITH DRUG RESISTANT VIRUS: IMPLICATIONS FOR POST-EXPOSURE PROPHYLAXIS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 423) Wensing A.1, van de Vijver D.1, Angarano G.2, Asjo B.3, Balotta C.4, Boeri E.5, Camacho R.6, De Luca A.7, de Mendoza C.8, Derdelinckx I.9, Grossman Z.10, Hamouda O.11, Hatzakis A.12, Hemmer R. (13), Hoepelman A.1, Horban A. (14), Korn K. (15), Kücherer C.11, Leitner T. (16), Loveday C. (17), Macrae E. (17), Maljkovic I. (16), Nielsen C. (18), Ormaasen V. (19), Perrin L. (20), Paraskevis D.12, Puchhammer E. (21), Ruiz L. (22), Salminen M. (23), Schmit J. (13), Schneider F. (13), Schurrmann R.1, Soriano V.8, Stanczak G. (14), Stanojevic M. (24), Vandamme A.9, Van Laethem K.9, Violin M.4, Wilbe K. (16), Yerly S. (20), Zazzi M. (25), Boucher C.1 Within Europe a considerable chance exists to become infected with a virus with reduced drug-susceptibility. The risk of resistance to a particular drug varies largely (4-56%). We propose that patterns observed in this study will be taken into account when developing recommendations for specific regimens used for post-exposure prophylaxis.
424	LBF11/1 - THE BOTSWANA NATIONAL ARV TREATMENT PROGRAM: ONE YEAR OUTCOME OF THE FIRST 176 PATIENTS IN RURAL MAUN European AIDS Conf 2003 Oct 25-29;9:(abstract no. 424) Mudiayi T.K.1, Beltz E.1, Perenboom R.M.2, Claessen F.A.P.2, Darkoh E.3 ART in a district hospital in rural setting in Botswana is feasible. Many patients started in late-stage HIV infection. Results are comparable with routine practice in western settings.
425	LBF11/2 - ONCE DAILY REGIMEN FOR TREATMENT-naïve HIV PATIENTS WITH STAVUDINE-XR, LAMIVUDINE, AND EFAVIRENZ: 24 WEEK INTERIM EFFICACY AND SAFETY RESULTS FROM THE DART II TRIAL European AIDS Conf 2003 Oct 25-29;9:(abstract no. 425) Jayaweera D.1, Becker S.2, Felizarta F.3, Sands M.4, Slater L.5, Gothelf S.6, Maa J.6, Dezii C.6, Hodder S.6, Tudor J.6 Stavudine-XR, lamivudine, and efavirenz administered once daily to treatment-naïve HIV subjects demonstrated significant reductions in VL and increases in CD4 cell counts while providing a simplified, convenient alternative for patients with HIV.
426	LBP7/1 - RESPONSES TO MOTHER-TO-CHILD TRANSMISSION OF HIV: A PILOT PROGRAMME IN THE RUSSIAN FEDERATION European AIDS Conf 2003 Oct 25-29;9:(abstract no. 426) Postnov D., Fuller V.L., Bijl M. It is anticipated that this programme will significantly reduce the rate of MTCT to 2% per year in selected maternal clinics. Additionally, women will receive psycho-social counselling and support through the programme, as well as instruction regarding safer practices before and after delivery for their health and the health of of their babies.
427	LBP7/2 - AIDS FOUNDATION EAST-WEST (AFEW): RESPONSES TO THE HIV EPIDEMICS IN EASTERN EUROPE AND CENTRAL ASIA European AIDS Conf 2003 Oct 25-29;9:(abstract no. 427) van de Braak I., van Esch J. The following models have been developed in specific regions and countries in which AFEW operates: mass media campaigns on safer sex; harm reduction programmes and training; creating information centres for health professionals; health promotion and HIV prevention in penal systems and among sex workers; pre- and post-HIV test counselling; and, treatment, care and support activities.
428	LBP7/3 - BUILDING NATIONAL CAPACITY FOR THE IMPLEMENTATION OF SAFER SEX MASS MEDIA CAMPAIGNS: EXPERIENCES FROM THE RUSSIAN FEDERATION, MONGOLIA AND UKRAINE European AIDS Conf 2003 Oct 25-29;9:(abstract no. 428) Grechukhina T., van de Braak I. On-going pre- and post-campaign research among target groups shows that the campaigns were well understood and accepted by youth. Additionally, analysis suggests a significant increase in condom use, and provided evidence for decision-makers regarding appropriate information strategies. Based on models developed and refined local NGOs now conduct their own media campaigns.
429	LB2.2/3 - THE IMPAIRMENT OF NK CELL CYTOLYTIC FUNCTION IN HIV-1 INFECTED PATIENTS DEPENDS ON A DECREASED EXPRESSION OF NATURAL CYTOTOXICITY RECEPTORS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 429) Fogli M.1, De Maria A.1, Costa P.1, Murdaca G.1, Puppo F.1, Moretta A.2,3, Moretta L. (2,3,4) The present study indicates that the reduced expression of NCRs could provide an explanation for the impairment of NK cell function in HIV-1 infected patients and could help to explain the relative high frequency of opportunistic tumours reported in untreated HIV-patients.
430	LB4.2/13 - DRUG MONITORING OF ATAZANAVIR IN HIV-INFECTED PATIENTS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 430) Kruse G.1, Staszewski S.2, Kurowski M.1 The described method can be applied to monitor ATV concentrations in HIV-patients. Due to the interaction potential and the highly variable levels of Atazanavir we recommend therapeutic drug monitoring after starting a therapy and in certain clinical situations.
431	LB4.5/7 - THE RAPID ADSORPTION OF PROTEASE INHIBITORS TO PLASTIC AND GLASS SURFACES MAY SIGNIFICANTLY INFLUENCE THE RESULTS OF LABORATORY PROCEDURES LIKE TDM, PHENOTYPIC RESISTANCE TESTING, DETERMINATION OF IC50S AND OF INTRACELLULAR DRUG CONCENTRATIONS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 431) Stocker H.1,2,3, Kruse G.2,3, Kahlich S.3, Hampf D.3, Dienst J.3, Kurowski M.2,3, Arasteh K.1,3 Under certain conditions PI adsorb to a variety of surfaces which may explain the high variability of test results.
432	LB9.2/11 - EFFICAY AND SAFETY OF PRAVASTATIN FOR MANAGING HAART-RELATED HYPERCHOLESTEROLEMIA European AIDS Conf 2003 Oct 25-29;9:(abstract no. 432) Blanco F., García-Benayas T., García A., Alcolea A., González-Lahoz J., Soriano V. 86 patients included. Age: 44±9 years, male: 79%. Data at baseline, 4 and 8 months shown in table. LDL-cholesterol variations in patients receiving 2 NRTI + 1 NNRTI (60%), and 2 NRTI + 1 IP (16%) were: a) 4 months: -21%, -11% (p=0.05), respectively; b) 8 months: -25%, -36% (p=0.08), respectively. Overall, 29% and 40% of pts achieved a good control of cholesterolemia (NCEP III criteria) after 4 and 8 months, respectively. 19% required 40 mg/d of pravastatin after the 4th month. Pravastatin was stopped in 6% of pts due to unremarkable side effects. No muscle or liver toxicity occurred.
433	LB9.4/6 - DECREASE IN MTDNA LEVELS IN PBMC DUE TO HIV INFECTION CAN FURTHER DECREASE ÓR INCREASE DEPENDING ON THE USED ANTIVIRAL DRUG COMBINATION European AIDS Conf 2003 Oct 25-29;9:(abstract no. 433) de Baar M.P., Timmermans E.C., Smolders K., Buitelaar M., van Gemen B., de Ronde A. Measuring mtDNA levels in PBMC is a powerful tool to assess and monitor toxic effects of HIV and antiviral drugs on the mitochondria. As HIV infection itself can cause mtDNA decline, the more toxic therapies will lead to a further decline of the mtDNA levels, possibly leading to severe adverse effects. The observed rise in mtDNA levels during therapy is probably due to recovery from HIV infection combined with less toxicity of the antiviral drugs itself.
434	LB13.2/2 - PREVELANCE OF HIV AND HEPAITIS B AND C AMONG DRUG ADDICTS IN THE HOLY CITY OF AMRITSAR European AIDS Conf 2003 Oct 25-29;9:(abstract no. 434) Aggarwal A., Tiwari R. Sexual route of transmision of HIV remaining number one cause the importance of drug addiction can not be overlooked. Hence there is an urgent need to bring the drug trafficking to a halt otherwise there is a potential danger of HIV epidemic spreading in the border towns of any two countries. Better attention in the form of surveillence and prevention oriented health education measures in the region are the order of the day.
435	LB13.2/15 - NEED FOR LIVER TRANSPLANT FOR HIV+ SUBJECTS IN ITALY. (PROJECT HOST- HIV, ORGAN SHARING AND TRANSPLANTATION) European AIDS Conf 2003 Oct 25-29;9:(abstract no. 435) Zagnoli A., Costigliola P., Tumietto F., Chiodo F. We can underline that application of HIV infection related parameters as selection criteria has a great strength in reducing the waiting list of HIV+ subjects suitable for liver transplants and could be carefully considered when planning inclusion/exclusion criteria for experimental purposes. Our data represent the first evaluation of eligibility for liver trasplantation for HIV+ subjects with end-stage liver disease.
436	LB14.1/4 - HIV MOTHER TO CHILD TRANSMISSION IN THE SLOVAK REPUBLIC European AIDS Conf 2003 Oct 25-29;9:(abstract no. 436) Staneková D.1, Habeková M.1, Mokrás M.2, Truska P.3, Mayer V.1 Regarding to the success of mother to child prophylaxis the establishment of mandatory testing of pregnant women is by now under the discussion in Slovakia.
437	LB17.2/10 - DOMINANCE OF SUBTYPE A AMONG IDU IN THE NORTH-WESTERN DISTRICT OF THE RUSSIA FEDERATION European AIDS Conf 2003 Oct 25-29;9:(abstract no. 437) Smolskaja T.1, Golovanova E.1, Zetterberg V.2, Sevastianova K.2, Kevlova N.1, Liitsola K.2, Leinikki P.2, Salminen M.2 The Eastern European subtype A strain has spread to most parts of the North-Western region of the Russian Federation. In addition to IDUs subtype A has become the majority strain in the sexual transmission category. This is the first report of a CRF03-A/B epidemic outside the Kaliningrad region, where the strain caused the first local explosive epidemic among IDU's in the Russian Federation in 1996.
438	LB18.1/8 - CLINICO-EPIDEMIOLOGICAL STUDY OF HIV POSITIVE PATIENTS ATTENDING SEXUALLY TRANSMITTED DISEASES CLINIC OF MEDICAL COLLEGE, AMRITSAR (INDIA) European AIDS Conf 2003 Oct 25-29;9:(abstract no. 438) Malhotra S.K., Amarjit K., Ahuja S., Malhotra S. HIV infection and other STDs continue to be substantial health problems in sexually active age group. Socioeconomic factors and substance abuse appear to be stronger risk factors for HIV and STDs, compared to traditional measures of sexual behavior. The findings suggested a need to strengthen STD clinical services
439	LB18.2/1 - A STUDY OF SEROPREVALENCE OF HUMAN IMMUNODEFICIENCY VIRUS HIV-I& HIV II IN PATIENTS ATTENDING SEXUALLY TRANSMITTED DISEASES (STD) CLINIC European AIDS Conf 2003 Oct 25-29;9:(abstract no. 439) Malhotra S.K., Sidhu A.K., Ahuja S. The results of HIV seropositivity in a small study like this should be enough to ring up the alarming bells of health planners in India. Any delay, otherwise, could be devastating for the society & country at large.
440	LB18.4/14 - NEED FOR KIDNEY TRANSPLANT FOR HIV+ SUBJECTS IN ITALY. (PROJECT HOST- HIV, ORGAN SHARING AND TRANSPLANTATION) European AIDS Conf 2003 Oct 25-29;9:(abstract no. 440) Zagnoli A. , Tumietto F., Costigliola P., Chiodo F. We can underline that application of HIV infection related parameters as selection criteria strengthfully reduces the waiting list of HIV+ subjects suitable for kidney transplant and could be carefully considered when planning inclusion/exclusion criteria for experimental purposes. Our data represent the first evaluation of the need and eligibility for kidney trasplantation for HIV+
441	LB19.6/12 - EFFICACY OF HAART IN PATIENTS WITH EXTREMELY ADVANCED HIV DISEASE IN A MIDDLE INCOME COUNTRY European AIDS Conf 2003 Oct 25-29;9:(abstract no. 441) Vasquez P., Beltran C., Wolff M., Gallardo D., Bustos M. The high mortality rate and progression of AIDS was directly related with CD4 below 100 at start. OI at baseline were: 44,3% candidiasis, 20,4% Pneumocystiis carinii pneumonia , 11,7% herpes zoster infection, 10,7% Oral Leukoplakia , 9,1% Tuberculosis , 6,1% Kaposi Sarcoma and other OI less then 3%. Inmune reconstitution associated diseases were seen in a 18,5% in patients with CD4 below 50 cell/ ml which was statistical significative when compared to the 5,5% in CD4 200 and up.
442	LB20.5/5 - PROGRAM OF PREVENTION AND CONTROL OF THE PAEDIATRIC AIDS IN CUBA European AIDS Conf 2003 Oct 25-29;9:(abstract no. 442) Gonzalez Nuñez I., Díaz Jidy M., Pérez Avila J. Cuban HIV Control and Prevention Program is effective since the number of infected children remains low when compared to other countries.
443	LB20.6/9 - DECREASED EFFICIENCY OF THE NUCLISENS-QT ASSAY TO QUANTITATE THE EASTERN EUROPEAN SUBTYPE-A STRAINS European AIDS Conf 2003 Oct 25-29;9:(abstract no. 443) Brummer-Korvenkontio H.1, Liitsola K.1, Suni J.2, Smolskaja T.3, Salminen M.1 The NucliSense-QT assay severely underestimated viral loads in individuals infected with the Eastern European subtype A and A/B strains. In its current form the test may not be suitable for patient clinical management monitoring or diagnostic purposes in regions where these strains of HIV-1 are prevalent.

---

This information is designed to support, not replace, the relationship that exists between you and your doctor.
©1980, 2003. AEGiS.